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Summary 
 
Interleukin-33 (IL-1F11), the most recent addition to the IL-1 family, is a potent pro-
inflammatory cytokine that stimulates the generation of Th2-associated cytokines. 
Two pivotal aspects of the IL-33 system are characterized in this study: First the 
composition and function of the IL-33 receptor complex on IL-33 responder cells and 
second the generation of biologically active IL-33 by the IL-33 producer cell.  
IL-33 binds to the IL-33 receptor α-chain (formerly known as the orphan receptor 
ST2) and as is shown here, this results in the recruitment of interleukin-1 receptor 
accessory protein (IL-1RAcP) as the co-receptor. The IL-33-dependent interaction of 
membrane bound and soluble form of IL-1RAcP and IL-33Rα-chain was 
demonstrated in co-immunoprecipitation assays. IL-33-induced formation of the 
receptor heterodimer is the first necessary step for IL-33-mediated activation of T 
cells and mast cells. Lack of the IL-1RAcP abrogated responses to IL-33 and IL-1 in 
the mouse thymoma clone EL-4 D6/76. Responsiveness to IL-33 and IL-1 was 
restored with the expression of full length IL-1RAcP, while a mutant protein lacking 
the Toll/IL-1 Receptor domain (TIR) was not sufficient to restore IL-33 or IL-1 
responsiveness in EL-4 D6/76 cells. Moreover the monoclonal antibody 4C5, which 
neutralizes IL-1β effects by blocking of murine IL-1RAcP, inhibited IL-33-stimulated 
signaling in mouse thymoma cells and bone marrow-derived mast cells. In these 
cells, IL-33 activated the classical IL-1 signaling pathway including IL-1 receptor 
associated kinase (IRAK-1), cJun-N-terminal kinase, p38 MAPK and the NF-κB 
pathway in an IL-1RAcP –dependent manner.  
In search for putative further components of the IL-33 receptor complex, TIR8 / 
SIGIRR was studied, as it was proposed to be a candidate IL-33 receptor 
component. Using wild type TIR8 and chimeric fusion proteins it could be excluded 
that TIR8/SIGIRR can substitue for IL-1RAcP as a co-receptor. Furthermore, no 
experimental proof could be generated to show that this molecule is participating in 
the signaling IL-33 receptor complex.  
Like IL-18 and IL-1β, IL-33 was found to have strong immunomodulatory functions. 
However, whereas IL-1β and IL-18 promotes pro-inflammatory and Th1-associated 
responses, IL-33 induces Th2-associated cytokines. In order to find the differential 
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gene regulation in response to these cytokines, IL-1-, IL-18- and IL-33 -induced gene 
expression profiles were compared by microarray from a triple responsive T cell line. 
Although a large number of genes were regulated by the IL-1 family members, no 
differentially regulated gene could be identified, suggesting the use of the same 
signaling molecules/pathways by all three cytokines, at least in this cellular system. 
Thus, it is proposed that the unique expression profile of the cytokines in specific 
cell/tissue types, and expression of specific receptors on effector cells may specifiy 
the differential function of these cytokines in different cell types. 
Common notion in the field is that IL-33, like IL-1β and IL-18, requires processing by 
caspase-1 to a mature form, in order to achieve biological activity as a cytokine. 
Contrary to the current dogma, here it is described that IL-33 is biologically active as 
unprocessesed full length molecule. Full length IL-33 binds to the IL-33 receptor-α 
chain and mediates the recruitment of IL-1RAcP to activate cells. IL-33 is processed 
in cells, however not by caspase 1 to a mature, biologically active, IL-33 but instead it 
is cleaved by caspase 3 at aa175 to yield two products which are both unable to bind 
to the IL-33 receptor. Thus caspase 3 processing inactivates IL-33 as a cytokine. Full 
length IL-33 and its N-terminal caspase 3 breakdown product, however, translocate 
to the nucleus of the producing cell. Interestingly, bioactive IL-33 is not released by 
cells constitutively or after activation of the inflammasome as is the case with other 
IL-1 family members, like IL-1β and IL-18. Thus, it is tempting to speculate that IL-33 
is not a classical cytokine but a molecule with dual function which normally exerts its 
function in the nucleus of intact cells and only activates others cells via the IL-33 
receptor complex if cells are destroyed. Thus IL-33 may act as an endogenous 
danger signal, to alert cells of the innate immune system of the destruction of the IL-
33 producing cells during hypoxia or after mechanical injury to initiate a sterile 
inflammation.  
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Zusammenfassung  
Interleukin-33 (IL-1F11) der jüngste Zugang zur IL-1 Familie, ist ein potentes 
entzündungsförderndes Zytokin, das die Herstellung von Th2 -artigen Zytokinen 
stimuliert. Zwei zentral wichtige Aspekte des IL-33 Systems werden in dieser Studie 
charakterisiert: Zuerst der Aufbau und die Funktion des IL-33 Rezeptorkomplexes auf 
Zellen, die auf IL-33 reagieren und zweitens die Bildung des biologisch aktiven IL-33 
durch die produzierende Zelle. 
IL-33 bindet an die IL-33 Rezeptor α-Kette (früher als “Waisenrezeptor” ST2 bekannt) 
und, wie hier gezeigt, resultiert dies in der Rekrutierung des Interleukin-1 Rezeptor 
Akzessorischen Proteins (IL-1RAcP) als Korezeptor. Die IL-33- abhängige 
Wechselwirkung des Membran-gebundenen und löslichen IL-1RAcP und der IL-33Rα-
Kette wurde in Ko-immunopräzipitationsexperimenten gezeigt. IL-33-induzierte Bildung 
des Rezeptor-Heterodimers ist der erste notwendige Schritt der IL-33 vermittelten 
Aktivierung von T-Lymphozyten und Mastzellen. Das Fehlen des IL-1RAcP verhinderte 
Antworten auf IL-33 and IL-1 in der Maus Thymoma Linie EL-4 D6/76. Die Fähigkeit auf 
IL-33 und IL-1 zu reagieren, wurde durch die Expression des intakten IL-1RAcP wieder 
hergestellt, während eine Mutante, welcher die Toll/IL-1 Rezeptor Domäne (TIR) fehlte, 
nicht in der Lage war, die IL-33- oder IL-1-Antwort in EL-4 D6/76-Zellen wieder 
herzustellen. Darüberhinaus inhibierte der monoklonale Antikörper 4C5, welcher IL-1β -
Effekte durch das Blockieren des murinen IL-1RAcP zu neutralisieren vermag, die IL-33-
stimulierte Signaltransduktion in Maus Thymoma Zellen und in Mastzellen, die frisch aus 
Knochenmark ausdifferenziert worden waren. In diesen Zellen aktivierte IL-33 den 
klassischen IL-1 Signalweg einschließlich der IL-1 Rezeptor assoziierten Kinase (IRAK-
1), der cJun-N-terminalen Kinase, der p38 MAP- Kinase und des NF-κB Wegs in einer 
IL-1RAcP –abhängigen Weise. 
Auf der Suche nach möglichen weiteren Komponenten des IL-33 Rezeptorkomplexes 
wurde TIR8 / SIGIRR untersucht, da vorgeschlagen worden war, dass dies ein Kandidat 
hierfür sein könnte. Unter Verwendung von Wildtyp-TIR8/SIGIRR und chimären 
Fusionsproteinen konnte ausgeschlossen werden, dass TIR8/SIGIRR IL-1RAcP als 
Korezeptor ersetzen kann. Weiterhin konnte kein experimenteller Nachweis erbracht 
werden, dass dieses Molekül ein Teil des Signal-transduzierenden IL-33 
Rezepptorkomplexes ist. 
Wie IL-18 und IL-1β übt IL-33 starke immunmodulatorische Funktionen aus. Während IL-
1β und IL-18 jedoch proinflammatorische und Th1 -assoziierte Antworten fördern, 
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induziert IL-33 Th2-assoziierte Zytokine. Um eine differentielle Genregulation in Antwort 
auf diese Zytokine herauszufinden, wurden IL-1-, IL-18- und IL-33 –induzierte 
Genexpressionsprofile mittels Microarrays in einer Triple-responsiven T-Zelllinie 
aufgenommen und verglichen. Obwohl eine große Zahl von Genen durch die Mitglieder 
der IL-1 Familie reguliert wurden, konnten keine differenziell regulierten Gene identifiziert 
werden, was vermuten lässt, dass alle drei Zytokine denselben Signalweg nutzen, 
zumindest in dem untersuchten Zellsystem. Es wird daher vorgeschlagen, dass die 
diskreten Expressionsprofile der einzelnen Zytokine in bestimmten Zell- bzw. 
Gewebetypen und die Expression der spezifischen Rezeptoren auf Effektorzellen die 
jeweilige differentielle Funktion dieser Zytokine in unterschiedlichen Zelltypen 
bestimmen. 
Es wird in Fachkreisen allgemein angenommen, dass IL-33, wie IL-1β und IL-18, das 
Prozessieren durch die Caspase-1 zur reifen Form benötigt, um als Zytokin biologisch 
aktiv sein zu können. Dem Dogma widersprechend, wird hier beschrieben, das IL-33 als 
unprozessiertes Molekül biologisch aktiv ist, also in seiner gesamten durch die 
Primärsequenz definierten Länge. Unprozessiertes IL-33 bindet an die IL-33 Rezeptor-α 
Kette und vermittelt die Rekrutierung von IL-1RAcP, um Zellen zu aktivieren. Dabei wird 
IL-33 in Zellen prozessiert, jedoch nicht durch Caspase 1 zu einer reifen, biologisch 
aktiven Form, sondern es wird durch Caspase 3 an Position175 gespalten, wobei zwei 
Produkte entstehen, die beide nicht in der Lage sind, an den IL-33 Rezeptor zu binden. 
Insofern inaktivert Caspase 3 IL-33 als Zytokin. Unprozessiertes IL-33 und sein N-
terminales Caspase 3 -Abbauprodukt können jedoch in den Kern der produzierenden 
Zelle translozieren. 
Interessanterweise wird bioaktives IL-33 nicht durch die Zellen freigesetzt, weder 
konstitutiv noch nach Aktivierung des Inflammasoms, wie es der Fall ist mit anderen 
Mitgliedern der IL-1 –Familie, z.B. IL-1β und IL-18. Daher ist es verlockend zu 
spekulieren, dass IL-33 gar kein klassisches Zytokin ist, sondern ein Molekül mit dualer 
Funktion welches normalerweise seine Aufgaben im Kern der produzierenden Zelle 
ausübt und nur dann andere Zellen über den IL-33 Rezeptorkomplex aktiviert, wenn die 
produzierenden Zellen zerstört werden. Damit mag IL-33 als ein endogenes Alarmsignal 
wirken, welches Zellen des angeborenen Immunsystems darauf aufmerksam macht, 
dass Zellen durch Zerstörung zu Grunde gegangen sind, zum Beispiel nach 
Sauerstoffunterversorgung oder durch mechanische Verletzung, um eine sterile 
Entzündung in Gang zu setzen. 
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Chapter 1 
 
 
Introduction 
 
Cytokines are protein mediators of the immune system that activate leukocytes and 
tissue cells by binding to specific plasma membrane receptors. Cytokines can be 
grouped in families by different criteria such as their source, e.g. lymphokines are 
produced by lymphocyts, or their role in the immune reponse, e.g. whether they 
initate and support an acute inflammation or whether they dampen and turn off 
inflammation. Interleukin-1 (IL-1) α and IL-1β are two of the best known and best 
characterized cytokines of the immune system that organize acute inflammation at 
the site of infection and systemically. In the last years it has become evident that a 
family of IL-1 like cytokines exist, which act in innate and adaptive immunity. 
1.1. Biological activities of IL-1 family cytokines 
Cytokines of the IL-1 family play a major role in a wide range of inflammatory, 
infectious, and autoimmune diseases (Dinarello, 1996). IL-1 family cytokines, such as 
IL-1 itself, IL-18, and IL-33 are critical for successful clearance of extra- and 
intracellular pathogens and they participate in mounting the host defense against 
malignant transformations. Normally, their production is tightly controlled in acute 
inflammation to avoid tissue damage due to their overall catabolic action. However, if 
control fails their overproduction can lead to autoimmune disorders such as 
rheumatoid arthritis. IL-1, IL-18 and IL-33 are potent inducers of secondary cytokine 
production by leukocytes or tissue cells, yet the individual profiles induced by the 
respective cytokine differ. IL-1α and IL-1β (IL-1) are important pro-inflammatory 
cytokines of the innate arm of immunity. IL-1 plays an important role in immune 
regulation and inflammatory processes by inducing expression of many effector 
proteins, e.g. cytokines/chemokines, nitric oxide synthetase and matrix 
metalloproteinases (MMPs) (Dinarello, 2002). In addition, IL-1 is also known as a 
lymphocyte activating factor (LAF) promoting proliferation of sub-optimally stimulated 
thymocytes (Th0) in vitro (LAF-assay), thus participating in adaptive immunity as well. 
6 
Excessive and/or dysregulated activity of IL-1 cytokines is associated with tissue 
destruction and therefore the synthesis, release and biological activity of IL-1 
cytokines have been identified as therapeutic targets for common inflammatory 
disorders such as rheumatoid arthritis (RA) (Salvi and Lang, 2005; Burger et al., 
2006). 
IL-18 is also able to induce the release of pro-inflammatory cytokines, however its 
major feature, in collaboration with IL-12, is the induction of Interferon-γ production. 
(Yoshimoto et al., 1998). Using animal models, it has been shown that IL-18 is 
required for the IFN-γ-dependent eradication of several microbial infections. IL-18 
skews Th0 cells in the beginning of the adaptive immune response towards Th1 
differentiation, favoring a cellular adaptive immune response. In addition to IFN-γ 
production and Th1 polarization, IL-18 induces both T- and NK-cell maturation and 
potentiates cytotoxicity (Dinarello and Fantuzzi, 2003) and is also involved in Th17 
cell responses (Harrington et al., 2006). IL-18 can induce TNF-α production both in 
vitro and in vivo, an effect that links this cytokine to the development of the 
inflammatory response and the pathogenesis of several autoimmune diseases. 
Altogether, it is clear that by regulating T-helper cell differentiation, B-cell activation 
and Immunoglobulin production as well as its activity on Dendritic cells (DC), Natural 
Killer (NK) cells and neutrophilic granulocytes, IL-18 is a cytokine that has an 
important role in both the innate as well as the adaptive immune response (reviewed 
in (Carroll et al., 2008). 
Recently, six novel members of the IL-1 cytokine family (IL-1F5-IL-110) were 
identified on the basis of sequence homology, three-dimensional structure, gene 
location and receptor binding (Debets et al., 2001; Towne et al., 2004; Nicklin et al., 
2002; Taylor et al., 2002; Sims et al., 2001; Dunn et al., 2001). Still, little is known 
about the biological effects of these novel members of the IL-1 family cytokines. 
Interleukin-33 (IL-33, IL-1F11) is the most recently identified member of the family of 
IL-1-like cytokines (Schmitz et al., 2005). IL-33 activates basophils, mast cells, 
eosinophils, NK and NKT cells, Th2 lymphocytes, cardiomyocytes and cultured glial 
cells (reviewed in (Haraldsen et al., 2009). Recombinant IL-33 was found to drive 
production of Th2-associated cytokines in mast cells (Ali et al., 2007; Allakhverdi et 
al., 2007; Hayakawa et al., 2007; Ho et al., 2007; Iikura et al., 2007; Moulin et al., 
2007; Schmitz et al., 2005), to induce chemotaxis of Th2 cells (Komai-Koma et al., 
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2007) and to protect the heart against cardiac stress (Sanada et al., 2007) and 
atherosclerosis (Miller et al., 2008). Moreover, IL-33 is also able to induce pro-
inflammatory cytokines suggesting its involvement in pro-inflammatory disorders 
(Dinarello, 2005; Moulin et al., 2007; Smithgall et al., 2008; Ali et al., 2007). Despite 
its involvement in the classical inflammatory diseases such as asthma, rheumatoid 
arthritis, atherosclerosis and urticaria, IL-33 has now also been shown to participate 
in cardiovascular pathophysiology (reviewed in (Kakkar and Lee, 2008; Gabay and 
McInnes, 2009). In addition to its clasical cytokine activity IL-33 translocates to 
nucleus of producing cells and acts as chromatin associated nuclear factor (Carriere 
et al., 2007; Roussel et al., 2008). Thus similar to IL-1α and chromatin-associated 
cytokine High-mobility group box 1 (HMGB1), IL-33 is also a dual function protein that 
may act as both a cytokine and an intracellular nuclear factor (reviewed in (Gadina 
and Jefferies, 2007; Haraldsen et al., 2009).  
1.2. Expression, processing and release of IL-1 family cytokines 
1.2.1. Expression 
IL-1 family members IL-1α, IL-1β and IL-18 are released by a variety of cell types 
including monocytes, macrophages, dendritic cells, epithelial cells, keratinocytes 
endothelial cells, smooth muscle cells, and synovial fibroblasts (Dinarello, 1999; 
Gracie et al., 2003; McInnes et al., 2000; Dinarello and Fantuzzi, 2003). IL-1F6, 8 
and 9 are expressed predominantly in the skin (Towne et al., 2004). Furthermore, IL-
1F6 is also expressed in the trachea and thymus, IL-1F8 in skeletal muscle and glial 
cells (Wang et al., 2005), and IL-1F9 in the trachea, uterus and in bronchial epithelia 
(Vos et al., 2005).  
Very little is known yet about the cellular sources of IL-33 in vivo. Expression of IL-33 
was initially found in human high endothelial venules (HEV) (Baekkevold et al., 
2003). These endothelial cells are specialized cells in secondary lymphatic tissues 
which express specific adhesion molecules allowing lymphocytes the transmigration 
from the blood into the lymphoid tissue. Expression of IL-33 mRNA has also been 
seen in endothelial cells from other lymphoid tissues, chronically inflamed rheumatoid 
arthritis, synovium and intestine of patients with Crohn’s disease, keratinocytes, 
dendritic cells, activated macrophages, fibroblasts, smooth muscle cells, normal 
endothelial cells and epithelial cells (Carriere et al., 2007; Moussion et al., 2008; 
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Schmitz et al., 2005). However, whether all these different cell types actually produce 
protein and release biologically active IL-33 is unclear. 
1.2.2. Processing  
IL-1α and IL-1β are translated as 31 kDa leaderless precursor molecules. IL-1α is 
biologically active in this full length form (Mosley et al., 1987), whereas precursor IL-
1β has to be cleaved intracellularly by caspase 1 (also known as IL-1β converting 
enzyme ICE) to the 17 kDa mature and active form (Dinarello, 1998). IL-18 also lacks 
a signal peptide and is produced as an inactive 23 kDa precursor that is cleaved by 
caspase 1 to form the biologically active 18 kDa species (Gu et al., 1997). 
Proteinase-3, caspase 3, cathepsins and elastase can also cleave the precursor 
polypeptide, but this can result in the production of inactive forms of IL-18 (Akita et 
al., 1997; Robertson et al., 2006; Sugawara et al., 2001). 
IL-33 is closely related to IL-18 and IL-1α/IL-1β. Like IL-18 and IL-1β, IL-33 is 
synthesized as a 31 kDa precursor form lacking a leader peptide. Recently, IL-33 has 
been reported to be processed to the mature cytokine form by caspase 1 in vitro 
(Schmitz et al., 2005), but a more recent study failed to find any evidence for 
caspase-1 processing of IL-33 in vivo (Carriere et al., 2007). IL-1F5, -6, -8, -9 and -10 
lack signal peptides and, to date, no caspase-1 cleavage sites have been identified 
(Kumar et al., 2000; Smith et al., 2000; Lin et al., 2001), whereas IL-1F7 contains a 
putative signal peptide and has been shown to be cleaved by caspase-1 (Kumar et 
al., 2002). 
1.2.3. Release 
It has been postulated that cells such as monocytes require a second stimulus to 
release active IL-1 cytokines. The initial stimulus, e.g. LPS, causes large 
accumulation of precursor IL-1β in the cytosol and only a modest IL-1β secretion 
(Dinarello, 1998). IL-1β release is induced strongly by extracellular adenosine 
triphosphate (ATP), which signals via the P2X7R receptor causing K+ efflux from 
cells activating procaspase-1 and hence processing of precursor IL-1β (Ferrari et al., 
2006). Release of IL-18 involves a similar mechanism (Dinarello and Fantuzzi, 2003). 
There is evidence to suggest that IL-1β may be packaged into small plasma 
membrane microvesicles that are released into the extracellular space (MacKenzie et 
al., 2001; Andrei et al., 2004). Similar to IL-1, maturation and release of IL-33 has 
been proposed to be a caspase 1 -dependent mechanism (Dinarello, 2005; Schmitz 
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et al., 2005). Although in vitro evidence of caspase 1 cleavage has been published 
(Schmitz et al., 2005; Sharma et al., 2008), it is not yet clear how IL-33 may be 
released from the cells to exert its cytokine activities towards target cells expressing 
the IL-33 receptor. A caspase 1 cleavage sequence within the primary IL-33 protein 
structure is not conserved across all species (reviewed in (Kakkar and Lee, 2008) 
and definitive localization of precursor IL-33 within lysosomal structures has not yet 
been reported. However, alum-induced activation of the inflammasome resulted in 
release of IL-33 (Li et al., 2008). The heterochromatin-binding of IL-33 resembles the 
biology of IL-1α more closely than other members of the IL-1 family and, as has 
recently been suggested for precursor IL-1α (which is not processesed by caspase 1 
but by calpain!), it is possible that in fact caspase 1 acts as a secretory targeting 
factor for precursor IL-33 (Keller et al., 2008).   
Despite the transcriptional regulatory properties of precursor IL-1α, it is doccumented 
that precursor IL-1α can bind to IL-1 receptor and acts as a pro-inflammatory 
cytokine (Dinarello, 1998; Mosley et al., 1987). It is possible that like precursor IL-1α 
which binds to IL-1 receptor type 1, precursor IL-33 may also have the ability to bind 
to the IL-33 receptor and can exert pro-inflammatory or regulatory functions.  
1.3. The interleukin-1 receptor family 
The interleukin-1 receptor (IL-1R) family comprises transmembrane proteins [the type 
I receptors (IL-1RI, IL-18Rα, IL-33Rα, IL-1Rp2, TIGIRR and SIGIRR), the type II 
receptor (IL-1RII), and the receptor accessory proteins/co-receptors (IL-1RAcP, IL-
18Rβ)] and their soluble forms. All transmembrane molecules are characterized by 
three extracellular immunoglobulin (Ig)-like domains (except SIGIRR, which contains 
only one Ig-like domain). Type I recptors and co-receptors possess an intracellular 
region comprising a Toll/IL-1 receptor (TIR) domain (Fig.1.1) which is lacking in IL-
1RII. The prototype molecules of the family of IL-1 receptors are IL-1RI (Sims et al., 
1988) and its co-receptor molecule IL-1RAcP (Greenfeder et al., 1995). IL-1α and IL-
1β bind to IL-1RI or IL-1RII, of which only IL-1RI can initiate signal transduction 
where as IL-1RII serves as a regulatory molecule. IL-1 signal transduction is initiated 
by binding of either form of IL-1 to IL-1RI, which undergoes a conformational change 
allowing IL-1RAcP to recognize the ligated IL-1RI (Fig.1.2). IL-1RAcP itself does not 
recognize IL-1 alone. Upon ligand binding both transmembrane proteins, IL-1RI and 
IL-1RAcP, form a heterodimeric complex which results in the close association of the 
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signaling domains located in the cytoplasmic regions of the two chains (reviewed in 
(Martin and Wesche, 2002; O'Neill, 2008). These signaling domains are found in 
rather conserved form in nearly all members of the Toll-like receptor and IL-1 
receptor families. This is why they were termed TIR-domains (Toll-like Interleukin-1 
Receptor homology domains). It has been demonstrated that IL-1RAcP is essential 
for IL-1 signaling (Korherr et al., 1997; Wesche et al., 1997b; Cullinan et al., 1998) 
and that the C-terminal TIR-domains of both chains are required to facilitate down-
stream signaling (Lang et al., 1998; Radons et al., 2002).  
IL-18 signals through the IL-18 receptor complex (IL-18R), which is homologous to 
the IL-1RI complex, a heterodimer consisting of IL-18Rα (IL-1 receptor related protein 
1 or IL-1Rrp1) and IL-18Rβ (Accessory protein like or AcPL) subunits. In agreement 
with the IL-1 receptor system the extracellular domains of both IL-18R chains contain 
three Ig-like domains and an intracellular region comprising a Toll/IL-1 receptor (TIR) 
domain each. In the IL-18 receptor system mature IL-18 binds to IL-18Rα and then 
the IL-18Rβ-chain recognizes the ligated IL-18Rα-chain to form a transmembrane 
heterodimer. IL-18Rβ is unable to bind to IL-18 alone. Again both chains carry a TIR-
domain in their cytoplasmic parts allowing the formation of a scaffolding structure 
after heterodimerization which enables the recruitment of adaptor proteins to the TIR-
domain dimer (Boraschi and Tagliabue, 2006; Subramaniam et al., 2004) and 
initiates downstream signaling.  
Ligand-mediated heterodimerization with subsequent intracellular association of 
strongly homologous but discrete TIR domains seems to be a typical feature of the 
IL-1 receptor subfamily of TIR-domain containing receptors. Although the molecules 
of the IL-1R complex and the IL-18 receptor complex are closely related, they can not 
substitute for each other. The receptors are specific for their respective ligands and 
the co-receptors recognize only the respective ligated receptors.  
A series of IL-1 receptor family members share the features of the receptors for IL-1 
and IL-18 (Born et al., 2000). IL-1Rrp2 and ST2 (T1, Der4) also contain three 
extracellular Ig-like domains, they are type I transmembrane molecules and possess 
a TIR domain in their cytoplasmic part. One family member, single Ig-domain 
containing IL-1R related (SIGIRR), possesses a single extracellular Ig-like domain 
(Thomassen et al., 1999). SIGIRR or TIR8 (for Toll / IL-1R 8), also contains a TIR 
domain in its intracellular region, and has been discussed to compete with the other 
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TIR domain containg receptors for the intracellular adaptor molecule MyD88 and the 
downstream signaling moelcule TRAF6, thus inhibiting IL-1, IL-18 and LPS activity 
(Wald et al., 2003). 
IL-1R-related protein 2 (IL-1Rrp2) is the receptor for three novel members of the IL-1 
family, IL-1F6, IL-1F8, and IL-1F9 , which was reported to require IL-1RAcP as co-
receptor for activity (Dunn et al., 2001; Kumar et al., 2000; Smith et al., 2000; Towne 
et al., 2004). The recently identified receptor for IL-33 (IL-1F11), ST2, has been 
known as a member of the IL-1 receptor family for many years (Klemenz et al., 1989; 
Tominaga et al., 1991) although its ligand had remained elusive until 2005 when IL-
33 was identified as its ligand (Schmitz et al., 2005). As the IL-33Rα-chain is very 
homologous to IL-1RI and IL-18Rα-chain it was speculated that the IL-33Rα-chain 
also required a β-chain containing a TIR-domain for signal transduction and it was 
also suggested that this β-chain itself will not bind to IL-33 and that it is a member of 
the IL-1 receptor family (Dinarello, 2005). 
IL-1RII is a transmembrane molecule with the extracellular feature of the IL-1R family 
lacking a cytoplasmic TIR domain (McMahan et al., 1991). Soluble versions of IL-1R 
family members also exists, however they do not initiate signal transduction 
(reviewed in (Barksby et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 1.1: IL-1 receptor-like family. 
The IL-1 receptor-like family includes soluble and 
transmembrane receptors. They share the common feature of 
three immunoglobulin-like motifs within the extracellular 
domain, linked by an α-helix to an intracellular Toll/IL-1R
homology domain (red box). Members of this family include the 
type I and type II IL-1 receptors (IL-1RI and IL-1RII), the IL-18 
receptor (IL-18Rα), their accessory proteins IL-1RAcP and IL-
18Rβ, the IL-33 receptor (ST2), single Ig-domain containing IL-
1R related (SIGIRR) and others (such as IL-1Rrp2 and 
TIGIRR). Soluble receptors lacking the transmembrane and 
cytosolic parts of protein are also exists. 
IL-1RII 
IL-1RI 
IL-1RAcP 
IL-18Rα 
IL-18Rβ 
IL-33Rα 
IL-1Rrp2 
TIGIRR 
SIGIRR 
Ig like domain 
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sIL-1RI, sIL-1RAcP, sIL-18Rα, 
sIL-18Rβ, sIL-33Rα (sST2), sIL-1Rp2  
sIL-1RII 
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1.3.1. Regulation of the biological activity of IL-1 like cytokines 
Control of IL-1 family member expression occurs primarily through processing of the 
precursor cytokine into the active form and its subsequent release (Novick et al., 
1999; Kim et al., 2000). In addition to controlled expression and release, activities of 
IL-1 family members are also regulated by soluble receptors, natural antagonists and 
inhibitors. IL-1 activities are also regulated by IL-1RII. IL-1RII lackes a cytoplasmic 
TIR domain (McMahan et al., 1991) and functions as a regulatory receptor (Lang et 
al., 1998). IL-1RII, binds IL-1α/β as a decoy receptor and can not initiate signal 
transduction (Lang et al., 1998; Colotta et al., 1993). Two mechanisms have been 
described for IL-1RII which modulate the responsiveness of cells to IL-1: One is 
ligand sequestration (Colotta et al., 1994), and the other one is competition for the 
co-receptor (Lang et al., 1998; Mantovani et al., 2001). Soluble versions of IL-1R 
family members are well documented (reviewed in (Barksby et al., 2007). Soluble 
versions of IL-1 receptor family members exert regulatory functions by sequestering 
cytokines. Respective soluble receptors bind to IL-1, IL-18 or IL-33; they do not 
initiate signal transduction (reviewed in (Barksby et al., 2007). Moreover the soluble 
forms of co-receptors enhances the ability of soluble type I and soluble type II 
receptors to inhibit cytokine action (Lang et al., 1998; Smith et al., 2003; Smeets et 
al., 2003). 
In addition to soluble receptors IL-1 induced signaling via the IL-1RI receptor can be 
blocked by the binding of the receptor antagonist, IL-1Ra. The biological activity of IL-
18 is also controlled by IL-18 binding protein (IL-18BP) (Novick et al., 1999; Kim et 
al., 2000). IL-18 BP is a constitutively expressed and secreted natural inhibitor (not a 
receptor) of IL-18 activity. IL-18BP possesses a high-affinity binding site and 
neutralizes IL-18 (reviewed in (Dinarello et al., 2003). Interestingly, IL-18BP 
expression in keratinocytes and intestinal cell lines is up-regulated in response to 
IFN-γ (Paulukat et al., 2001), indicating a negative feedback loop for IL-18-induced 
IFN-γ production by Th1 cells. The IL-1 homologue, IL-1F7, also binds to IL-18BP 
and it has been proposed that it plays a role as a negative regulator of IL-18 activity. 
When bound to IL-18BP, IL-1F7 can form a complex with IL-18Rα chain preventing 
the formation of a functional receptor complex (Carroll et al., 2008; Bufler et al., 
2002).  
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1.3.2. Signaling of the IL-1 family: the MyD88/IRAK/TRAF6 module 
1.3.2.1. IRAK recruitment to the receptor complex  
After ligand binding and formation of the heterodimeric receptor complex, presumably 
the close spatial association of the two TIR domains allows homotypic protein–
protein interactions of the TIR domains. As a consequence, probably the 
conformation of the TIR domains is altered, or the combination of the cytoplasmic 
domains creates novel scaffolds. This is allowing an interaction of the adapter 
proteins MyD88 with the TIR domains at conserved surface patches (reviewed in 
(Martin and Wesche, 2002). MyD88, mediates a homophilic interaction with the TIR 
domains of receptor and co-receptor complex (Muzio et al., 1997; Wesche et al., 
1997a; Janssens et al., 2002), possibly as a dimer (Burns et al., 1998). Recruitment 
of MyD88 leeds to the recruitment and activation of down stream molecules of the 
IRAK family of protein kinases namly IRAK-1, 2 and 4 (reviewed in (Akira and 
Fig. 1.2: Regulation of signaling in the IL-1 receptor system. 
IL-1RI binds IL-1α or IL-1β and then interacts with IL-1RAcP to form a heterodimeric signaling 
receptor complex. Receptor and co-receptor each contribute an individual TIR domain. Soluble 
type I or type II, IL-1 receptors and membrane-inserted type II IL-1R regulate IL-1 responsiveness 
by sequestering ligand or IL-1RAcP. 
IL-1 α/β 
IL-1RII 
IL-1RI 
Receptor complex
IL-1/IL-1RI 
Receptor complex 
IL-1RAcP IL-1RI 
IL-1RII 
Receptor complex 
sIL-1RII sIL-1RI 
Receptor complex
IL-1/sIL-1RI 
Receptor complex 
sIL-1RAcP sIL-1RI sIL-1RII 
Receptor complex 
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Takeda, 2004) via their death domains (reviewed in (Liew et al., 2005). In addition 
Tollip mediated translocation of IRAK-1 to the active IL-1R complex is also reported 
(Xiao et al., 1999; Burns et al., 2000).  
1.3.2.2. IRAK phosphorylation and departure from the receptor complex 
As, IRAK-1 binds MyD88 at the receptor complex, it gets phosphorylated, both by the 
related kinase IRAK-4 as well as by autophosphorylation. IRAK-4 mediated 
phosphorylation of IRAK-1 (Burns et al., 2003) triggers IRAK-1's own kinase activity, 
resulting in multiple autophosphorylation events (Cao et al., 1996; Kollewe et al., 
2004). Both IRAK-4 and IRAK-1 then dissociate from MyD88 rapidly and interact with 
tumor necrosis factor receptor (TNFR)- associated factor-6 (TRAF6) (reviewed in 
(O'Neill, 2008).  
1.3.2.3. Formation of the IRAK/TRAF6 signalosome 
The interaction of the activated IRAKs with the adaptor protein TNF receptor-
associated factor 6 (TRAF6, an E3 ubiquitin ligase) induces activation of TRAF6. 
TRAF6 is then thought to auto-ubiquinate, attaching K63-polyubiquitin to itself 
(reviewed in (Vallabhapurapu and Karin, 2009). K63-polyubiquitinated TRAF-6 then 
recruits already preexisting complexes of TGF-β-activated kinase 1 (TAK1) and two 
TAK1 binding proteins, TAB2 and TAB3 (Jiang et al., 2002; Takaesu et al., 2000) 
through the recognition of polyubiquitin chains on TRAF6 by highly conserved zinc 
finger domains in TAB2 and TAB3. This activates TAK1 which then couples to the 
inhibitor of NF-κB (IκB) kinase (IKK) complex. Phosphorylated IRAK1 is degraded by 
proteasomes after recognition of specific phosphorylated amino acids on IRAK-1 by 
ubiquitin ligases (Ordureau et al., 2008). The Pellino proteins might also be involved 
in degradatation of activated IRAKs resulting in termination of TLR signaling 
(reviewed in (Moynagh, 2009).  
1.3.2.4. Activation of NF-κB and JNK/p38 MAPKs 
The interaction of K63-polyubiquitinated TRAF6 and TAK1 complex is believed to 
induce the dimerization, autophosphorylation and activation of TAK1. Activated TAK1 
then interact with the inhibitor of NF-κB (IκB) kinase (IKK), which contains the 
scaffold protein NF-κB essential modulator (NEMO) and IKK2, the kinase responsible 
for phosphorylation of IκB. TAK1 also couples to the upstream kinases for p38, JNK 
and ERK1/2 leading to activation of NF-κB, JNK/p38, MAPKs and ERK1/2 (reviewed 
in (Moynagh, 2009). Activated NF-κB and other transcription factors can translocate 
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to the nucleus and mediate an increase in inflammatory cytokine gene expression, 
leading to pro-inflammatory responses.  
The role of the TAK1:TAB1/2/3 complex in IKK activation remains controversial, 
although it is generally agreed that this complex is needed for JNK and p38 
activation. Indeed, a TAK1:TAB1 fusion protein is constitutively active and capable of 
stimulating AP-1 activity (reviewed in (Vallabhapurapu and Karin, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3: Proposed model of TLR/IL-1R-dependent activation of NF-κB and MAPK pathways. 
Ligand binding to IL-1R complex triggers the recruitment of MyD88 via a homophilic TIR-TIR 
interaction. MyD88 brings IRAK-4 into the receptor complex. In addition, preformed Tollip/IRAK-1 
complexes are recruited to the receptor, which allows IRAK-1 to bind MyD88 via its death domain. In 
this way, IRAK-1 and IRAK-4 come in close proximity, which allows IRAK-4 to phosphorylate IRAK-1 
on critical residues that are necessary to trigger IRAK-1. (a) The stimulation of TLRs or IL-1R 
promotes the association of Pellino proteins with IRAK1 and TRAF6. The K63-linked 
polyubiquitylation (Ub) of TRAF6 facilitates recruitment and activation of a pre-associated TAK1–TAB 
complex; (b) IRAK1 phosphorylates (P) Pellino proteins, leading to activation of their E3 ligase activity 
and Pellino-mediated K63-linked polyubiquitylation of IRAK1; (c) The NEMO binds to 
polyubiquitylated IRAK1, bringing the IKK and TAK1 complexes into close proximity; (d) TAK1 
activates the IKKs, resulting in the phosphorylation (P) of the inhibitory IκB proteins and enabling for 
translocation of NF-κB into the nucleus; (e) In addition to interacting with and activating the IKK 
complex, TAK1 can also trigger the ERK1/2, p38 and JNK MAPK pathways. The MAPK pathways 
activate several transcription factors that co-operate with NF-κB to induce the expression of a range 
of IL-1R/TLR-responsive genes. Figure is taken from (Moynagh, 2009). 
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In addition to the TAK1 dependent NF-kB activation, co-existence of the parallel IL-1-
mediated MEKK3-dependent signaling pathways has recently been reported for NF-
kB activation (Yao et al., 2007). These two pathways are regulated at the level of 
IRAK modification. The TAK1-dependent pathway causes IKKα/β phosphorylation 
and IKKβ activation, leading to classic NF-kB activation through IκBα phosphorylation 
and degradation. The TAK1-independent MEKK3-dependent pathway induces IKKγ 
phosphorylation and IKKα activation, resulting in NF-κB activation through IκBα 
phosphorylation and subsequent dissociation from NF-κB but without IκBα 
degradation (Fraczek et al., 2008).  
Presently, there is no information available that the mechanisms discussed here for 
the IL-1R complex are different for the IL-18 receptor complex. As far as investigated, 
no qualitative differences in the major signal pathways activated by IL-18 were 
revealed to those reported for IL-1 (Thomassen et al., 1998). The mode by which IL-
33 exerts its effect has not been fully established but it probably acts similarly to other 
members of the IL-1 family, specifically IL-1β and IL-18 (reviewed in (Kakkar and 
Lee, 2008). 
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1.4. Aims of the study 
Interleukin-33 is a member of the IL-1 family of cytokines which is involved in health 
and disease. Understanding the immunobiology of IL-33 promises to provide further 
insight not only into the normal function of this novel mediator of the immune system 
but also into the pathogenesis of diseases such as asthma, rheumatoid arthritis, 
atherosclerosis and cardiovascular disorders. This knowledge may help to identify 
novel therapeutic targets to treat these diseaes.  
 
The experiments of this study address two central aspects of the biology of IL-33. 
First, they focus on the cell responding to the cytokine, where it was the aim to  
• identify and characterize the components of the IL-33 receptor complex 
required for signal transduction.  
• compare signaling and gene regulation of IL-33 with that of IL-1 and IL-18 
using micro-arrays.  
And second, they focus on the cell producing IL-33, where it was the aim to 
• clarify whether precursor-IL-33 requires caspase 1 processing to be able to 
bind to the IL-33R on responder cells and exert its biological functions as a 
classical cytokine. 
• investigate whether IL-33 is released from intact cells as full length molecule 
or after proteolytical maturation comparable to other members of the IL-1 
family.  
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Chapter 2 
 
Materials and Methods 
 
 
2.1. Mammalian cell culture  
All murine thymoma cell lines (EL-4 6.1, D6/76 (a clone of EL-4 cells lacking IL-
1RAcP, generated by von Hoegen (von Hoegen et al., 1989), 6-IRAK-19 cells (EL-4 
6.1 cells stably transfected with a plasmid encoding human IRAK-1 generated by J. 
Knop, unpublished) and EL-4 1B1 cells (EL-4 6.1 cells stably transfected with mIL-
33Rα encoding plasmid, generated in this laboratory by Jessica Endig during her 
Diploma thesis) were cultured in RPMI1640, with the addition of 2 mM L-glutamine, 1 
mM Na-Pyruvate, non essential amino acids, and 5 % fetal calf serum (all PAA, 
Germany) at 5% CO2 in a humidified incubator at 37 ºC. Cells were passaged after 
every 2-3 days by diluting the cultures to 5 x 104 cells/ml with fresh medium. 
Human HEK293RI (Cao et al., 1996) cells were maintained in DMEM medium with 
addition of 2 mM L-glutamine and 10% FCS at 10% CO2 in humidified incubator. 
Murine bone marrow derived mast cells were generated by Prof. Dr. Michael Huber 
(Max Plank Institute of Immunobiology, Freiburg Germany) as described recently 
(Gimborn et al., 2005). 
Mouse keratinocytes (generated from IL-1 receptor knock out animals by Prof. 
Werner Falk, University of Regensburg, Germany) murine fibroblasts, NIH 3T3, 
mouse embryonal fibroblasts (IRAK- control) and L929 were cultured and maintained 
in DMEM medium with the addition of 2 mM L-glutamine and 10% FCS (all PAA, 
Coelbe, Germany) at 10% CO2. Cells were passaged after 2-3 days by 
trypsinization. 
Mouse T cell lines D10G4.1 and D10N were cultured in RPMI1640, supplemented 
with 2 mM L-glutamine, 1 mM Sodium-Pyruvate, non essential amino acids, 2 μg/ml 
Concanavalin A (Pharmacia, Freiburg, Germany), 3 x 10-5M β-mercaptoethanol, 
interleukin-2 (as 10% (v/v) conditioned medium mouse spleen cells stimulated with 
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Concanavalin A for 1 day), 1 ng/ml hIL-1β (a kind gift from Dr. D. Boraschi, Institute 
for Biomedical Technology, Pisa, Italy) and 10% fetal calf serum (PAA, Coelbe, 
Germany) at 5% CO2 in humidified incubator at 37 ºC. For stimulation cells were 
cultured overnight without IL-2 and IL-1. Cells were passaged after every 2-3 days by 
diluting the cultures to 5 x 105 cells/ml fresh medium.  
Human U937 cells, mouse B cells (WEHI 231 and 70Z/3) and macrophages 
(P388D1, RAW264.7) were cultured in RPMI1640, with the addition of 2 mM L-
glutamine, non essential amino acids, 5 x 10-5 M β-mercaptoethanol, and 5% fetal 
calf serum (all PAA, Coelbe, Germany) at 5% CO2 in humidified incubator. Cells were 
passaged after every 2-3 days. 
Dendritic cells (Xs106) were cultured in IMDM medium, with the addition of 1 mM Na-
Pyruvate, 5% (v/v) supernatant of NS47 cells and 10% fetal calf serum (PAA, Coelbe, 
Germany) at 5% CO2 in a humidified incubator at 37 ºC. Cells were passaged after 
every 2-3 days. 
Unstimulated and CD3- stimulated (for 6 hours) Th0, Th1, Th2 and Th17 cells were 
obtained from Prof. Michael Lohoff, Microbiology, Philip University Marburg, 
Germany, as frozen cell pellets. 
2.2. Transient transfections 
EL-4, EL-41B1, 6-IRAK-19 and EL-4 D6/76 cells were transiently transfected with 
plasmids as indicated in figure legends using the DEAE dextran-chloroquine 
transfection method as previously described (Knop et al., 1998). Briefly, cells were 
seeded at cell density of 5 x 105 cells/ml a day before transfection. For transfection 
cells were collected by centrifugation (500 x g for 8 minutes), washed with PBS (137 
mM NaCl + 2.7 mM KCl +10 mM Na2HPO4 + 1.76 mM KH2PO4 and pH 7.4 with HCl, 
autoclaved) and resuspended in TBS (25 mM Tris + 123 mM NaCl + 5 mM KCl + 0.7 
mM CaCl2.2 H2O + 0.5 mM MgCl2.6 H2O + 0.6 mM Na2HPO4. 2H2O, pH 7.4 with HCl 
and filtre sterlized) at the cell density of 5 x 106 cells per ml. 15 μl DEAE dextran (10 
mg/ml in H2O and filter sterlized, Pharmacia) and 12 μl chloroquine (2 mg/ml in water 
and filter sterilized, Sigma) were diluted with 273 μl of TBS. One μg of required 
plasmid DNA (in total) as indicated in figures was diluted in 300 μl of TBS. Total 
amount of plasmid DNA was always adjusted to the same amount using empty vector 
in all assays. This DEAE dextran-chloroquine solution and diluted DNA were mixed 
just before addition to the cells. Cells were collected by centifugation at 500g for 4 
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minutes at room temperature and supernatant was discarded. Cells were 
resuspended in 600 μl of DEAE dextran-chloroquine-DNA solution and allowed to 
rotate on rotor at room temperature for 30 minutes. Cells were centrifuged as earlier, 
supernatant was discarded and cells were washed twice with 1 ml medium (each 
wash). After washing cells were cultured in 10 ml of RPMI 1640 medium with 1 x 
penicilline/streptomycin (100 x stock, PAA, Cölbe, Germany) untill further use as 
described in each experiment. 
HEK293RI cells were transfected by a modified polyethylenimine (PEI) transfection 
method (Ehrhardt et al., 2006). Briefly 3.6 x 106 cells were seeded into 56 cm2
 
Petri 
dishes in a volume of 10 ml medium. On the next day, 12 μg plasmid DNA were 
diluted with serum-free medium to a total volume of 330 μl and mixed with 30 μl of a 
1 mg/ml (pH 7) PEI (Sigma-Aldrich) solution, and allowed to rest for 10 minutes. The 
cell culture medium was adjusted to 3 ml prior to addition of the DNA-PEI mixture. 
After the following incubation for 4 hours at 37 ºC in a CO2 incubator, medium was 
topped up to 10 ml and the cells were incubated overnight. 
Murine L929 cells were also transfected with PEI method as described for 
HEK293RI. For transfection of keratinocytes 3 x 106 cells / plate and 60 μl PEI was 
used. 
2.3. Cytokines and other recombinant proteins 
hIL-1α was a kind gift from Dr. J. Sims, formerly Immunex Seattle, USA. hIL-1β was 
a kind gift from Dr. D. Boraschi, Institute for Biomedical Technology, Pisa, Italy. mIL-
18 was purchased from MBL, Japan. Recombinant mIL-33 and hIL-33 were 
purchased from Alexis, Lörrach, Germany. mIL-33-Bio was a kind gift from Prof. W. 
Falk, University of Regensburg, Germany. TNFα was a kind gift from BASF AG, 
Ludwigshafen, Germany. LPS was purchased from Difco Laboratories, USA. 
mST2:hIgG(Fc), was purchased from R & D Systems, Wiesbaden, Germany. 
Full length cytokines (IL-1α/β, IL-18, and IL-33) and soluble receptors (sIL-
33Rα:hIgG(Fc) and IL-33 cytokine trap, sIL-33Rα-sIL-1RAcP:hIgG(Fc) fusion 
proteins) were expressed in HEK293RI cells or keratinocytes. Cytokines were 
immunoprecipitated from cell lysates or supernatants (where specified) using anti-
Flag M2 agarose (Sigma) or anti-Myc agarose (Sigma). Soluble IL-33Rα:hIgG(Fc) 
fusion protein and IL-33 cytokine trap were precipitated from cell free supernatants 
using protein A sepharose (Sigma). Precipitated proteins were eluted from the beads 
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by incubation with 100 mM glycine pH 2 and pH was neutralized with 0.1 volume of 
1.5 M Tris pH 8.6. 
2.4. Measurement of cytokine production  
For determination of cytokine production, transfected and untransfected EL-4, EL-4 
1B1 or EL-4 D6/76 cells were seeded into 96 well plates at density of 2.5 × 104
 
cells 
per well in 200 μl of culture medium. 24 hr after transfection cells were either kept 
unstimulated or stimulated with varying concentrations (as indicated in figures) of 
rmIL-33, rhIL-1β, rmIL-18 (MBL, Japan) or incubated with anti-Myc agarose 
(unstimulated) or indicated amounts of full length mIL-33 captured on anti-Myc 
agarose (Sigma) in the presence of 0.5 μM Calcium ionophore A 23187 for 16 hours 
at 37 ºC. Mouse IL-2 was determined in the supernatants by enzyme linked 
immunosorbent assay (ELISA, OptEIA mIL-2 Set, Becton Dickinson, Heidelberg, 
Germany). 
HEK293RI cells were transfected with IL-33Rα or empty vector using the PEI 
transfection method. 16-20 hours after transfection, cells were seeded into 96 well 
plates at 2.5 × 104
 
cells per well, and after additional 4 hours stimulated with different 
concentrations of mIL-33. After 16-20 hours of stimulation human IL-8 concentration 
in the cell culture supernatants was determined by ELISA (hIL-8 Cytoset, Biosource / 
Invitrogen, Karlsruhe, Germany).  
Mouse IL-6 was measured in supernatants from bone marrow-derived mast cells 
using an IL-6 ELISA kit (OptEIA TM mIL-6 ELISA set, Becton Dickinson Biosciences, 
Germany). 
If the anti- mouse IL-1RAcP mAb 4C5 (kind gift of Dr. N. Dimoudis, Roche, 
Penzberg) was used in inhibition studies, the cells were always preincubated with the 
neutralizing antibody for 30 min at 37 ºC before cytokines were added. The rat IgG 
mAb RA3-6B2 (anti-B220) served as an isotype control. 
2.5. MTT assay / D10 assay 
D10 cells need IL-1 or IL-33 for proliferation. In order to measure the cell 
proliferation/cell viability, the MTT Formazan-assay was performed. This assay 
measures the activity of mitochondrial dehydrogenases in living cells. (4, 5-
dimethylthiazole-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) is taken up by the 
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cells and metabolized in the presence of NADH, resulting in NAD and blue formazan 
crystals. 
D10G4.1 cells were seeded in 96 well cell culture plates (2 x 104 cell in 200 μl/well 
RPMI medium) with or with out IL-1 or IL-33 and allowed to grow for three days at 37 
ºC with 5% CO2. On the third day medium was reduced to 100 μl and 10 μl of MTT 
solution (5 mg/ml, Sigma) was added. Cells were incubated in the presence of MTT 
for 90 minutes. Cells were spun down and supernatant was removed. The blue 
tetrazolium crystals were dissolved by adding 100 μl of isopropanol containing 5% 
formic acid to each well followed by sonication in water bath sonicator. The plates 
were analyzed photometrically at 570 nm excitation in an ELISA reader. 
MTT assay was also performed for EL-4 cells and HEK293RI cells to normalize the 
difference of live cell number in different wells. For this purpose stimulated or 
unstimulated cells were incubated as described for ELISA. After removing the cell 
supernatant for determination of cytokines by ELISA, the cells were incubated with 
MTT and the assay was performed as described earlier. 
2.6. Reporter gene assay 
Cells were transfected with 3 x NF-kB-Luc plasmid (0.5 μg / 5 x 106 EL-4 cells/ 
derivatives and 1μg / 3.6 x 106 HEK293RI or L929 cells) along with other plasmids as 
indicated in each experiment. 0.5 million transfected EL-4 cells (4 hours after 
transfection) or 50.000 HEK293RI or L929 cells (next day) were seeded in 96 well 
plate and stimulated if needed in 300 μl (EL-4) / 200 μl (HEK293RI or L929) of total 
volume and incubated overnight at 37 ºC in CO2 incubator. Next day cells were 
centrifuged in 96 well plate at 1250rpm for 8 minutes and supernatant was discarded. 
Cells were washed with 250 μl PBS and lysed with 35 μl / well of 1 x passive lysis 
buffer (Promega) directly in 96 well plate by incubation for 15 minutes on ice. Cell 
debries were removed by centrifugation of 96 well plate at 3500rpm for 15 minutes at 
4 ºC and luciferase activity was measured 1 sec after addition of 100 μl of substrate 
solution (436 µM D-Luciferin, (Acid free Biomol #54568) + 436 µM NaOH (Luciferin in 
5 ml Water + NaOH solution drop by drop) + 20 mM Tricin + 2.67 mM MgSO4 . 7 H2O 
+ 1.07 mM Magnesiumcarbonathydroxid . 5H2O + 33.3 mM DTT + 530 µM ATP, 
Disodiumsalt Grade 1, Sigma #A2383 + 290 µM Coenzym A, Trilithiumsalt Dihydrat 
MP Biomedicals #100493) to 25 μl of cell lysate, Luciferase activity was measured for 
10 sec using a microplate luminometer (MicroLumatePlus LB 96V, Berthold 
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Technologies, Bad Wildbad, Germany) using WinGlow software provided with 
instrument.  
For activation of NF-κB in response to full length IL-33, its N and C terminal 
fragments transfected EL-41B1 cells (0.5 x 106) were incubated either with anti-Myc 
agarose (unstimulated), or with indicated amount, flmIL-331-266, mIL-331-175, mIL-
33175-266, flIL-33D175A captured on anti-Myc agarose (Sigma) or recombinant IL-33 
(Alexis). If IL-33Rα:Fc fusion protein was used, IL-33 was preincubated of 30 minutes 
with indicated amount of soluble IL-33Rα:Fc before stimulation. 
2.7. Measurement of protein concentration from cell lysate 
The protein concentrations from cell lysates were determined by the Bradford method 
using Bio-Rad Protein Assay reagent (dye reagent concentrate, Cat.No. 500-0006, A 
Coomassie Brillant Blue G-250 in Phosphoric acid and Methanol). BSA was used as 
standard protein and the reaction was carried out in 200 μl volume in 96 well plate. A 
protein standard of BSA was prepared from 80 μg / ml to 0 μg / ml (i.e. 80, 60, 40, 30, 
20, 10 , 5 and 0 μg / ml) and 2 μl proteins from cell lysates were diluted with water to 
100 μl. Bio-Rad Protein Assay reagent (2 volume) was also diluted with water (3 
volume). 100 μl of the standards and samples were mixed with equal volume of 
diluted Bio-Rad Protein Assay reagent and alowed to stay for 5 minutes. The 
absorbance at 595 nm was measured in an ELISA reader (SPECTRAmax® 340 
PC384). The protein concentrations were calculated by comparing the absorbence 
from test samples with that of standard using SOFTmax PRO 4.3 LS software 
provided with the instrument.   
2.8. Western blotting 
Cells were stimulated or kept unstimulated as described in figure legends and lysed 
by 500 μl lysis buffer (50 mM HEPES (Acid free) + 250 mM NaCl + 20 mM β-
Glycerophosphat + 5 mM Na2-4-Nitrophenylphosphate . 6H2O + 1 mM Na2EDTA . 2 
H2O pH 7.9 and 10% (w/v) Glycerol + 0.5% (w/v) IGEPAL = NP-40 (Sigma) + 1 × 
Protease inhibitors complete (Roche) + 5 mM DTT + 1 mM Na-Orthovanadate) (Cao 
et al., 1996) for immunoprecipitation and Western blots), JNK assay lysis buffer (for 
JNK assay and anti JNK western blots), or by Laemmli buffer (17.6 mM Tris pH 6.8 + 
6% SDS + 30% Glycerol + 15% β-Mercaptoethanol + 0.024% Bromphenolblue, 
(Laemmli, 1970)) for p38, phospho p38, and IL-33 processing experiments). Before 
lysis, cells were washed twice with ice cold PBS. Cells were incubated with 500 μl of 
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lysis buffer for 30 min at 4 ºC with gentle rotation. For direct lysis by Laemmli buffer, 
cells were harvested by trypsinization, scrapping or centrifugation, washed with 1 ml 
PBS and heated for 20 minuts with Laemmli buffer at 95 ºC. The cell lysate was 
centrifuged at 13.000 rpm for 20 min before the supernatant was used for further 
experiment.  
Proteins were immunoprecipited when needed. Proteins from cell lysates and or 
immunoprecipitates were seperated in 7.5%-15% discontinous SDS-PAgels 
(Laemmli, 1970) using denaturing electrophorsis buffer (192 mM Glycin + 25 mM Tris 
Base, pH ~8.5 + 0.1% SDS). Proteins were transfered to PVDF membrane in a semi 
dry electroblotter. For electroblotting 1 mA current / 1 cm2 of membrane was sullplied 
for 2 hours in presence of blot buffer (192 mM Glycin + 25 mM Tris Base, pH ~8.5 + 
10% Methanol). After electroblotting, the PVDF membrane was blocked in a buffer 
containg either 5% skimmed milk or 5% BSA solution in 1 x TBS/T (20 mM Tris +137 
mM NaCl, pH 7.6 with HCl + 0.1% Tween-20)  for 1 hour at room temperature with 
gentle shacking. Thereafter the membrane was washed thrice in 1 x TBS/T buffer, 
then incubated with the primary antibody (sources and dilutions are given in table 
2.1) for overnight at 4 ºC with gentle shacking. The next day the membrane was 
washed thrice with 10 ml TBS/T (10 minutes each) and incubated with appropriate 
secondary antibody conjugated with horseraddish peroxidase for 1-2 hours at room 
temperature with gentle shacking. The membrane was washed thrice (10 min each) 
with 10 ml of TBS/T buffer and specific signals were visulized after enhanced 
chemiluminescence (ECL) reaction. 
 
Table 2.1. Primary antibodies and their dilutions used in Western blotting 
Epitope Source Species from Dilution Buffer 
Flag (bioM2) Sigma Mouse 1:500 TBS/T 
GAPDH  Santa Cruz  
sc-25778 
Rabbit 1:400 5 % MP in TBS/T 
JNK Becton Dickinson 
BD #610627 
Mouse 1:500 5 % MP in TBS/T 
Myc (clone A-14) Santa Cruz sc-789 Rabbit 1:2.000 1 % MP in TBS/T 
ST2 (IL-33Rα) MD Biosciences 
(DJ8) 
Rat 1:1000 5 % MP in TBS/T 
p38 Cell singlling 
CST :9212 
Rabbit 1:4.000 5 % BSA in TBS/T 
Phospho-p38  Cell singlling  
CST: 9211S 
Rabbit 1:1.000 5 % BSA in TBS/T 
IkB Santa Cruz sc:371 Rabbit 1:400 5 % MP in TBS/T 
Phospho IkB Cell singlling  
CST: 9246 
Mouse 1:1000 5 % MP in TBS/T 
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For ECL reaction, one ml of blot reagent A was mixed with one drop of blot reagent B 
(both Interchem, France) and poured directly on the PVDF membrane placed on 
transparent plastic sheet. The membrane was incubated for one minute at room 
temperature and covered with transparent plastic sheet. The membrane was 
exposed to camera for imaging (INTAS Chemiluminescence, Intas Science Imaging 
Instruments GmbH, Göttingen, Germany) untill the clear signal was observed.  
For second staining of the membrane the 1st antibodies were removed by incubating 
the membrane in 10 ml of the stripping buffer (25 mM Glycin-HCl, pH 2.0 + 1% SDS) 
for 30 minutes. The membrane was washed thrice with the TBS/T and 
immunostained again as described above. 
 
2.9. Immunoprecipitations 
HEK293RI or murine keratinocytes were transfected with 12 μg of mammalian 
expression plasmids or empty vector. Transfected cells were kept unstimulated or 
stimulated as described in figure legends. Cells were washed twice with 10 ml of ice 
cold PBS and lysed with 500 μl of lysis buffer (Cao et al., 1996) for 30 min at 4 ºC 
with gentle rotation. The cell lysate was centrifuged at 13,000 rpm for 20 min before 
the supernatant was incubated with antibodies for 16 hours at 4 ºC with gentle 
rotation. For anti-Flag immunoprecipitation, 15 μl of anti-Flag M2 agarose beads 
(Sigma) were used. For anti-Myc immunoprecipitation, 0.6 μg of anti c-Myc antibody 
(A-14, Santa Cruz Biotechnology, sc-789 Heidelberg, Germany) and for IL-33, 1 μg 
anti-IL-33 Nessy-1 (Alexis) with Protein A sepharose (GE Healthcare, Freiburg, 
Germany) were used instead. Beads were washed thrice with lysis buffer and once 
with PBS before being resuspended in 30 μl of Laemmli sample buffer, and heated to 
95 ºC for 10 min. Proteins were separated on a 10%-15% discontinous SDS PAgel 
Table 2.2. Secondary antibodies / reagents used in Western blotting 
Secondary reagent  Source (Concentration) Dilution Buffer 
Streptavidin-HRP conjugate  Dianova (0.5 mg/ml) 1:10000 1% MP in  TBS/T 
HRP conjugate Mouse anti Rabbit 
IgG (light chain)  
Dianova (0.8 mg/ml) 1:10000 1% MP in  TBS/T 
HRP conjugate Goat anti Rabbit 
IgG (heavy & light chain) 
Jackson ImmunoResearch 
(0.8 mg/ml) 
1:10000 1% MP in  TBS/T 
HRP conjugate Rabbit anti Mouse 
IgG (heavy & light chain) 
Jackson ImmunoResearch 
(0.8 mg/ml) 
1:10000 1% MP in  TBS/T 
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and transferred to PVDF membrane in a semi-dry fashion. Proteins were detected by 
staining with specific antibodies (anti c-Myc A-14, Santa Cruz Biotechnologies, sc-
789; anti-Flag bioM2, Sigma, F9291). 
2.10. Co-immunoprecipitation and Western blotting  
HEK293RI cells were transfected with 6 μg of pMyc-mIL33Rα and/or 6 μg of pFlag-
mIL1RAcP or any other plasmid following the PEI transfection method. 6 μg of empty 
vector pMyc-Zeo were added when only one of either plasmids was transfected. 
Transfected cells were kept unstimulated or stimulated with 10 ng/ml rhIL-1β or 100 
ng/ml rmIL-33 for 15 min at 37 ºC. Cells were washed thrice with 10 ml of ice cold 
PBS and lysed with 500 μl of lysis buffer (Cao et al., 1996) for 30 min at 4 ºC with 
gentle rotation in the absence or presence of 10 ng rhIL-1β or 100 ng rmIL-33. The 
cell lysate was centrifuged at 13,000 rpm for 20 min before the supernatant was 
incubated with 12 μl of anti-Flag M2 agarose beads (Sigma) for 16 hours at 4 ºC with 
gentle rotation. For anti-Myc immunoprecipitation, 0.6 μg of anti c-Myc antibody (A-
14, Santa Cruz Biotechnology, sc-789 Heidelberg, Germany) with Protein A 
sepharose beads (GE Healthcare, Freiburg, Germany) were used instead. Beads 
were washed thrice with lysis buffer and once with PBS before being resuspended in 
30 μl of Laemmli sample buffer, and heated to 95 ºC for 10 min. Proteins were 
separated on a 10 % SDS PAgel and transferred to PVDF membrane in a semi-dry 
fashion. Myc-tagged and Flag-tagged proteins were detected by staining with specific 
antibodies (anti c-Myc A-14, Santa Cruz Biotechnologies, sc-789; anti-Flag bio M2, 
Sigma, F9291,  Anti-IL-33Rα (Anti-T1/ST2, MD Biosciences).  
For binding of full length IL-33 to IL-33 receptor on intact cells, transfected cells were 
incubated for 1hour on ice with flmIL-33-Flag or Myc-flmIL-33-Flag (obtained from 3 
cycles of freez thawing followed by sonication from Flag tagged flIL-33 over 
expressing HEK293RI cells or empty vector trasfected cells). For anti-Myc 
immunoprecipitation anti-Myc Agarose (Sigma) was used.  
2.11. Interaction of sAcP and sIL-33Rα  
N-terminally Flag- and His(6)-tagged recombinant mouse soluble AcP (Genbank 
accession no. NM_134103) was expressed in stably transfected HEK293RI cells. 
Flag affinity agarose (Sigma–Aldrich) was loaded with sAcP by incubation with cell 
supernatant and washed. Then 50 μl of loaded gel was resuspended in 1 ml of PBS 
with 2% BSA and incubated at room temperature for 1 h with or without rmIL-33 and 
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with or without mouse sIL-33Rα:Fc (1004-MR; R&D Systems) at 1 μg/ml. Agarose 
pellets were again washed, and bound proteins were resolved by SDS/PAGE and 
blotted onto PVDF membrane. Coprecipitated sIL-33Rα:Fc was visualized by using 
horseradish peroxidase (HRP)-coupled anti-human IgG antibody (A0170; Sigma–
Aldrich). The experiment was performed in collaboration with Prof. Werner Falk at 
University of Regensburg.  
2.12. Measurement of signaling pathways  
2.12.1. cJun-N-terminal kinase (JNK) assay 
EL-4 cells were transfected with mouse IL-33Rα encoding plasmid (pMyc-mIL33Rα) 
using the DEAE dextran method. 20 hours after transfection 2 × 106
 
cells were 
stimulated with rhIL-1β (10 ng / ml) or rmIL-33 (200 ng / ml) for 0, 4, 8, 12, 16, 20, 24, 
28, 32, and 36 minutes at 37 ºC. Cells were harvested by centrifugation for 5 minutes 
at 500g at 4 ºC, washed with cold PBS and lysed with 60 μl of lysis buffer (20 mM 
Tris-HCl pH 7.4, 1 mM EGTA, 1 mM EDTA, 2 mM DTT and 0.5 % Triton X-100). 
Protein concentration was measured with Bio-Rad Protein Assay Reagent (Bio Rad 
Laboratories, Munich, Germany) as described earlier. 10 μg of lysate was subjected 
to an in vitro kinase assay in the presence of kinase buffer (25 mM HEPES pH 7.5, 
10 mM MgCl2, and 25 μM ATP), 2 μCi γ[32P]-ATP and 1.3 μg of GST-cJun substrate 
(amino acids 1-79, Stratagene, Amsterdam, The Netherlands) in 40 μl of total 
reaction volume. The assay was performed at 30 ºC for 30 min, stopped by addition 
of Laemmli-buffer followed by heating at 95 ºC for 10 min. Proteins were separated 
on a 12% SDS gel, which was subsequently dried and exposed over night to a film 
for autoradiography. Parallel samples were run on gels, electroblotted and total 
amount of JNK was measured by Western blotting.  
2.12.2. IRAK-1 autophosphorylation activity 
6-IRAK-19 cells (generated by J. Knop during his Ph D thesis at MH Hannover) were 
transiently transfected with a plasmid encoding mIL-33Rα-chain alone or in 
combination with a plasmid encoding ΔC-IL-1RAcP. 24 hr after transfection 2 x 107 
cells were either left unstimulated or were stimulated for 15 min at 37 ºC with either 
10 ng/ml rhIL-1β or 100 ng/ml rmIL-33. Subsequently, cells were lysed and IRAK-1 
was immunoprecipitated using the mAb 2A9 (kind gift of Z. Cao and H. Wesche, 
formerly Tularik), and subjected to an in vitro kinase assay as described previously 
(Kollewe et al., 2004). Briefly, washed immunoprecipitates were resuspended in a 
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kinase reaction mixture containing 20 mM HEPES, pH 6.5, 150 mM NaCl, 5 mM 
MgCl2, 5 mM MnCl2,1 µM ATP, and 1 µCi of [γ-32P]-ATP and incubated for 20 min at 
30 ºC. The kinase reaction was stopped by heating in SDS sample buffer. 
Phosphorylated proteins were separated by SDS-PAGE. The gels were dried, and 
autoradiographies were performed. 
2.12.3. Measurement of phosphorylation and degradation of IκBα  
EL-41B1 cells (2.5 x 106/point) were stimulated with full length mIL-33 (eluted with 
glycine-HCl after immunoprecipitation of flmIL-33 with anti-Myc Agarose) for 0, 5, 10, 
15 and 30 min at 37 ºC. Phospho IκBα and total IκBα were detected by Western blot 
analysis using anti-Phospho IκBα (BD Biosciences) and anti- total IκBα (Santa Cruz 
Biotechonology) antibodies.  
2.13. Heat inactivation of IL-33 
Recombinant mIL-33 (Alexis, USA) was diluted in RPMI medium to 20 ng/ml and 200 
ng/ml and  IL-1β was diluted to 200 pg/ml. The diluted IL-33 and IL-1β were heat 
treated for 10 or 30 minutes at 95 ºC and used for stimulation of EL-4 cells.  
2.14. Pull-down assay 
IL-33Rα-IL-1RAcP:hIgG(Fc) or IL-33Rα:hIgG(Fc) fusion proteins were expressed in 
HEK293RI cells by transient transfection. Cells were incubated for 3 days after 
transfection and fusion proteins were precipitated by incubating cell supernatants 
with protein A agarose (1μl / ml) for overnight at 4 ºC. Precipitates were washed with 
lysis buffer and again incubated (20 μl / ml of cell lysate) for over night at 4 ºC with 
cell lysate from stimulated keratino cells, expressing N-Myc and/or C-terminaly Flag 
tagged mIL-33. Beads were washed thrice with lysis buffer followed by washing with 
PBS. All the liquid was removed, 30 μl of Laemmli buffer (3x) were added and heated 
for 10 minutes at 95 ºC. Proteins were separated on 12.5% SDS-PAGE, transfered to 
PVDF membrane and IL-33 was detected by anti-Flag and/or anti- Myc staining by 
Western blot. 
2.15. In vitro caspases cleavage assays 
N-terminally Myc- and C-terminally Flag-tagged flmIL-331-266, its mutant IL-33D175A, 
flIL-1β and flIL-18 were immunoprecipitated from cell lysate of transiently transfected 
HEK293RI using anti-Flag agarose. Beads were washed thrice with lysis buffer 
followed by two washes with the caspase reaction buffer (50 mM HEPES, pH 7.4, 
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100 mM NaCl, 0.1% CHAPS, 1 mM EDTA, 10% glycerol, 10 mM DTT). flmIL-331-266, 
its mutant IL-33D175A and flIL-1β captured on anti-Flag agarose were incubated with 
various amounts of caspase 1 (Calbiochem) in 20 μl caspase recaction buffer for 4 hr 
at 30 ºC. flmIL-331-266, IL-33D175A and flIL-18 were incubated with various amounts of 
caspase 3 (kind gift of G. Meiss, Biochemistry, JLU Giessen). Reaction mixture was 
heated with 20 μl of 3x SDS-PAGE sample buffer and proteins were detected by 
Western blot analysis using anti-Flag (Sigma) or anti-Myc (Santa Cruz 
Biotechnology) antibodies. 
2.16. Cleavage of IL-33 by apoptotic U937 cell lysate 
Caspase 3 was activated by induction of apoptosis in U937 cells (by incubation with 1 
ng/ml TNFα and 50 μg/ml cycloheximide for 1.5 h). Washed cells were lysed by 3 
cycles of freeze thawing followed by sonication in caspase reaction buffer. flmIL-33 
and mutant flmIL-33D175A were incubated with lysates from control cells or apoptotic 
cells for 0, 10 or 30 minutes at 30 ºC. Proteins were denatured in sample buffer and 
seperated on 12.5% SDS PAGE. IL-33 was detected by anti-Flag or and anti-Myc 
staining by Western blotting. 
2.17. Nuclear translocation studies 
N-terminally Myc-tagged IL-331-266, IL-331-175, IL-33176-266 or IL-33D175A were 
expressed in HEK293RI or murine keratinocytes after transient transfections. Cells 
were lysed with lysis buffer (Cao et al., 1996) as described above. Nuclear and 
cytosolic fraction were separated by centrifugation at 500g for 10 minutes. The 
separated nuclei were washed thrice with lysis buffer and lysed by sonication in 200 
μl KE buffer (20 mM HEPES, pH 7.9 + 400 mM NaCl + 1 mM EDTA, pH 8.0 + 1 mM 
EGTA, pH 7.6 + 1 mM DTT and 1 mM PMSF). The IL-33 was detected from cytosolic 
or nuclear fraction by Western blotting using anti-Myc antibodies. 
2.18. RT-PCR analysis  
2.18.1. RNA isolation 
Total RNA from stimulated or unstimulated mammalian cells was isolated using 
NucleoSpin® RNA II (MACHEREY-NAGEL GmbH & Co. KG, Düren Germany) RNA 
extraction kit following manufactures recommendations. For RNA extraction 1 x 106 - 
5 x 106 cultured cells were collected by centrifigation, washed with PBS and lysed by 
direct addition of the RA1 buffer (350 μl RA1 buffer + 3.5 μl β-mercaptoethanol) to 
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cell pellet followed by vigorous vortexing. Viscosity of the cell lysate was reduced by 
filtration of the cell lysate through NucleoSpin® filter columns. The binding conditions 
were adjusted by addition of 350 μl of the 70% ethanol and homogenization by 
pipetting in and out. The nucleotides were bound to silica membrane by loading the 
mixture to NucleoSpin® RNA II column and centrifugation for 30 sec at 11000g. The 
membrane was desalted by addition of 350 μl of membrane desalting buffer (MDB). 
DNA was digested by 15 minutes incubation of membrane at room temperature with 
95 μl of DNAase reaction mixture (containing DNAse in 1 x reaction buffer). DNase 
was inactivated by addition of the 200 μl of RA2 buffer. The membrane was washed 
twice by addition of 600 μl and 250 μl of RA3 buffer and dried by an additional 
centrifugation of 2 minutes at 11000g. RNA was eluted with 60 μl of RNase free 
water. 
Quantity and quality of RNA was determined by spectrophotometer by measuring OD 
at 260 and 280 (1 OD at 260=40 μg RNA), running on agarose gel or by Bioanalyzer 
(Agilent technologies). RNA was stored at -80 ºC untill further use. 
2.18.2. cDNA synthesis 
cDNA was synthesized by reverse transcription reaction using M-MuLV H- reverse 
transcriptase (Fermentas, Germany). The reverse transcription reaction contains 1 x 
RT buffer (Fermentas, Germany), 100 ng/μl of RNA, 5 μM oligos (randam hexamer), 
1 mM dNTPs (each) and 10 units of reverse transcriptase (Fermentas, Germany) in 
DEPC water. The reverse transcription reaction was carried out in 20 μl of total 
volume. Two μg of RNA and oligos (5 μM final) were diluted with DEPC water and 
incubated at 70 ºC for 5 minutes. The reaction tube was kept on ice and 4 μl of 5 x 
RT buffer and 2 μl of dNTPs mix (from 10 mM each) were added. The reaction 
mixture was incubated at 37 ºC for 5 minutes and 200 units of M-MuLV H- reverse 
transcriptase was added. The reverse transcription was carried out at 42 ºC for 60 
minutes followed by inactivation of reverse transcriptase at 70 ºC for 10 minutes. The 
cDNA was used directly for PCR or stored at –20 ºC untill further use. 
2.18.3. PCR amplification 
Different cell types were seeded (2 x 106 cells) and either kept unstimulated of 
stimulate with IL-1β, LPS or other stimuli as described in table 3.1. The next day cells 
were harvested (by centrifugation for suspenstion cells or by trypsin treatment for 
adherant cells) and total RNA was isolated using NucleoSpin® RNA II  (MACHEREY-
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NAGEL GmbH & Co. KG, Düren Germany) RNA extraction kit. cDNA was generated 
using random hexamer primers. IL-1 family receptors (hIL-33Rα, mIL-1R1, mIL-
1RAcP, mIL-18Rα, mIL-18Rβ, mIL-33Rα) and cytokines (mIL-1α, mIL-1β, mIL-18, 
mIL-33) gene expression was analyzed from resting and stimulated cells by PCR 
using specific primers. List of primers used with target genes and annealing 
temperature is given in table 2.3.  
All reactions were carried out in Eppendorf master cyclers (personal or gradient) in 
30 μl reaction volume. Master mixtures were prepared containing, 1 x PCR reaction 
buffer with MgCl2 (Fermentas), 200 μM dNTPs (each), 1 μM forward and reverse 
primers (each) and 1 unit of Taq DNA polymerase (Fermentas). Master mixture was 
divided in 0.2 ml PCR tubes (Thermo scientific) and 100 ng - 200 ng of template 
cDNA was used for each reaction. For the amplification of mIL-18Rα 200 ng of 
template cDNA but for all other genes 100 ng template was used. Positive (10 pg of 
plasmid DNA) and negative (No template and RT negative) controls were used to 
control the specificity and realiability of the PCR. The PCR was performed with the 
following profile; initial denaturation at 95 ºC for 3 minutes followed by 37 cycles for 
receptors and 30 cycles for cytokines of denaturation at 94 ºC for 30 seconds, 
annealing (temperature given in table blow) for 30 seconds and extension at 72 ºC 
for 30 seconds. The reaction was ended with a final extension of 5 minutes at 72 ºC 
and kept on hold at 4 ºC untill tubes were taken out of the cycler. 
Table 2.3. List of primers for detection of gene expression 
Primer Name Target 
gene 
Annealing 
Temperature 
Sequence 5´-3´ Product 
Size  
hIL-33R1_fwd ATCAAGGTACAGGGCGCACA 
hIL-33R1_rev 
hIL-33Rα 51 ºC 
CCATTAAGCTGCCACAGGAC 
297bp 
mIL-1R1_fwd TCATCCTCACGGCTACAATTG 
mIL-1R1_rev 
mIL-1R1 55 ºC 
AAGCCTCCCATATCTCTCAC 
355bp 
mIL-1RAcP_fwd CTGGTTATTCCCTGCAAAGTC 
mIL-1RAcP_rev 
mIL-1RAcP 55 ºC 
TTCTCCAAAACTCCACGCAG 
509bp 
mIL-18R1_fwd ATTGGAGCATCAGGAAAGAGG 
mIL-18R1_rev 
mIL-18Rα 51 ºC 
CCAGGCACCACATCTCTTTC 
523bp 
mIL-18RAcP_fwd TGGGAACACAGCACAAGATG 
mIL-18RAcP_rev 
mIL-18Rβ 55 ºC 
AATGGAGTTCTGGGCAAAGC 
565bp 
mIL-33R1_fwd ACTTGTCAATTCACACACGC 
mIL-33R1_rev 
mIL-33Rα 52 ºC 
CTGGAACTTTCATTTCGACC 
290bp 
mIL-1a-S115s_fwd TCAGCACCTTACACCTACCAGAG 
mIL-1a-
S270as_rev 
mIL-1α 52 ºC 
TGATATCTGGAAGTCTGTCATAG
AGG 
468bp 
mIL-1b_fwd AGCAGCACATCAACAAGAGC 
mIL-1b_rev 
mIL-1β 55 ºC 
TCGTTGCTTGGTTCTCCTTG 
355bp 
mIL-18_fwd AACTTTGGCCGACTTCACTGT 
mIL-18_rev 
mIL-18 55 ºC 
TGGCAAGCAAGAAAGTGTCC 
377bp 
mIL-33_fwd ATCGGGTACCAAGCATGAAG 
mIL-33_rev 
mIL-33 55 ºC 
ATCACCTTCTTCCCATCCAC 
321bp 
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2.19. Relative quantification of gene expression 
Relative mRNA expression of different genes in response to IL-1β, IL-33 and IL-18 in 
EL-4 1B1 cells was analyzed by quantitative PCR (Stragene). EL-41B1 cells (5 x 106) 
were kept unstimulated or stimulated with IL-1β (100 pg/ml), IL-33 (100 ng/ml) or IL-
18 (100 ng/ml) for 2 hours. RNA was isolated using NucleoSpin® RNA II 
(MACHEREY-NAGEL GmbH & Co. KG, Düren Germany) RNA extraction kit, cDNA 
was generated and changes in mRNA level for IL-2, Csf2, IL-22, Ccl5, Cxcl10, 
Tnfrsf9, Icam1 and Serpinc1 were measured. Expression of GAPDH (a house 
keeping gene) was used to normalize the data. 
Primers for the quantification of above described genes were selected from primer 
data bases (mIcam1 from http://medgen.ugent.be/rtprimerdb; mIL-2, mCcl5, mCxcl10 
and mTnfrsf9 from  http://pga.mgh.harvard.edu/primerbank/index.html; mCsf2, mIL-
22, mSerpinc1 and GAPDH from http://mouseprimerdepot.nci.nih.gov) and costum 
synthesized (Sigma). All the quantitative PCR were performed on Stratagene 
quantitative PCR (Mx3005PTM) and the data was analyzed using the MxPro software, 
provided with the instrument followig the manufacturer´s guidlines.  After an initial 
activation step at 95 ºC for 10 min, 40 cycles (95 ºC for 30 sec and 60 ºC for 60 sec) 
were performed and a single fluorescence reading was obtained at 60 ºC of each 
cycle step. A melting/dissociation curve was determined at the end of cycling to 
ensure the amplification of a single PCR product. 
Table 2.4. List of primers for quantification of gene expression 
Primer Name Sequence 5´-3´ Final 
Conc. 
Gene / template 
Conc.  
Product 
Size 
mCxcl10-7f CCAAGTGCTGCCGTCATTTTC 300 nM 
mCxcl10-163r GGCTCGCAGGGATGATTTCAA 300 nM 
mCxcl10 
5ng 
157 
mIL-2176f  TGAGCAGGATGGAGAATTACA 600 nM 
mIL-2-295r GTCCAAGTTCATCTTCTAGG 600 nM 
mIL-2 
10ng 
120 
mTnfrsf9-69f CGTGCAGAACTCCTGTGATAAC 300 nM 
mTnfrsf9-172r GTCCACCTATGCTGGAGAAGG 150 nM 
mTnfrsf9 
10ng 
104 
mCcl5-98f GCTGCTTTGCCTACCTCTCC 300 nM 
mCcl5-201r TCGAGTGACAAACACGACTGC 300 nM 
mCcl5 
5ng 
104 
mIcam1-1063f CCGCAGGTCCAATTCACACT 150 nM 
mIcam1-1205r TCCAGCCGAGGACCATACAG 300 nM 
mIcam1 
10ng 
104 
mCsf2-104f CCATCAAAGAAGCCCTGAAC 300 nM 
mCsf2-243r CCGTAGACCCTGCTCGAATA 300 nM 
mCsf2 
10ng 
140 
mIL-22-384f GCTCAGCTCCTGTCACATCA 150 nM 
mIL-22-490r TCGCCTTGATCTCTCCACTC 150 nM 
mIL-22 
20ng 
107 
mSerpinc1-326f TTTTCCTGTCACCCTTGAGC 300 nM 
mSerpinc1-460r AGTGGATCTGGTCGGATGTC 300 nM 
mSerpinc1 
10ng 
135 
mGAPDH-301f ACCACCATGGAGAAGGC 600 nM 
mGAPDH-534r GGCATGGACTGTGGTCATGA 150 nM 
mGAPDH 
all above 
234 
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All the quantitative PCR were performed in triplicate in 12 μl of the reaction volume 
containing 1 x master mixture with SYBR Green (Stratagene), 30 nM ROX as 
reference dye, 150-600 nM forward and reverse primers, template cDNA. Three 
kinds of assays were performed for each gene. At first the optimal primer 
concentrations were defined by analyzing various concentrations (150, 300 and 600 
nM) of forward and reverse primers and 10 ng of template. Primer concentrations 
with minimum cycle threshold (ct) and single amplification product (based on 
dissociation curve) were considered optimal (optimum concentration and sequence of 
each primer with the traget gene is given in table 2.4). In the second assay optimal 
amount of template was determined for each gene by analysing the various amounts 
of template (40 ng to 0.31 ng, it was obtained with 1:1 serial dilution from maximum 
to minimum) and plotting the standard curve. The amount of template which results in 
a standard curve having 90-110% efficiency was selected for relative gene 
expression analysis. Finally the relative gene expression was analysed by 
amplification of mRNA from unstimulated or stimulated cells. The amout of cDNA 
templates (based on initial RNA concentration) used for final relative gene expression 
assay is given in table 2.4. The data obtained was normalized against expression 
level of GAPDH and calibrated against basal gene expression (unstimulated) in all 
relative gene expression asays. 
2.20. Expression plasmids  
For construction of the expression plasmids, genes were amplified or fused by PCR. 
Detailed PCR conditions are explained in discription of individual expression 
plasmids. All PCR reactions for gene amplification were performed in 50 μl volume 
and pfu DNA polymerase (Fermentas, having proof reading activity) was used. The 
primers sequences, used for gene fusion or amplification are given in table 2.5. The 
PCR reaction consists of 1 x PCR buffer with MgSO4, 200 μM dNTPs (each), 0.4 μM 
forward and reverse primers (each), 2.5 units of pfu DNA polymerase, template (100 
ng cDNA or 1 ng plasmid DNA) and water to make up total volume to 50 μl. All 
enzymes used to clone genes were purchased from Fermentas, Germany. 
pFLAG-mIL33Rα was used for cell surface expression of amino acids 18–567 of 
mouse IL-33 receptor α chain (IL-33Rα) (without signal peptide, NM_001025602, 
Pro18–Phe567) with N-terminal 3 × Flag epitope tag under control of the CMV 
promoter. It was generated by inserting the mouse IL-33Rα coding sequences 
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(without signal sequence) into the HindIII and BamHI cloning site of vector p3×Flag-
CMV-9 (Sigma, Deisenhofen, Germany). Mouse IL-33Rα chain was cloned from 
mouse mast cells (kindly provided by Prof. Dr. M. Huber, MPI Freiburg). Total RNA 
was isolated, cDNA was generated and full length information for the mouse IL-33Rα 
chain was amplified by PCR using mIL-33R1-P18s-Hind and mIL-33R1F567as-Bam 
primers. The PCR was performed in Eppendorf master cycler (gradient) using the 
following profile: initial denaturation for 5 minutes at 95 ºC followed by 35 cycles of 
denaturation at 94 ºC for 45 sec, primer annealing at 52 ºC for 30 sec and extension 
at 72 ºC for 200 sec. Programe was ended with a final extension of 10 minutes and 
kept on hold at 4 ºC.  
The amplified gene was cloned in p3 x FLAG-CMV-9 in HindIII and BamHI cloning 
sites. Ligation of insert was confirmed by restriction with HindIII and BamHI. 
pMyc-mIL33Rα was used for cell surface expression of amino acids 18–567 of 
mouse IL-33Rα (NM_001025602, Pro18–Phe567) with N-terminal c-Myc epitope tag 
under control of the CMV promoter. It was generated by inserting the mouse IL-33Rα 
coding sequence (without signal sequence) into the HindIII and BamHI cloning site of 
vector pMyc-CMV-9 (kind gift from Prof. W. Falk). pMyc-CMV-9 is generated by 
insertion of the mouse IL-2 signal sequence and the c-Myc epitope sequence in 
pcDNA3.1/Zeo(+) (Invitrogen, Karlsruhe, Germany). 
Murine IL-33Rα coding sequences were cut from pFlag-mIL-33Rα with HindIII and 
BamHI restriction enzymes. This HindIII and BamHI fragment was purified from the 
gel and ligated in the pMyc-CMV-9 vector digested with same set of restriction 
enzymes. Ligation of mIL-33α gene was confirmed by restriction of pMyc-mIL-33Rα 
with HindIII and BamHI. 
pFlag-mIL1RAcP was used for cell surface expression of human IL-1RAcP 
(NM_008364, Ser21–Val570) with N-terminal Flag epitope tag under control of the 
CMV promoter. It was generated by inserting the human IL-1RAcP coding sequence 
into the multiple cloning site of vector pFlag-CMV-1 (Sigma). The vector was a kind 
gift of Prof. W. Falk, University of Regensburg Germany. 
The 3×NF-κB-Luc reporter plasmid, expresses firefly luciferase after binding of 
activated NF-κB to three consecutive NF-κB binding sites in the promotor region of 
the plasmid. Plasmid was used for the NF-κB reporter gene assays. 
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ΔC-mIL-1RAcP (ΔC-AcP) encodes amino acids 1-384 of murine IL-1RAcP in pEF-
Bos vector (generated by R. Hofmeister, Regensburg). This mutant is expressed on 
the cell surface but lacks the cytoplasmic TIR domain. The vector was a kind gift of 
Prof. W. Falk. 
pEGFP-C1 (Clontech) plasmid was used as transfection control plasmid. 
pmIL-1α-FL expresses C-terminally Flag-tagged murine interleukin-1α precursor 
(NM_010554) under CMV promoter. Plasmid was generated by Mr. Björn Gerlach 
during his diploma work by insertion of full length murine interleukin-1α encoding 
sequence in pC-Flag. 
pmIL33-Myc/His (a kind gift from Prof Werner Falk) expresses C-terminally Myc- and 
6×His-tagged mouse interleukin-33 (IL-33, NM_133775.1) under CMV promoter. 
Plasmid was generated by insertion of full length IL-33 information in  
pcDNA3.1/myc-His A (Invitrogen). 
pmIL33-FL was used for mammalian expression of C-terminally Flag-tagged murine 
interleukin-33 precursor (NM_133775.1, Met1–Ile266). IL-33 coding sequence was 
amplified by PCR from pmIL33-Myc/His using mIL-33-M1s-Hind and mIL-33-1266as-
Bam primers. The PCR was performed in Eppendorf master cycler (personal) using 
the following profile: initial denaturation for 3 minutes at 95 ºC followed by 25 cycles 
of denaturation at 94 ºC for 30 sec, primer annealing at 51 ºC for 30 sec and 
extension at 72 ºC for 120 sec. Programe was ended with a final extension of 10 
minutes and kept on hold at 4 ºC untill the samples were taken out of the thermal 
cycler. 
The amplified mIL-33 sequences was replaced with human IL-1α gene from phIL-1α-
Flag using HindIII and BamHI restriction enzymes. Ligation of the IL-33 gene was 
confirmed by restriction with EcoRI and BamHI. 
pFL-hTIR8 was used for cell surface expression of N-terminally Flag-tagged human 
Toll/Interleukin-1 receptor 8 (NM_021805, Pro2–Met410). This was a gift kind 
provided by Prof. Alberto Mantovani, Instituto Clinico Humanitas, Via Manzoni 56, 
20089 Rozzano (MI), Italia. 
pFL-mTIR8 was used for cell surface expression of N-terminally Flag-tagged murine 
Toll/Interleukin-1 receptor 8 (NM_023059, Ala2–Val409 + 132 bp of 3’-UTR). This 
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was a gift kind provided by Prof. Alberto Mantovani, Instituto Clinico Humanitas, Via 
Manzoni 56, 20089 Rozzano (MI), Italia. 
Table 2.5. List of primers used for amplification/fusion of genes for cloning in expression 
vectors 
Primer Name Target gene Sequence 5´- 3´ 
FLAGs Flag GCTGACTACAAAGACGATGACGAC 
mAcP-S21s-Hind mIL-1RAcP TGTAAGCTTTCGGAGCGCTGTGATGACTG 
mAcP-V570as-Bam mIL-1RAcP TGTGGATCCTCATACGTTTTTCAGGGATGAG 
mAcP-TIR8as mIL-1RAcP TCAGCCGACACTTAACAAAGAGGACCATCTCCAGC 
mAcP-TIR8s mTIR8 GAGATGGTCCTCTTTGTTAAGTGTCGGCTGAACATGC 
mIL-33-M1s-Hind mIL-33 CGAAAGCTTGCCACCATGAGACCTAGAATGAAGTAT 
mIL-33-1266as-Bam mIL-33 CAAGGATCCCGGATTTTCGAGAGCTTAAACATA 
mIL-33R1F567as-Bam mIL-33Rα CGAGGATCCTCAAAAGTGTTTCAGGTCTAAG 
mIL-33R1-P18s-Hind mIL-33Rα GTGAAGCTTCCCATGTATTTGACAGTTAC 
mTIR8-Acp-as mTIR8 AAGTGAGCTCGGTAATAGAGCAGGGCCACCAGCAG 
mTIR8-Acp-s mIL-1RAcP TGGCCCTGCTCTATTACCGAGCTCACTTTGGAACAG 
mTIR8-V310as-Xba mTIR8 CATTCTAGACTACACCTTCCGTGGCAGTGCT 
mTIR8-V409as-Xba mTIR8 CACTCTAGACTACACATCATCCTCAGACAC 
mIL33-M1s-Sal mIL-33 GTGGTCGACTATGAGACCTAGAATGAAGTA 
FLAGas-Not Flag AGAGCGGCCGCTAGACCTTGTCATCGTC 
IL33-D175as-Not mIL-33 TATGCGGCCGCTAATCCACACCGTCGCCT 
IL33-G176s-Sal mIL-33 GTGGTCGACTGGGAAGAAGGTGATGGT 
mIL33-D175As mIL-33 AGGCGACGGTGTG GCT GGGAAGAAGGTG 
mIL33-D175Aas mIL-33 CACCTTCTTCCC AGC CACACCGTCGCCT 
IL1b-M1s-Sal IL-1β CTCGTCGACAATGGCAACTGTTCCTGAACTC 
IL1b-S269as-Age IL-1β GTTACCGGTGGGGAAGACACGGATTCCATGG 
IL18-M1s-Sal IL-18 GAAGTCGACAATGGCTGCCATGTCAGAAGA 
IL18-S192as-Age IL-18 AGGACCGGTGGACTTTGATGTAAGTTAGTGAGA 
 
pFL-mTIR8-AcP was generated for mammalian expression of an N-terminally 
3×Flag-tagged fusion protein of extracellular & trans-membrane part of the murine 
TIR8 [single immunoglobulin IL-1R-related molecule (SIGIRR) (NM_023059, Ala2–
Tyr138)] and the intracellular part of the murine interleukin-1 receptor accessory 
protein [(NM_008364, Tyr389–Val570)] on mammalian cell surface. For the 
construction of the TIR8-AcP chimera, the sequences encoding the extracellular and 
transmembrane parts (amino acid 1-138) of murine TIR8 was amplified by PCR using 
FLAGs and mTIR8-Acp-as. The sequence encoding the intracellular rest of mIL-
1RAcP (amino acid 389-570) was amplified by PCR  using mTIR8-Acp-s and mAcP-
V570as-Bam primers. The PCR profile used was as follows: initial denaturation for 3 
minutes at 95 ºC followed by 20 cycles of denaturation at 94 ºC for 30 sec, primer 
annealing 52 ºC for 30 sec and extension at 72 ºC for 110 sec. And then a final 
extension of 10 minutes and hold at 4 ºC.  
The two amplified gene fragments were fused and again amplified by PCR using 
FLAGs and mAcP-V570as-Bam primers. One μl of two above described PCR 
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reactions were used as template for fusion and reamplification of chimeric genes. 
Profile used was as follows: initial denaturation for 3 minutes at 95 ºC then 5 cycles 
of denaturation at 94 ºC for 45 sec, primer annealing 48 ºC for 30 sec and extension 
at 72 ºC for 120 sec followed by 25 cycles of denaturation at 94 ºC for 45 sec, primer 
annealing 55 ºC for 30 sec and extension at 72 ºC for 120 sec and then a final 
extension of 10 minutes followed by hold at 4 ºC. This TIR8-AcP chimeric sequence 
was ligated in pFlag-CMV-9 in EcoR1 and BamHI cloning sites. Ligation was 
confirmed by restriction with EcoR1 and BamHI.  
pFL-mAcP-TIR8 was used for mammalian cell surface expression of an N-terminally 
3×Flag-tagged fusion protein of extracellular & trans-membrane part of the murine 
interleukin-1 receptor accessory protein, [(NM_008364, Ser21–Phe388)] and the 
intracellular part of the murine single immunoglobulin toll-interleukin-1 receptor 
related (SIGIRR, TIR8), [(NM_023059, Val139–Val409). mAcP-TIR8 gene was 
generated by PCR based fusion of extracellular & trans-membrane part of the murine 
interleukin-1 receptor accessory protein, (NM_008364, Ser21–Phe388) and the 
intracellular part of the murine TIR8, (NM_023059, Val139–Val409). The extra-
cellular and trans-membrane region coding sequences of mIL-1RAcP was amplified 
using mAcP-S21s-Hind and mAcP-TIR8as primers and 1 ng of pFl-mIL-1RAcP as 
template. The primers were allowed to anneal at 53 ºC. The cytoplasmic region of 
mTIR8 was amplified from pFl-mTIR8 using mAcP-TIR8s and mTIR8-V409as-Xba 
primers. The annealing temperature for binding of mAcP-TIR8s and mTIR8-V409as-
Xba primers was 58 ºC. The rest of the profile was same for both reactions i.e. initial 
denaturation for 3 minutes at 95 ºC then 25 cycles of denaturation at 94 ºC for 45 
sec, primer annealing as described for 30 sec and extension at 72 ºC for 90 sec. The 
two amplified gene fragments were fused and reamplified by PCR using mAcP-S21s-
Hind and mTIR8-V409as-Xba primers. Following profile was used for fusion and 
amplification of mAcP-TIR8: initial denaturation for 3 minutes at 95 ºC then 5 cycles 
of denaturation at 94 ºC for 45 sec, primer annealing 48 ºC for 30 sec and extension 
at 72 ºC for 200 sec followed by 35 cycles of denaturation at 94 ºC for 45 sec, primer 
annealing 57 ºC for 30 sec and extension at 72 ºC for 200 seconds and then a final 
extension of 10 minutes. 
The amplified murine AcP-TIR8 chimeric gene was ligated in the pFlag-CMV-9 in 
HindIII and XbaI cloning sites. Ligation of murine AcP-TIR8 chimeric gene was 
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verified by restriction of pFl-AcP-TIR8 plasmid with HindIII and NheI, followed by 
restriction with HindIII and BamHI.  
pFL-mAcP-TIR8-ΔC was designed for mammalian cell surface expression of an N-
terminally 3×Flag-tagged fusion protein of extracellular & trans-membrane part of the 
murine interleukin-1 receptor accessory protein, [(NM_008364) Ser21–Phe388] and 
the C-terminally truncated intracellular part of the murine TIR8, [single 
immunoglobulin toll-interleukin-1 receptor related, (NM_023059, Val139–Val310)]. 
AcP-TIR8-ΔC chimeric genes was gererated by fusion of the PCR amplified extra-
cellular and trans-membrane region coding sequences of mIL-1RAcP and 
cytoplasmic region of mTIR8 (as described for mAcP-TIR8 section). The two 
amplified genes were fused by PCR and chimeic gene was amplified using mAcP-
S21s-Hind and mTIR8-V310as-Xba primers. The amplification conditions were same 
as for mAcP-TIR8 amplification. 
The amplified murine AcP-TIR8-ΔC chimeric genes was ligated in the pFlag-CMV-9 
in HindIII and XbaI cloning sites. Ligation of murine AcP-TIR8-ΔC chimeric gene was 
verified by restriction of pFl-AcP-TIR8-ΔC plasmid with HindIII and NheI. Further 
confirmation was made by restriction cuts of the plasmid by HindIII and BamHI. 
pFL-mTIR8-ΔC encodes a N-terminally 3×Flag-tagged C-terminally truncated murine 
TIR8, [single immunoglobulin toll-interleukin-1 receptor related (NM_023059, Ala2–
Val310)] on mammalian cell surface. C terminally truncated version of mTIR8 (995bp 
TIR8-ΔC lacking last 99 amino acids coding sequences) was amplified by PCR using 
FLAGs and mTIR8-V310as-Xba primers and 1 ng of pFl-mTIR8 as template DNA. 
PCR programe was as follows: initial denaturation for 3 minutes at 95 ºC then 25 
cycles of denaturation at 94 ºC for 30 sec, primer annealing 52 ºC for 30 sec and 
extension at 72 ºC for 120 sec followed by a final extension of 10 minutes and hold at 
4 ºC.  
The amplified murine TIR8-ΔC was ligated in the pFl-CMV-9 in HindIII and XbaI 
cloning sites. Cloning of mTIR8-ΔC gene in pFl-CMV-9 was confirmed by restriction 
of plasmid DNA (pFl-TIR8-ΔC) with HindIII and NheI and restriction with HindIII and 
BamHI.  
pFl-smIL-33Rα:Fc was used to express Flag-tagged soluble form of IL-33Rα-chain 
fused with the Fc fragment of human IgG. pFL-IL-33Rα-IL-1RAcP:Fc was used for 
mammalian expression of IL-33 inline cytokine trap (Economides et al., 2003) fusion 
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protein consisting of the extracellular part of the murine IL-33 receptor alpha chain, 
extracellular part of murine IL-1 receptor accessory protein and the Fc fragment of 
human immunoglobulin IgG1. Plasmids were prepared by Daniel Radtke and Meike 
Thomas during their bachelor thesis work.  
pMyc-mIL-1β-Fl, pMyc-mIL-18-Fl and pMyc-mIL-331-266-Fl encode full length 
murine IL-1β, IL-18 and IL-33, respectively with N-terminal Myc tag and C-terminal 
Flag tag. pMyc-mIL-331-266-Fl was generated by cloning of full length IL-33-Flag 
peptide encoding sequences from pmIL-33-Fl using mIL33-M1s-Sal and FLAGas-Not 
primers in pRK7 N-Myc (Schall et al., 1990). pMyc-mIL-1β-Fl, pMyc-mIL-18-Fl were 
generated by replacing full length IL-33 encoding sequence with PCR amplified IL-1β 
and IL-18  encoding sequences from cDNA obtained from murine macrophage cell 
line, RAW264.7. IL-1β was amplified using IL1b-M1s-Sal and IL1b-S269as-Age 
primers. For the amplification of mIL-18 IL18-M1s-Sal and IL18-S192as-Age primers 
were used. Cloning of full length IL-33 was confirmed by restriction of the 
recombinant plasmids with Sal1 and Not1 where as full length IL-1β and IL-18 were 
confirmed by restriction with Sal1 and Age1 restriction enzymes.  
pMyc-mIL-33176-266-Fl encodes N-terminally Myc- and C-terminally Flag-tagged mIL-
33 aa 176-266. pMyc-mIL-33176-266-Fl was generated by cloning mIL-33 aa 176-266-
Flag peptide amplified from pmIL-33-Fl using mIL33-G176s-Sal and FLAGas-Not 
primers in pRK7 N-Myc. pMyc-mIL-331-175 was used for expression of N-terminally 
Myc-tagged mIL-33 aa 1-175. mIL-33 aa 1-175 was amplified from pmIL-33-Fl  using 
mIL33-M1s-Sal and IL33-D175as-Not primers and ligated in pRK7 N-Myc in Sal1 and 
Not1 cloning sites. Ligation of mIL-331-175 and mIL-33176-266 was confirmed by 
restriction with Sal1 and Not1 enzymes. 
Full length IL-1β, IL-18 and IL-33, IL-331-175, and IL-33176-266 all were amplified in 
Mastercycler (Eppendorf, Germany) using amplification program: initial denaturation 
for 3 minutes at 95 ºC then 25 cycles of denaturation at 94 ºC for 30 sec, primer 
annealing 52 ºC for 30 sec and extension at 72 ºC for 120 sec followed by a final 
extension of 10 minutes and hold at 4 ºC. 
pMyc-mIL-33D175A-Fl encodes flIL-33 with mutation D175A. pMyc-mIL-33D175A-Fl was 
generated by PCR based point mutation D175A in pMyc-mIL-331-266-Fl using mIL33-
D175As and mIL33-D175Aas primes. Mutation was generated using QuikChange 
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Site-Directed Mutagensis Kit (Stratagene, USA) following manufacturers 
recomendations. 
The nucleotide sequences of all above described genes was confirmed by 
sequencing (done commercially by Eurofins MWG Operon Sequencing Department,  
Martinsried Germany). 
2.21. DNA isolation and purification  
One colony or 5 μl of glycerol culture of transfected bacterial cells were cultured in 3-
5 ml of LB medium (171 mM NaCl +10 g/l Bacto-Trypton (Roth, Germany) + 5 g/l 
yeast extract (Roth, Germany), pH 7.0 with 5 M NaOH, autoclaved) containing 
appropriate antibiotic (50 μg/ml Ampicillin, sodium salt (Roth, Germany) or 30 μg/ml 
kanamycin sulphate (Roth Germany), 0.2 µm sterile filtered) at 37 ºC with shacking 
(180rpm). Bacterial cultures were allowed to grow overnight for miniprep or 6-8 hours 
and subcultured for midi or maxi preps.  
Bacterial cells were collected by centrifugation at 5000rpm for 5 minutes. Small 
amounts of plasmid DNA (miniprep) was purified from 1.5 ml bacterial cultures using  
JETQUICK Plasmid Spin Kit (GENOMED GmbH Löhne Germany). The midi preps 
was performed for plasmid purification from 50-100 ml bacterial cultures using Jetstar 
2.0 plasmid purification Midi kit, (GENOMED GmbH, Löhne Germany) and larger 
amouts of plasmids were purified using Jetstar 2.0 plasmid purification Maxi kit 
(GENOMED GmbH, Löhne Germany). All the kits were used following the protocol 
described by the manufacturer. After purification plasmid DNA was air dried and 
dissolved in 10 mM Tris/HCl pH 8 and stored at –20 ºC. 
DNA from PCR products and from gel slices were purified using NucleoSpin® Extract 
II (MACHEREY-NAGEL GmbH & Co. KG, Düren Germany) kit following the 
manufacturer´s recomendations. 
DNA concentrations and quality was determined by spectrophotometer by measuring 
OD at 260 and 280 (from 1:50 diluted DNA). The quantity of DNA was calculated as: 
1 OD260= 50 μg / ml DNA. The ratio OD 260/280 should be 1.8 - 2 for pure DNA. 
2.22. DNA digestion with restriction endonucleases  
For the digestion of DNA with restriction endonucleases, 1-5 μg of plasmid DNA or 
purified PCR product was incubated with 5 - 10 units of  restriction endonucleases 
(Fermentas, Germany) in appropiate buffer system (as recommended by Fermentas) 
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in 20 μl reaction volume. The reaction mixture was incubated at the recommended 
temperature (usually at 37 ºC) for 2 hours and restriction endonucleases were 
inactivated by heating at 65 ºC - 80 ºC (specific for endonucleases). 
2.23. Agarose gel electrophoresis 
Agarose gels (1% to 2%) were used to resolve DNA fragments. The agarose was 
dissolved in 1 x TAE buffer (40 mM Tris + 1 mM EDTA + 20 mM Acetic acid) by 
boiling in a microwave oven. The solution was allowed to cool down to about 50 ºC – 
60 ºC (approximately). Agarose was poured in gel tray fixed in gel casting plate 
(PeQLab Biotechnology GmbH, Germany) and equipped with desired comb. The gel 
was allowed to stay untill solidified. DNA samples were mixed with 1/10 volume of 10 
x loading buffer (5 mM Tris-HCl, pH 8.0 + 0.0025% Bromphenolblue + 0.0025% 
Xylen Cyanol + 5% Glycerol) and loaded on agarose gel. Gel was run at 100 - 120 
Volts in 1 x TAE buffer in gel tank (PeQLab Biotechnology GmbH, Germany). DNA 
was stained by dipping gel in ethidium bromide solution ( 1μg / ml in water, Roth, 
Germany) for 15 minutes and visualized using UV transilluminator in gel 
doccumentation system (Syngene, UK). 
2.24. Ligation 
The vector (plasmid DNA) and/or PCR amplified fragments digested by restriction 
endonuclases were separated on agarose gel, stained with ethidium bromid and 
desired fragments were purified from gel slices using NucleoSpin® Extract II kit 
(MACHEREY-NAGEL GmbH & Co. KG, Düren Germany). The purified vectors and 
inserts were ligated in 20 μl reaction volume containing, 100 – 250 ng linear plasmid 
DNA, 3 M ratio of insert (compared to plasmid) and 5 units of T4 DNA ligase 
(Fermentas) in 1 x T4 DNA ligase reaction buffer (Fermentas). The reaction contents 
were mixed and incubated for one hour at 22 ºC in Eppendorf thermal cycler 
(Personal). And 5 μl of the ligation mixture was transformed to the competent E-Coli 
XL1 blue cells by heat shock method.  
2.25. Bacterial transformations 
2.25.1. Preparation of competent cells 
One colony or 5 μl of glycerol culture of E-Coli XL1blue strain (recA1 endA1 gyrA96 
thi-1 hsdR17 supE44 relA1 lac [F´ proAB lac1q ZΔM15 Tn10 (TetR) – Stratagene, 
USA) was cultured overnight in 3 ml of LB medium at 37 ºC with shacking (180rpm). 
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The next day 500 μl of this overnight culture was subcultured in 50 ml LB medium at 
37 ºC with shacking until the OD 600nm was reached between 0.3 to 0.4. The bacteria 
were harvested by centrifugation at 5000 rpm for 5 minutes at 4 ºC and resuspended 
in 5 ml of ice cold TSS (50 mM MgCl2 ·6 H2O + 10% Polyethylenglycol (6000 or 8000, 
Serva Finbiochemica, GmbH & Co, Heidelberg Germany) + 5% DMSO in LB medium, 0,2 
µm sterile filtered). Cells were aliquoted (100μl) in 1.5 ml Eppendorf cups, frozen 
directly in liquid nitrogen and stored at – 80 ºC untill further use.  
2.25.2. Transformation by heat shock 
Competent bacterial cells were thawed on ice and 5 μl of ligation mixture or 50-100 
ng of plasmid DNA was mixed by pipetting in and out and allowed to stay on ice for 
30 minutes. A heat shock of 2 minutes at 42 ºC was given to this transformation 
mixture and again kept on ice for 2 minutes. 900 μl of LB medium containing 20 mM 
glucose, 12.5 mM MgCl2 and 12.5 mM CaCl2 was added in each tube and incubated 
at 37 ºC for 1 hour with shacking. A part (100 μl) of this cell suspension was spread 
on LB-Agar plates (LB-Medium + 1.5% Bacto-Agar (Roth, Germany), autoclaved + 
Antibiotic) containing the appopriate selection antibiotic. The rest of the cells were 
collected by centrifugation at 5000 rpm for 5 minutes, resuspended in 100 μl of the 
LB medium and spread on separate plate. Plates were incubated for 16-20 hours at 
37 ºC.  
2.26. Microarray analysis 
In order to identify differentially regulated genes by IL-1, IL-18, and IL-33 stimulation, 
microarrays were performed on the triple responsive cell line EL-41B1. EL-41B1 cells 
were either kept unstimulated or stimulated with 100 pg/ml IL-1β, 100 ng/ml IL-33 or 
100 ng/ml IL-18 for 2 hours. Total RNA isolated as described above and cDNA was 
prepared, labelled with flourescent dyes and microarray was performed (all arrays 
were perfomed at the Institute of Pharmacology, Hannover Medical School  by Dr. 
Oliver Dittrich-Breiholz). 
At first the gene expression was determined using the inflammation array (Inflamus, 
2nd version inflamation array) developed by the cytokine microarray project at the 
Institute of Pharmacology, Hannover Medical School (Dr. Oliver Dittrich Breiholz and 
Prof. Michael Kracht). Arrays contained 160 selected gene probes including 
cytokines, chemokines and their receptors, receptor associated factors, growth 
factors, acute phase proteins, adhesion molecules, signal transduction proteins, 
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transcription factors, matrix metallo proteases, enzymes, matrix proteins, some 
housekeeping genes and some control oligos. Array data was normalized by 
comparing the average signal obtained by house keeping genes expression and 
control oligos. 
Whole mouse genome oligo microarrays (4 x 44 k, Agilent Technologies) were 
performed using same RNA from unstimulated and IL-1, IL-33 or IL-18 stimulated EL-
41B1 cells. RNA was converted to cRNA and labelled with Cy5 or Cy3 for 
unstimulated or stimulated cells respectively. Labelled cRNAs of stimulated or 
unstimulated cells were mixed and co-hybridized on to whole mouse genome oligo 
microarrays (4 x 44 k, Agilent Technologies), which carry oligonucleotide probes for 
the mouse genome. Flourescent intensity values of all spots were measured from 
sacnned microarrays using MAVI software (MWG Biotech, Germany). The ratio of the 
stimulated and unstimulated signal was derived and data was analyzed using Excel 
(Microsoft office, 2001).  
2.27. Radiolabelling of IL-33 and IL-1α 
In order to measure the binding affinity of IL-33 to the IL-33 receptor 3 μg of IL-33 (a 
kind gift from Prof. W. Falk, University of Regensburg, Germany) was labelled with 
125I (1 mCi) using the chloramine T method. IL-1α (5 μg, a kind gift from Dr. J. Sims, 
formerly Immunex Seattle, USA) was also labelled in parallel as control.  
2.27.1. Preparation of column 
Sephadex G25 (2.5 g) was soaked in 20 ml of PBS for 30 minutes at room 
temperature. Column was prepared from 10 ml plastic pipette by positoning a small 
amount of cotton at the bottom of the pipette. A small piece of silicon tube (2-3 cm) 
was applied to the tip of the pipette with stopper. Presoaked Sephadex G25 was 
poured air-free into the column slowly up to 10 ml by allowing the liquid to flow 
through until  homogenious Sephadex G25 gel reached the 10 ml mark. Unspecific 
protein binding sites of the column were saturated by incubating with 0.25% gelatine 
in PBS (preboiled and cooled to room temperature) for 10 minutes and allowed to 
stay until use. 
2.27.2. Iodination of IL-33 and IL-1α  
Carrier protein-free recombinant cytokines were diluted with 0.5 M phosphate buffer 
(pH 7.5) up to 25 μl volume. 1 mCi of Na125I (I-RB-31 74TBq/mmol in 40 mM NaOH, 
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Hartmann Analytic, Braunschweig, Germany) was added along with the 40 μl of 
freshly prepared 1 mg/ml solution of Chloramine-T and mixed. The mixture was 
allowed to react at room temperature for 2 minutes. Then the reaction was stopped 
by adding 30 μl freshly prepared Na2S2O5 solution (10 mg/ml), followed by addition of 
50 μl of 10 mg/ml KI solution. The whole reaction mixture was mixed with 300 μl of 
0.25% gelatin, loaded on Sephadex G25 column and 15 fractions of one ml were 
collected. During this size exclusion chromatography column was not allowed to dry 
by slowly adding PBS on the top of colume. 10 μl from each fraction was analyzed for 
the presence of radioactive material on liquid scientilation counter (Beckman Coulter, 
USA) and another 10 μl were mixed with Laemmli buffer for SDS-PAGE and rests 
were frozen at –20 ºC. 
2.28. Crosslinking of IL-1α and IL-33 to respective receptors 
IL-33 and IL-1α, ligand recepetor complexes were cross linked with BS3 (Pierce). For 
crosslinking studies HEK293RI cells (3.6 x 106 cells in 56cm2 plates) were 
transfected with Flag tagged IL-33Rα encoding plasmid alone or in combination with 
Flag-IL-1RAcP encoding plasmid. The next day the transfected cells were washed 
twice with PBS and incubated either with radiolabelled cytokines (12 μl IL-1α-125I or 
50 μl IL-33-125I) for 15 minutes at 37 ºC in 1 ml PBS. In order to prove the specificity 
of the binding of radiolabelled cytokines a part of the transfected cells were also pre 
incubared with the nonradiolabelled cytokines (10 ng/ml IL-1α or 100 ng/ml IL-33). 
The cells were washed twice with PBS (pH 7.5) and incubated with freshly prepared 
5 mM BS3 (Pierce) in PBS at 4º C for one houre in 1 ml volume. Thereafter 50 μl of 1 
M Tris (pH 7.5) were added to quench the reaction and allowed to stay for 15 minutes 
on ice. Cells were washed with PBS and lysed. Flag tagged proteins were 
immunoprecipitated using anti-Flag M2 agarose. For IL-1α treated cells 2 μg/ml anti-
IL-1R1 (12A6, Pharmingen, USA) was also used for immunoprecipitation. Proteins 
from cell lysates and immunoprecipitates were separated on 15% SDS/PAGE. The 
gel was dried in gel drier and exposed to the photographic film overnight. Molecules 
crosslinked with radiolabbled cytokines were visualized from developed photographic 
film. 
2.29. Saturation and competition studies 
EL-41B1 (5 x 106 / point, EL-4 cells stably transfected with IL-33Rα) cells were 
incubated with increasing amounts of either radio-labelled IL-1α (0.31, 0.62, 1.25, 
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2.5, 5 or 10 ng / ml) or radio-labelled IL-33 (3.13, 6.25, 12.5, 25, 50, 100 ng / ml) for 
15 minutes at 37 ºC followed by 45 minutes on ice in 200 μl RPMI medium. For 
competition studies EL-41B1 cells were incubated with radiolabelled IL-1α (10 ng / 
ml) or  IL-33 (100 ng / ml) with or without 100 fold excess of unlabelled ligand. Cells 
and supernatant were separated by centrifugation at 1250rpm for 5 minutes in the 
presence of 200 μl of silicon oil (Wacker Chemie AR20/AR200 1:1). Radioactivity in 
the fractions (cells = bound; supernatant = unbound) was determined via liquid 
scintillation in a counter in the presence of 1 ml scintillator. 
2.30. Statistical analysis 
The data were analysed using Excel software, from Microsoft Office 2001. The 
quantitative PCR data were analyzed using MxPro software (stratagene, USA) 
provided with the thermal cycler. 
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Chapter 3 
 
Results 
 
The aim of this study was to characterize in detail the IL-33 / IL-33 receptor system 
and compare it with the well known and closely related IL-1 / IL-1 receptor system 
and IL-18 / IL18 receptor system. Cytokine production, processing to biologically 
active forms and release from producing cells was one aspect to be investigated. The 
other one was to elucidate the receptor system on the responding cell and to 
compare the signal transduction mechanisms initiated by binding of the cyotkines to 
their respective receptor complexes. While well-characterized expression plasmids 
encoding IL-1 and IL-18 receptor components were already used in the laboratory, 
no tools were available to study IL-33 production and IL-33 signaling. At the onset of 
this work, only the sequence for ST2 was published, a beta-chain was proposed but 
not demonstrated experimentally. Thus the first task was to create tools in order to 
investigate the IL-33 receptor complex and allow the search for a beta-chain. 
 
3.1. Characterization of the IL-33 receptor complex  
3.1.1. Cloning of the IL-33 receptor α-chain 
As ST2 had been identified as the IL-33 receptor, the sequence was available. With 
this information mouse IL-33 receptor alpha-chain was cloned using mRNA from 
murine bone marrow derived mast cells and a RT-PCR approach as described in 
material and methods. For easy handling of the proteins the sequences encoding N-
terminal Myc- or Flag-epitope tags were added in the expression plasmids. 
The cloned IL-33Rα was expressed in mammalian cells upon transient transfection 
(Fig.3.1A). HEK293RI cells do not express endogenous IL-33Rα, and thus do not 
respond to IL-33 but they readily respond to IL-1 (data not shown). 
Expression of IL-33Rα-molecules rendered HEK293RI cells responsive to IL-33. This 
was true for either Flag-tagged IL-33Rα-chain (Fig.3.1B left) or Myc- tagged IL-33Rα-
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chain (Fig.3.1B right). Stimulation of transfected HEK293RI cells with IL-33 resulted 
in the activation of the transcription factor NF-κB in dose dependent manner with 
respect to receptor and ligand concentration (Fig.3.1B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.2. Identification of IL-33 receptor β-chain 
All known receptor complexes in the family of IL-1R proteins consist of heterodimers. 
One chain recognizes the corresponding IL-1 cytokine family member, this being the 
formal receptor, and the second chain recognizes the ligated receptor but not the 
lignad itself. In these heterodimers both chains each contribute a TIR-domain. In 
contrast to the Toll-like receptors where homodimers are able to transduce a signal, 
Fig. 3.1: Expression and biological evaluation of mouse IL-33Rα (ST2).  
(A). HEK293RI cells express IL-33Rα upon transient transfection with a plasmid encoding mIL-
33Rα. Flag-tagged and Myc-tagged mIL-33Rα-chain was expressed in HEK293RI cells by transient 
transfection of pFl-mIL-33Rα and pMyc-mIL-33Rα, respectively. The tagged mIL-33Rα was detected 
by Western blotting after immunoprecipitation using anti-Flag M2 or antiMyc (A14) antibodies. 
(B). Flag-tagged and Myc-tagged mIL-33Rα chain is functional. HEK293RI cells were transiently 
transfected with different amounts of Flag-mIL-33Rα (left) or Myc-IL-33Rα encoding expression 
plasmid along with 1 μg of the NF-κB driven luciferase reporter gene plasmid, cells were stimulated 
with rmIL-33 as indicated and NF-κB driven reporter gene activity (luciferase) was measured (RLU = 
relative light units). Cells respond to mIL-33 upon transfection with pFl-mIL-33Rα plasmid or pMyc-
mIL-33Rα in dose dependent fashion.  
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homodimers have not been reported in the IL-1 receptor family to date. Given the 
very close relationship of IL-1 and IL-33 it was tempting to speculate that IL-1RAcP 
was able to function as beta-chain not only in the IL-1 receptor complex but also in 
the IL-33 receptor complex. 
3.1.2.1. Murine EL-4 D6/76 cells do not respond to IL-33 due to the lack of IL-
1RAcP  
The murine thymoma cell line EL-4 6.1 (EL-4) responds to IL-1 (Zubler et al., 1985), 
IL-18, and IL-33 by release of IL-2 (Fig.3.2A). This finding demonstrates that EL-4 
cells express functional receptors and all other molecules required for signal 
transduction for all three members of the IL-1 cytokine family. Although picomolar 
concentrations of rhIL-1β were sufficient to induce IL-2 synthesis, lower nanomolar 
concentrations were required of either rmIL-18 or rmIL-33. The different levels of mIL-
2 production in response to IL-1, IL-18 and IL-33 may relate to different affinities of 
the three cytokines for their specific receptor components and/or to different receptor 
numbers for IL-1β, IL-18 and IL-33 expressed on the cell surface. 
EL-4 D6/76 cells are derived from EL-4 cells (von Hoegen et al., 1989). Although 
these cells express functional IL-1RI that can bind IL-1 they do not respond to IL-1 
due to lack in IL-1RAcP expression (Hofmeister et al., 1997; Korherr et al., 1997; 
Wesche et al., 1997b). Transient or stable reconstitution of EL-4 D6/76 with full 
length IL-1RAcP restored completely the IL-1 responsiveness (Fig.3.2B) (Hofmeister 
et al., 1997; Korherr et al., 1997; Wesche et al., 1997b). While EL-4 D6/76 cells 
responded to IL-18 (Fig.3.6A), they did not respond to IL-33 (Fig.3.2B left). 
Reconstitution with full length mIL-1RAcP restored responsiveness not only to IL-1, 
but also to IL-33 (Fig.3.2B left), demonstrating that lack of IL-1RAcP is the reason for 
the inability of D6/76 to respond to both cytokines. It was not possible to reconstitute 
responsivenss to IL-1 or IL-33 by using a C-terminally truncated version of mIL-
1RAcP (ΔC-IL-1RAcP), which lacks the TIR domain, indicating that the TIR domain is 
required for IL-1 and IL-33 signaling. The response to either IL-33 or IL-1β could be 
increased by overexpressing mIL-1RAcP (Fig.3.2B right). This result demonstrates 
that full length IL-1RAcP is equally indispensable for IL-33- and IL-1-induced 
signaling by their respective receptor complexes. 
IL-33 did not induce the same level of IL-2 production in EL-4 or transfected D6/76 
cells as was reached with IL-1. To investigate whether the expression of endogenous 
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mIL-33Rα-chain was limiting in these cell lines, EL-4 cells were transiently 
transfected with increasing concentrations of plasmid encoding full length mIL-33Rα-
chain. In addition, D6/76 cells were transfected with a constant concentration of 
plasmid encoding full length mIL-1RAcP. In both situations, the response to IL-33 
was enhanced approaching the IL-1 response with respect to IL-2 production 
(Fig.3.2B left) and NF-κB activation (Fig.3.6B). This finding suggests that low 
expression of the endogenous IL-33Rα-chain is limiting IL-33 responses in this 
murine thymoma cell line. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.2: Cytokine production is induced by IL-33 and IL-1 only in the presence of IL-1RAcP. 
(A). Murine EL-4 6.1 cells respond to IL-33, IL-18 and IL-1 by producing IL-2 in a concentration 
dependent manner. 2.5 x 104 EL-4 6.1 cells were stimulated with the concentrations of rhIL-1β (grey 
diamonds), mIL-18 (black squares) or rmIL-33 (black circles) as indicated on the abscissa for 18 hr in
the presence of 50 nM Calcium ionophore A23187 in a total volume of 200 µl. Mouse IL-2 was 
measured in cell-free supernatants by ELISA. Recombinant mouse IL-33 was a thousand-fold less 
efficient than rhIL-1β in stimulating mIL-2 production.  
(B). The EL-4 D6/76 cell line responds to IL-33 or IL-1 only if reconstituted with full-length IL-
1RAcP. 5 x 106 EL-4 D6/76 cells were transiently co-transfected with 0.2 µg of plasmid encoding mIL-
33Rα-chain, and either empty vector or C-terminally truncated mIL-1RAcP (ΔC-IL-1RAcP) or full 
length mIL-1RAcP. Cells were subsequently stimulated with either 100 ng/ml rmIL-33 or 100 pg/ml 
rhIL-1β. 18 hr later mIL-2 was measured in cell-free supernatants by ELISA. Only full-length IL-1RAcP 
allowed a response to rhIL-1β (grey bars) or rmIL-33 (black bars) while the mutant form of mIL-1RAcP 
lacking the TIR-domain had no effect (left). Over expression of mIL-1RAcP resulted in an increase in 
IL-1 -(grey bars) or IL-33- induced IL-2 production (right).  
(C). After transfection with mIL-33Rα-chain the human embryonal kidney cell line HEK293RI 
responds to mIL-33 in a concentration dependent manner by producing IL-8. Transiently 
tranfected HEK293RI cells expressing mIL-33Rα were stimulated with the concentrations of rmIL-33 
as indicated for 18 hr and hIL-8 was detected by ELISA in the cell-free supernatants. 
Data depicted are means +/- standard deviations from one experiment (carried out in triplicates or 
quadruplicates) out of a series of three similar ones with comparable results. 
 
0
20
40
60
0 1.6 6.25 25 100
rmIL-33 [ng/ml]
hI
L-
8 
[p
g/
m
l]
C
0
50
100
150
200
250
0 0.05 0.125 0.25 0.5 1
mIL-1RAcP plasmid [µg / 5×106 cells]
m
IL
-2
 [p
g/
m
l]
0
50
100
150
200
e. v. ΔC-
AcP
AcP
m
IL
-2
 [p
g/
m
l]
B 
A 
50 
The human embryonic kidney cell line HEK293RI responds readily to IL-1 with the 
production of IL-8 due to the fact that it expresses endogenous IL-1RAcP and that it 
was stably transfected with IL-1RI (Cao et al., 1996). HEK293RI cells do not respond 
to either murine or human IL-33 since they do not express the endogenous human 
IL-33Rα-chain as measured by RT-PCR (data not shown). Murine IL-33 stimulated 
HEK293RI cells to IL-8 production when these cells were transiently transfected with 
murine IL-33Rα-chain (Fig.3.2C). These results demonstrate that murine IL-33Rα-
chain ligated with murine IL-33 is recognized by the endogenous human IL-1RAcP of 
HEK293RI cells. Thus, one must conclude that there is no species restriction in this 
direction, i.e. human IL-1RAcP can recognize murine IL-33Rα-chain when occupied 
by murine IL-33. Similar findings were also observed in EL-4 D6/76 cells transfected 
with either human or murine full length IL-1RAcP with respect to both IL-1 and IL-33 
responsiveness (data not shown).  
3.1.2.2. IL-1RAcP is required for IL-33 induced cytokine production 
The previous experiments proved that full length IL-1RAcP restored responsiveness 
to IL-1β and IL-33 in EL-4 D6/76 cells. In order to complement these gain-of-function 
studies upon full length IL-1RAcP expression, the loss-of-function studies were 
performed by either neutralizing IL-1RAcP with antibodies (Fig.3.3) or transfection of 
a dominant negative version of IL-1RAcP (ΔC-IL-1RAcP) which lacks the TIR domain 
(Fig.3.4) known to be required for IL-1 signal transduction.  
 
 
 
 
 
 
 
 
 
Fig. 3.3: The response to IL-33 in EL-4 cells is dependent on IL-1RAcP. 
IL-1 and IL-33 -stimulated IL-2 release in murine EL-4 6.1 cells is abrogated by the neutralizing anti-
mIL-1RAcP mAb 4C5. EL-4 cells were transiently transfected with mIL-33Rα-chain. A day after 
transfection 2.5 x 104 cells were preincubated for 30 minutes in the absence or presence (as indicated 
in bar chart) of neutralizing antibody 4C5 (anti mIL-1RAcP mAb, full bars) or the isotype control 
antibody RA3-6B2 (rat IgG anti mouse B200 antibody, hatched bars) and stimulated with either 
100pg/ml hIL-1β (left gray bars) or 50 ng/ml IL-33 (right black bars). mIL-2 was measured by ELISA 
from cell free supernatant 18 hours after stimulation (Data shown here is from EL-4 6.1 cells). Data 
shown here are means +/- standard deviations from one experiment (carried out in triplicates or 
quadruplicates) out of a series of at least three similar ones with comparable results. 
0
500
1000
1500
2000
0 0.1 1 10
antibody [µg/ml]
m
IL
-2
 [p
g/
m
l]
0
100
200
300
400
0 0.1 1 10
4C5 mAb [µg/ml]
m
IL
-2
 [p
g/
m
l]
 
51 
For neutralization studies the anti-mouse IL-1RAcP monoclonal antibody 4C5 was 
used. This antibody was described to neutralize IL-1β activity (Greenfeder et al., 
1995; Hestdal et al., 1994) by blocking IL-1RAcP. The pre-incubation of EL-4 6.1 and 
EL-4 D6/76 cells expressing mIL-33Rα-chain and full length mIL-1RAcP with different 
concentrations of mAb 4C5 (anti mIL-1RAcP mAb, Roche) abrogated IL-1β (Fig.3.3 
left) and IL-33 (Fig.3.3 right) induced mIL-2 production in a 4C5-concentration 
dependent manner. This effect was specific for the neutralizing anti-mIL-1RAcP 4C5 
mAb because the isotype control antibody RA3-6B2 (rat IgG anti- mouse B220 
antibody) neither affected hIL-1β (Fig.3.3 left and 3.7 left) nor mIL-33 (Fig.3.7 right) 
induced mIL-2 release. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to support the result achieved by the administration of the neutralizing anti-
mIL-1RAcP (4C5) mAb, a dominant negative version of IL-1RAcP that does not 
contain the TIR domain was used. Titration of a plasmid encoding ΔC-IL-1RAcP into 
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Fig. 3.4: The response to IL-33 in EL-4 or HEK293RI cells is dependent on IL-1RAcP. 
(A). IL-1 and IL-33 stimulated IL-2 release by EL-4 cells is inhibited by the over-expression of a 
C-terminally truncated IL-1RAcP molecule. 5 x 106 EL-4 6.1 cells were transiently transfected with 
0.5 μg of mIL-33Rα-chain encoding plasmid and plasmid containing C-terminally truncated mIL-1RAcP 
(ΔC-IL-1RAcP) lacking the TIR domain, which was not sufficient to allow signal transduction (as 
indicated). Cells (2.5 x 104) were stimulated with 100 pg/ml rhIL-1β or 50 ng/ml rmIL-33 and mIL-2 was 
measured from cell free supernatant by ELISA 18h after transfection. The answer to either rhIL-1β
(grey bars) or rmIL-33 (black bars) was significantly reduced in EL-4 6.1 cells by over expressing the 
ΔC-IL-1RAcP in a concentration-dependent manner.  
(B). IL-1 and IL-33 -stimulated IL-8 release by HEK293RI cells is inhibited by the over-
expression of a C-terminally truncated IL-1RAcP molecule. 3.6 x 106 HEK293RI cells were 
transiently transfected with 2 μg of mIL-33Rα-chain encoding plasmid and plasmid containing C-
terminally truncated mIL-1RAcP (ΔC-IL-1RacP), as indicated. Cells (2.5 x 104) were stimulated with 
either 100 pg/ml rhIL-1β (grey bars, left) or 50 ng/ml rmIL-33 (black bars, right) and hIL-8 was 
measured from cell free supernatant 18h after stimulation. The over expression of ΔC-IL-1RAcP in 
HEK293RI cells reduce hIL-8 production in a concentration-dependent manner. Data shown here (for 
A, and B) are means +/- standard deviations from one experiment (carried out in triplicates or 
quadruplicates) out of a series of at least three similar ones with comparable results. 
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EL-4 6.1 and HEK293RI cells (that were additionally transfected with a plasmid 
encoding mIL-33Rα) decreased the mIL-2 production in response to both IL-1β and 
IL-33 (Fig.3.4A) in EL-4 6.1 cells and hIL-8 production in response to IL-1β (Fig.3.4B 
left) and IL-33 (Fig.3.4B right) in HEK293RI cells in dose dependent manner. These 
results are consistent with the findings that IL-1RAcP is necessarily required for IL-1 
or IL-33 induced cytokine production. 
3.1.2.3. Activation of signaling events by IL-33 is dependent on the presence of 
IL-1RAcP  
The IL-1 receptor family uses the MyD88/IRAK/TRAF6 module to activate 
downstream signaling elements, such as cJun N-terminal kinase (JNK) or the 
transcription factor NF-κB. IRAK-1 activity was measured in 6-IRAK-19 cells (a stably 
transfected EL-4 cell clone that expresses hIRAK-1 (J. Knop & M. Martin unpublished 
data). 6-IRAK-19 cells were transiently transfected with mIL-33Rα-chain to increase 
IL-33 responses. Stimulation with either rhIL-1β or rmIL-33 resulted in enhanced 
autophosphorylation of IRAK-1 (Fig.3.5). Cotransfection with ΔC-AcP (ΔC-IL-1RAcP) 
reduced IRAK-1 activation. This result demonstrates that IRAK-1 is activated by the 
IL-33R complex and that this activation depends on the presence of the TIR domain 
in full length mIL-1RAcP. 
 
 
 
 
 
 
 
 
 
The activation of NF-κB is a central element of the signaling pathways activated by 
the IL-1 receptor family. Although D6/76 cells responded to IL-18 and TNFα, they did 
not respond to IL-1 or IL-33 by activation of NF-κB. Upon transfection with full length 
mIL-1RAcP, NF-κB activation was restored to both cytokines with no effect on TNFα 
Fig. 3.5: IL-33-induced IRAK1 phosphorylation depends 
on IL-1RAcP. C-terminally truncated IL-1RAcP reduces IL-33 
activation of IRAK-1. 6-IRAK-19 cells (a clone of EL-4 cells 
stably transfected with hIRAK-1) were transiently transfected 
with 1 μg of plasmid encoding mIL-33Rα-chain for every 107
cells. In addition, some of the cells were cotransfected with 1 
μg of plasmid encoding C-terminally truncated mIL-1RAcP 
lacking the TIR domain (ΔC-AcP). One day later, 
transfectants were either stimulated with 10 ng/ml rhIL-1β or 
100 ng/ml rmIL-33 for 15 min. IRAK-1 was 
immunoprecipitated from cell lysates by using mAb 2A9 (a 
kind gift from Z. Cao). Autophosphorylation of IRAK-1 was
measured in an in vitro kinase assay and visualized by 
autoradiography. Transfection efficiency was in the order of 
40% as ascertained by parallel transfections with EGFP 
plasmid and cytofluorometry. The data shown are of one 
representative experiment out of a series of three with 
comparable results. 
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or IL-18 response. Preincubation with mAb 4C5, which neutralizes murine IL-1RAcP, 
inhibited IL-1- and IL-33-stimulated NF-κB activation, but did not affect IL-18- or 
TNFα-stimulated activation of the transcription factor (Fig.3.6A right). ΔC-AcP was 
not able to restore IL-1 or IL-33 responsiveness with respect to NF-κB activation in 
D6/76 cells (data not shown). Transfection of EL-4 cells with increasing amounts of 
the plasmid-encoding ΔC-AcP resulted in a concentration-dependent reduction in IL-
33-induced NF-κB activation, demonstrating that the truncated form of mIL-1RAcP 
behaved in a dominant-negative fashion (Fig.3.6B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transfection of EL-4 cells with increasing amounts of the plasmid encoding full length 
mIL-33Rα-chain resulted in an increase in NF-κB activation after IL-33 stimulation 
while leaving the IL-1 response unaffected (Fig.3.6A left). This finding proves the 
Fig. 3.6: IL-33-induced activation of NF-κB depends on IL-1RAcP.  
(A). Activation of the transcription factor NF-κB by IL-33 depends on IL-1RAcP. D6/76 (Left) 
and EL-4 (Right) cells were transiently cotransfected with plasmids encoding mIL-33Rα-chain and an 
NF-κB-dependent luciferase reporter plasmid (D6/76 cells, 0.5 μg of plasmid each for 5 x 106 cells; 
EL-4 cells, 0.5 μg of reporter plasmid plus the indicated concentrations of plasmid for mIL-33Rα or 
empty vector). In addition, in D6/76 cells, full length mIL-1RAcP was overexpressed. Cells were 
stimulated with either 100 ng/ml rmIL-33 (black bars) or 100 pg/ml rhIL-1β (gray bars) and either 100 
ng/ml rmIL-18 or 100 ng/ml rhTNFα, and luciferase activity was determined in the cell lysates the 
next day. Preincubation with 50 μg/ml mAb 4C5 (white bars) was for 1 h before stimulation. Depicted 
is fold induction, relative light unit (RLU) values of stimulated samples/RLU values of controls.  
(B). IL-1RAcP lacking the TIR domain (ΔC-AcP) is dominant-negative in IL-33 signaling as 
measured in a NF-κB reporter gene assay. EL-4 cells were transiently transfected with increasing 
amounts of a plasmid encoding ΔC-IL-1RAcP (ΔC-AcP) in addition to an NF-κB-dependent luciferase 
reporter plasmid (1 μg for every 1 x 107 cells). The next day, cells were stimulated with 100 ng/ml 
rmIL-33 for a further 18 h. Luciferase activity was measured in the cell lysates.  
Data shown in A and B are duplicates or tripicates of one representative experiment out of a series of 
three with comparable results. 
A 
B 
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specificity of the observed effect for IL-33 and that the endogenous expression level 
of mIL-33Rα-chain limited the response to its ligand in this cell line. 
Preincubation of EL-4 or IL-1RAcP transfected D6/76 cells with mAb 4C5 resulted in 
a reduction of IL-1β- and IL-33-stimulated NF-κB activation (Fig.3.7). NF-κB 
activation was nearly completely inhibited by 4C5 after stimulation with rhIL-1β, 
whereas rmIL-33-stimulated activation was reduced to about 50%. The isotype-
matched control antibody had no effect on IL-1- or IL-33-stimulated NF-κB activation 
(Fig.3.6A left and Fig.3.7, open bars). 
 
 
 
 
 
 
 
 
 
 
 
IL-33 activates cJun kinase and p38 MAP kinase 
As was reported previously, the activation of JNK by IL-1 depends on the presence of 
IL-1RAcP in D6/76 cells (Wesche et al., 1997b). In order to investigate activation of 
JNK and p38 MAP kinases by IL-33, time course studies were performed. IL-33 and 
IL-1β induced activation of JNK was studied in EL-4 cells. IL-1 and IL-33 activated 
JNK in a transient fashion. The maximum activity was measured at 12–16 min in an 
in vitro kinase assay by using GST-cJun as substrate. The kinetic of JNK activation 
was identical between IL-1 and IL-33 (Fig.3.8A). IL-33 and IL-1β stimulate JNK 
activation transiently after stimulation which last up to 32 minutes with the peak of 
phosphorylation between 12-16 minutes. 
  
Fig. 3.7: IL-33-induced activation of NF-κB depends on IL-1RAcP.  
The neutralizing anti-mIL-1RAcP mAb 4C5 reduces IL-1β- and IL-33-stimulated NF-κB activity. EL-4 
cells were transiently cotransfected with a plasmid encoding mIL-33Rα-chain and an NF-κB-
dependent luciferase reporter gene. Subsequently, cells were preincubated for 30 min with either 4C5 
(filled bars) or the isotype control antibody RA3–6B2 (open bars) at 0, 0.1, 1, or 10 μg/ml and 
stimulated with either 100 pg/ml rhIL-1β (gray bars) or 50 ng/ml rmIL-33 (black bars). The next day, 
luciferase activity was determined in the cell lysates. Data shown are triplicates of one representative 
experiment out of a series of three with comparable results. 
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p38 phosphorylation time course study was performed in transiently transfected 
HEK293RI cells expressing IL-33Rα. Western blot analysis of phoso p38 and total 
p38 proteins reveled that IL-33 stimulate p38 phosphorylation after 10 minutes of 
stimulation which lasted longer than 60 minutes with the maximum at 60 minutes  
where as IL-1β resulted in p38 phosphorylation just after stimulation which was 
detectable longer than 60 minutes with the maximum at 30 minutes (Fig.3.8B).  
In summary, these results demonstrate that key elements of the classical signaling 
pathway used by the IL-1 receptor family such as IRAK-1, NF-κB, and JNK and p38 
were specifically activated by IL-33 only in the presence of full length IL-1RAcP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.8: IL-33 stimulates activation of cJun and p38 MAP kinase. 
(A). IL-33 and IL-1 induced activation of EL-4 cells leeds to JNK activation. A time course study 
was performed to measure the activation of the cJun kinase JNK. 2.5 x 106 EL-4 cells transiently 
transfected with IL-33Rα encoding plasmid were stimulated with either 50 ng/ml rmIL-33 or 10 ng/ml 
rhIL-1β for indicated time points. Cells were lysed and JNK assay was performed from 10 μg of the 
protein. Proteins were separated on 12.5% SDS-PAGE and phosphorylated GST:cJun was visualized 
by autoradiography after 3 days exposure  (upper). In parallel the same amount of protein was 
separated and total JNK protein was detectd by Western blotting using anti-JNK antibodies (lower).  
(B). Activation of p38 in transiently transfected HEK293RI cells by IL-33 and IL-1. A time course 
study was made for activation of p38 MAP kinase. HEK293RI cells were transiently transfected with 
IL-33Rα encoding plasmid. Next day these transfected cells were stimulated with either 50 ng/ml rmIL-
33 or 10 ng/ml rhIL-1β for 0, 5, 10, 15, 30 and 60 minutes. Cells were lysed with 100 μl of Laemmli 
buffer and phospho p38 and total p38 proteins were detected by Western blotting using anti-phospho 
p38 antibodies (upper) and anti-p38 antibodies (lower). 
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3.1.2.4. Demonstration of specificity of IL-33 effects 
3.1.2.4.1. Heat treatment reduces IL-33 bioactivity 
The data described above indicate that the response to IL-33 is specific to IL-1RAcP 
and IL-33Rα, as IL-33 response can be increased by either increasing the expression 
level of IL-1RAcP or IL-33Rα-chain (Fig.3.2B and 3.6A). However, in order to prove 
that IL-33 is the only causative reagent for the biological effects on cells treated with 
rmIL-33 and to rule out non-specific effects due to any contamination or indirect effect 
of IL-33, rmIL-33 and rhIL-1β were heat-treated for 10 or 30 minutes at 95 ºC to 
destroy the proteins. These heat-treated cytokines were used to stimulate EL-4 cells. 
Interestingly, rmIL-33 was rather heat stable in comparison to IL-1 as depicted in the 
results from the bioassay. However, by heating for 30 minutes at 95 ºC, practically all 
of the biological activity was destroyed when using low concentrations of IL-33 
(Fig.3.9). These results proof that the effects observed here are solely due to IL-33 
protein and not to a contamination e.g. by LPS. 
 
 
 
 
 
 
 
 
 
3.1.2.4.2. Soluble IL-33Rα-chain (ST2) inhibits IL-33 induced stimulation of EL-4 
cells 
In order to demonstrate the specificity of IL-33 -induced signaling, soluble mIL-
33Rα:Fc (soluble ST2) was used to inhibit the IL-33 induced mIL-2 production by EL-
4 cells. Soluble mIL-33Rα: Fc did not work to neutralize the IL-33 in the EL-4 system 
at a 100 fold molar excess when IL-33 induced IL-2 production was measured after 
overnight incubation (data not shown). Thus a different type of experiment was 
designed in which rmIL-33 was to be removed by ST2:Fc fusion protein in solution 
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30 min Fig. 3.9: Demonstration of specificity of IL-33 effects in EL-4 cells. Heat treatment of rmIL-33
inhibits mIL-2 production by EL-4 cells. rhIL-1β and 
rmIL-33 were heat treated at 95 ºC for 0, 10 and 30 
minutes. EL-4 cells (2.5 x 104 / well) were stimulated 
with heat treated rhIL-1β and rhIL-33 in 200 μl total 
volume for over night and mIL-2 was measured by 
ELISA from cell free supernatant. rmIL-33 is relatively 
stable to heat treatment.  
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before addition of IL-33 to the cells. In this experimental setup loss of IL-33 activity 
was achieved leaving unaffected the IL-1β -induced IL-2 production (Fig.3.10A), thus 
demonstrating the IL-33 specificity of the effect. However, due to costs of the Fc 
fusion protein, only a 100 fold molar excess of ST2:Fc could be tested, which did not 
suffice to achieve complete inhibition. In a different approach, mIL-33 or IL-1β was 
preincubated with IL-33Rα:Fc fusion protein and then the mixture was added to cells 
for 15 min to stimulate JNK activity. In this short term stimulation inhibition of IL-33 
stimulated JNK activity was achieved which was not seen on IL-1 stimulated JNK 
activity (Fig.3.10B), indicating that all the responses observed are specific for IL-33, 
rather than being caused by any contamination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.10: Soluble IL-33Rα-chain inhibits IL-33 effects. 
(A). Soluble mIL-33Rα-Fc (ST2) inhibits IL-33 induced mIL-2 production.  
Medium, 20 ng/ml rmIL-33 or 100 pg/ml rhIL-1β were incubated with mST2:hIgG(Fc) (as indicated) in 
the presence of protein A sepharose for one hour at 37 ºC and supernatant and beads were separated 
by centrifugation. 2.5 x 104 EL-4 cells were stimulated with preincubated medium, rhIL-1β (100pg/ml) 
or rmIL-33 (20 ng/ml) from protein A free supernatant for overnight and mIL-2 was measured by ELISA 
from cell free supernatant. Soluble ST2 inhibits specifically mIL-33 induced mIL-2 production in dose 
dependent manner.  
(B). Soluble mIL-33Rα-Fc (ST2) inhibits IL-33 induced activation of JNK.  
2.5 x 106 IL-33Rα transfected EL-4 cells were kept unstimulated or stimulated for 15 minutes with 
either 50 ng/ml rmIL-33 or 10 ng/ml rhIL-1β in the presence or absence of 20 μg/ml mST2:hIgG(Fc) 
(preincubated with stimulus for 30 minutes). 10 µg of whole cell lysates were used in a kinase assay 
with 1 µg of GST:cJun as substrate and 2 µCi [32Pγ]-ATP. Proteins were separated on 12.5% SDS-
PAGE and phosphorylated GST:cJun was visualized by autoradiography after 3 days exposure. In 
parallel same amount of protein was separated on 12.5% SDS-PAGE and total JNK protein was 
visualized by Western blot/ECL reaction with anti-JNK antibodies (lower). For IL-1β only 1/4 amount of 
sample was loaded compared to the unstimulated or stimulated with rmIL-33. 
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3.1.2.5. IL-1RAcP is required for IL-33-induced cytokine release in mast cells  
Freshly isolated and differentiated murine bone marrow-derived (BMD) mast cells 
(BMDMC) were used to confirm the results obtained with EL-4 cells on primary mast 
cell cultures. (BMDMC were isolated, differentiated and purity was analyzed by Prof 
Dr. Michael Huber (Max-Plank Institute of Immunobiology, Freiburg Germany) and 
most of the experiments on mast cells were also performed in Freiburg in 
collaboration with Dr. Huber). 
BMDMC express high levels of ST2 (IL-33Rα-chains) as determined by RT-PCR 
(data not shown) and FACS analysis (Fig.3.11A). BMMC also expressed IL-1RAcP 
mRNA (data not shown). The IL-33 receptor is functional in that IL-33 dose-
dependently stimulates production of the pro-inflammatory cytokine IL-6 to an extent 
comparable to LPS in BMDMC (Fig.3.11B), and this response is IL-33 specific and 
dependent on IL-1RAcP because it was suppressed by the neutralizing antibody 
(mAb) 4C5 (Fig.3.11D). 
To investigate the effects of IL-33 on the production of additional cytokines and 
chemokines in BMDMC, the levels of TNF-α, IL-1α, IL-1β, MCP-1, IL-10, IFNγ, 
IL12p70, IL-2, IL-4 and IL-13 were quantified in supernatants fo BMDMC using 
Beadlyte MultiCytokine Flex kits in a Luminex 100 instrument in collaboration with 
Prof. Werner Falk, University of Regensburg (cytokines were measured at University 
of Regensburg). It was found that IL-1α, MCP-1, IL-10, IFNγ, IL12p70, IL-2, and IL-4 
were below the detection limit for this assay in supernatants obtained from both 
resting and stimulated BMMC. Stimulation of BMDMC with IL-33 stimulated rapid 
(less than 3 hours) release of TNFα and IL-1β, but did not affect the low constitutive 
release of IL-13 (Fig.3.11C). Pretreatment with the monoclonal antibody (mAb) 4C5, 
which neutralizes IL-1RAcP (Greenfeder et al., 1995; Hestdal et al., 1994), resulted in 
a concentration-dependent reduction of the IL-33-induced cytokine production. If 
mast cells were stimulated with low concentrations of rmIL-33 (1–3 ng/ml), a 
complete inhibition of stimulated IL-6 production could be achieved (Fig.3.11D). 
TNFα release remained, 27% at 25 μg/ml or 12% at 50 μg/ml mAb 4C5, respectively. 
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Fig. 3.11: Bone marrow derived mast cells respond to IL-33 with cytokine production in an IL-
1RAcP-dependent manner (data from collaboration with M. Huber and W. Falk). 
(A). Murine bone marrow derived mast cells express ST2 / mIL-33Rα-chain on their cell surface.
Mast cells were incubated with an FITC-labelled anti-mouse ST2 antibody and surface expression was 
analysed by flow cytometry. 
(B). Murine bone marrow derived mast cells produce IL-6 after stimulation with rmIL-33 in 
concentration dependent manner. Cells were stimulated with 0, 1, 10, 10 100 ng/ml rmIL-33 or 1 
μg/ml LPS. The next day mIL-6 was detected by ELISA in cell-free supernatants. LPS served as a 
positive control. 
(C). Mast cells produce several pro-inflammatory cytokines after stimulation with rmIL-33. The 
1 x 106 cells per millilitre were seeded and stimulated with 2 ng/ml rmIL-33 for 0, 3, 6, and 24 h as 
indicated. Cytokine profiles were detected in the supernatants by using Beadlyte MultiCytokine Flex 
kits in a Luminex 100 instrument. 
(D). IL-33 stimulated IL-6 release in murine bone marrow derived mast cells is reduced by the 
neutralizing anti-mIL-1RAcP mAb 4C5. Cells were pre-incubated for 30 min with three different 
concentrations of 4C5 mAb (black bars = no mAb, dark grey bars = 1 µg/ml, light grey bars = 10 µg/ml, 
open bars = 50 µg/ml 4C5 each) and then either left untreated (con) or stimulated with 1 ng/ml or 10 
ng/ml rmIL-33. The next day murine IL-6 was measured by ELISA in cell free supernatants. Results 
are from one representative experiment of a series with comparable results (C) or are means of 
triplicates or quadruplicates of one typical experiment out of a series of at least three similar 
experiments with comparable results (B and D). For mast cell stimulation, only commercial rmIL-33 
was used (LPS < 0.1 units/μg protein). 
A B
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3.1.2.6. IL-1RAcP is required for IL-33 -induced proliferation of D10G4.1 cells 
D10G4.1 cells express functional IL-1 receptor and proliferate in response to IL-1β 
stimulation (Fig.3.12A). These cells also express IL-33Rα and IL-1RAcP mRNA as 
detected by RT-PCR (data not shown). The IL-33 receptor in D10G4.1 cells is 
functional in that the cells respond to IL-33 in dose dependent fashion in the D10 
proliferation assay (Fig.3.12A). Although the concentrations of IL-33 required to 
achieve comparable responses is 100 times higher than that of IL-1β in D10 cells,  
the relative IL-33 requirement in D10 cells is much less than in EL-4 cells (Fig 3.2A), 
indicating that the expression of IL-33 receptor is not as limiting as in EL-4 cells or, 
alternatively, that these cells may express some additional molecules which increase 
the binding affinity of the IL-33 to the receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to assess the role of IL-1RAcP in IL-33 -induced D10 proliferation, anti-IL-
1RAcP neutralizing antibodies 4C5 were used. As shown in Fig.3.12B, the 
neutralizing antibodies inhibited IL-1β induced D10 proliferation considerably while 
leaving unaffected the IL-33 induced D10 proliferation even at lower concentrations 
of IL-33. The neutralizing anti-IL-1RAcP antibody 4C5 neutralizes the effect of IL-1β 
in all cell types (tested). It also inhibited the IL-33 induced responsiveness in EL-4 
Fig. 3.12: D10G4.1 cells respond to IL-1 and IL-33 in D10 proliferation assay. 
(A). Concentration curve for IL-1β and IL-33 responsiveness in D10 assay. D10G4.1 (2.5 x 104/ 
well) cells were cultured in 96 well plate in the absence or presence of increasing concentration (as 
indicated) of either hIL-1β (grey triangles) or mIL-33 (black circles) for 5 days and MTT assay was 
performed on 5th day.  
(B). Neutralizing antibody inhibits D10 proliferation in response to IL-1β but not in response to 
IL-33. 2.5 x 104 cells were stimulated with indicated concentrations of IL-1 or IL-33 in the presence
(hashed bars) or absence (full bars) of 10 μg/ml anti-IL-1RAcP (4C5) antibody and MTT assay was 
performed after 5 days of incubation. Results shown for A and B are shown as means of three 
replicates in one experiment.  
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cells and mast cells but not in D10 cells. These results raise the question, whether IL-
1RAcP is definitely required for IL-33 induced signaling in D10 G4.1 cells or not. In 
order to answer the question, NF-κB dependent reporter gene assay was performed 
after overexpression of ΔC-IL-1RAcP (lacking TIR domain). Results depicted in 
Figure 3.13 demonstrate the dominant negative effect of ΔC-IL-1RAcP molecule 
(lacking TIR domain) overexpression in a dose dependent fashion. This dominant 
negative effect was comparable for IL-1β and IL-33-stimulated NF-κB activity 
indicating the absolute requirment of IL-1RAcP for IL-33 induced activation of D10 
G4.1 cells, demonstrating the need for IL-1RAcP also in D10 cells. 
 
 
 
 
 
 
 
 
3.1.2.7. The interaction of IL-33Rα-chain and IL-RAcP is dependent on IL-33 
It is well known that IL-1 receptors and IL-1RAcP form heterodimeric receptor 
complexes on the cell surface after binding of IL-1 to either IL-1RI or IL-1RII (Lang et 
al., 1998). To clarify whether such a complex also forms between IL-1RAcP and IL-
33Rα-chain, epitope-tagged versions of IL-1RAcP and IL-33Rα were co-expressed 
in HEK293RI cells. After stimulation with rmIL-33, complexes were co-
immunoprecipitated. IL-1RAcP was co-precipitable with IL-33Rα-chain (Fig.3.14A), 
and vice versa (Fig.3.14B), only in the presence of rmIL-33, but not if the cells were 
incubated with rhIL-1β (Fig.3.13A & B). In some experiments, a weak interaction in 
the absence of ligand was also observed, most likely due to the strong protein 
expression in HEK293RI cells. This result demonstrates that the interaction of the 
membrane-inserted forms of IL-1RAcP and IL-33Rα-chain is specific for and 
dependent on IL-33. It has been shown that soluble IL-1 receptors and IL-1RAcP 
interact in the presence of IL-1 (Smeets et al., 2003; Smith et al., 2003). Employing a 
Fig. 3.13: IL-1RAcP is required for IL-33 signaling in D10 
cells. 10 x 106 D10G4.1 cells were transiently transfected with 
1 μg of plasmid containing firefly luciferase gene under NF-κB 
promoter along with increasing amounts (as indicated) of TIR 
domain lacking IL-1RAcP (ΔC-IL-1RAcP) expressing plasmid. 
Cells were kept unstimulated or stimulated 4 hours after 
transfection with either 1 ng/ml IL-1β (grey bar) or 50 ng/ml IL-
33 (black bar). Next day reporter gene activity was analysed 
from cell lyates. Results shown here are representative of 3 
independent experiments with similar results and are shown as 
means of three replicates in one experiment + SEM. 
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soluble IL-33Rα:Fc fusion protein and an epitope-tagged soluble IL-1RAcP, it was 
demonstrated that a specific interaction in solution took place in the presence of IL-
33, which was stable enough to be immunoprecipitated (Fig.3.14C. (The depicted 
experiment was performed in collaboration with Prof. Werner Falk, Regensburg, 
subsequent experiments were performed in Giessen after cloning of own IL-33Rα:Fc 
fusion protein). This result extend the finding that IL-1RAcP is the co-receptor for IL-
33Rα-chain from the membrane-inserted forms to the soluble molecules. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.14: The interaction of IL-1RAcP with the IL-33Rα chain is dependent on IL-33. 
(A & B). Membrane IL-33Rα-chain and IL-1RAcP form a complex in the presence of IL-33.  
HEK293R1 cells were transiently transfected with plasmids containing Flag tagged mIL-1RAcP and/or 
Myc tagged mIL-33Rα alone or in combination. Transfected cells (next day) were left unstimulated or 
stimulated with 10 ng/ml rhIL-1β or 100 ng/ml rmIL-33 (as indicated at top edge of Fig) for 15 min at 37
°C. Cells were lysed in absence or presence of 10 ng rhIL-1β or 100 ng rmIL-33. Flag tagged mIL-
1RAcP (A) or Myc tagged IL-33Rα (B) molecules were immunoprecipitated for overnight at 4 °C using
anti-Flag M2 agarose beads (A) or anti-Myc antibodies (B). Precipitated proteins were washed, and 
visualized by Western blot/ECL reaction with anti-Myc and anti-Flag antibodies. A strong band in co-
immunoprecipitated Flag-mIL-1RAcP and Myc-mIL-33Rα only in IL-33 presence indicate strong 
physical interaction of both receptor chains. The results shown are representative of 5 independent 
experiments with similar results.  
(C). Soluble forms of IL-33Rα-chain and IL-1RAcP form a complex in the presence of IL-33.  
srmIL-33Rα:(hIgG) Fc fusion protein was incubated in the absence or presence of rmIL-33 with Flag-
epitope-tagged srmIL-1RAcP fixed on Flag-affinity gel. Coprecipitated fusion protein was visualized by 
Western blot after SDS/PAGE by using an anti-human IgG secondary antibody (Fig. 3.14C was 
generated in collaboration with Prof. Werner Falk at University of Regensburg). 
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3.1.2.8. IL-33 receptor works in heterodimeric form 
All known members of the IL-1 receptor family function as heterodimeric receptor 
complexes. Thus it was likely that the functional IL-33 receptor complex would also 
work in a heterodimeric form. However, in principle, also homodimers were possible. 
In order to demonstrate heterodimerization and exclude the possiblity of 
homodimerization of IL-33Rα upon IL-33 binding, Flag-tagged and/or Myc-tagged IL-
33Rα were expressed in HEK293RI cells along with or without untagged ΔC-IL-
1RAcP and incubated with IL-33. Co-immunoprecipitation results showed that the 
co-expressed Flag- or Myc-tagged IL-33Rα do not interact either in the absence or 
presence of ligand (Fig.3.15) indicating that IL-33 does not dimerize ST2 (IL-33Rα) 
but rather signals through recruitment of IL-1RAcP. 
From the above results it can be concluded that IL-1RAcP associates with IL-33Rα 
in a ligand-dependent manner (Fig.3.14A & B), furthermore, these results suggest 
that IL-33 does not dimerize IL-33Rα (Fig.3.15) but rather signals through 
recruitment of IL-1RAcP. Finally, the soluble form of IL-33Rα can recruit also the 
soluble IL-1RAcP in the presence of IL-33 (Fig.3.14C) suggesting that the 
combination of soluble IL-33Rα and soluble IL-1RAcP can act in a synergistic 
manner to inhibit IL-33 activities. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.15: IL-33 does not homodimerize ST2 (IL-33Rα). 
Flag-tagged and/or Myc-tagged IL-33Rα were expressed along with or without untagged ΔC-IL-1RAcP 
in HEK293RI cells. Next day cells were either kept unstimulated or stimulated with 100 ng/ml rmIL-33 
for 15 minutes. Cells were lysed and proteins were immunoprecipitated for overnight with Anti-Flag M2 
agarose. Immunoprecipitated IL-33Rα proteins were visualized after staining with anti-Myc antibodies 
(Upper) or anti-Flag antibodies (Lower). IL-33 does not dimerize ST2 (IL-33Rα). Results shown here 
are representative of 3 independent experiments with similar results. 
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3.1.3. Investigating the role of TIR8 (SIGIRR) in IL-33 signaling 
The series of experiments described above prove that IL-1RAcP is absolutely 
required for IL-33-induced activation of the cells. Thus, IL-1RAcP is definitely a 
component of the IL-33 receptor complex in addition to IL-33Rα. This does not, 
however, exclude that at least in some cell types additional molecules may 
participate in the functional IL-33R complex. It was proposed that a possible 
candidate was TIR8 (SIGIRR). The role of this member of the IL-1 receptor family 
remains unclear, although it has been published that it may function as a negative 
regulator of Toll like receptors. 
3.1.3.1. TIR8 over expression inhibits LPS and IL-1 induced signaling 
In order to define the role of TIR8 in IL-33 signaling, the expression vectors of 
human and murine TIR8 were obtained from Prof. Alberto Mantovani (Instituto 
Clinico Humanitas, Rozzano (MI), Italia). The expression of the proteins was 
analyzed in HEK293RI cells by Western blotting. Both expression vectors yielded 
high levels of Flag-tagged TIR8 proteins (Fig.3.16A).  
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Fig 3.16: TIR8 (SIGRR) is a negative regulator of IL-1 and LPS signaling. 
(A). Overexpression of human or mouse TIR8 inhibits IL-1 induced NF-κB activation in 
HEK293RI cells. HEK293RI cells were cotransfected with one μg reporter gene plasmid and either 
with 5 μg of empty vector (EV) vector, human or mouse TIR8 encoding plasmid. Next day cells were 
either stimulated with 100 pg/ml rhIL-1β or kept unstimulated. After overnight incubation reporter gene 
(luciferase) activity was measured from cell lysates. Depicted data are fold stimulations.  Expression of 
human and mrine TIR8 is also showen by Western blot analysis from transiently transfected 
HEK293RI cells after immunoprecibitation with anti-Flag mAb. 
(C). TIR8 inhibits LPS-induced mIL-6 production in L929 cells. L929 cells were transfected with 
indicated amount of hTIR8 (grey bars) or mouse TIR8 (black bars) encoding plasmid (total amount of 
plasmid DNA was maintained by adding empty vector). Next day 2.5 x 104 cells were either kept 
unstimulated or stimulated with 1ng/ml LPS in 96 well microtiter plate. After overnight incubation mIL-6 
was measured by ELISA from cell free supernatants. Results in A and B are representative of two 
independent experiments and are expressed as mean of three replicates in one experiment + SEM. 
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TIR8 is known as a negative regulator of Toll/Interleukin-1 receptor signaling. The 
overexpression of both human and murine TIR8 reduced IL-1 -induced activation of 
NF-κB in HEK293RI cells (Fig.3.16A) and LPS-induced production of IL-6 
(Fig.3.16B) in L929 cells in dose-dependent manner. As shown in Fig.3.16A and B 
TIR8 overexpression inhibited the IL-1β and LPS induced signaling. However, it was 
observed that this inhibition was only achievable when there is very high expression 
of TIR8, at lower plasmid concentrations, protein expression did not affect LPS 
induced signaling. 
3.1.3.2. TIR8 expression does not affect IL-33 signaling 
In order to clarify whether IL-33Rα can use TIR8 as co-receptor for IL-33 signaling 
instead of IL-1RAcP murine TIR8 was overexpressed either alone or in combination 
with mIL-1RAcP (AcP) in EL-4 D6/76 cells. TIR8 expression was not able to 
reconstitute the responsiveness to IL-1β (Fig.3.17 left) and IL-33 (Fig.3.17 right). 
Moreover, co-expression of mTIR8 with mIL-1RAcP did not affect IL-1β or IL-33-
induced mIL-2 production by EL-4 D6/76 cells, indicating that mTIR8 exerts neither 
stimulatory nor inhibitory effects on IL-1 and IL-33-induced IL-2 production in EL-4 
D6/76 cells.  
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Fig. 3.17: mTIR8 expression does not reconstitute IL-1 or IL-33 signaling in EL-4 D6/76 cells.  
EL-4 D6/76 cells (5 x 106) were transiently transfected with 0.25 μg of plasmid containing mIL-33Rα 
gene along with indicated plasmids. Next day 2.5 x 104 cells/well were stimulated with either 100 pg/ml 
IL-1β (left, grey) or 50 ng/ml IL-33 (right, black) for overnight. mIL-2 was measured from cell free 
supernatant by ELISA. Results shown are representative of 2 independent experiments with similar 
results. Results are shown as mean of three replicates in one experiment and are expressed as fold 
luciferase activity (stimulated/unstimulated) + relative error. 
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From the results it was clear that TIR8 expression was not able to render EL-4 D6/76 
cells responsive to IL-33. In addition, the results described above demonstrate that 
TIR8 was unable to inhibit the IL-1 signaling which was seen in HEK293RI cells 
(Fig.3.16A). A possible explanation may be the rather low protein expression of 
ectopically expressed proteins in EL-4 D6/76 cells when compared to that of 
HEK293RI cells. So to demonstrate the effect of TIR8 overexpression on IL-33 
signaling, HEK293RI cells were made responsive to IL-33 by transient transfection of 
mIL-33Rα encoding plasmid and the effect of TIR8 overpression on IL-33 signaling 
was analyzed in a reporter gene assay. The results of the NF-κB reporter gene 
showed slight inhibition of the IL-1 -induced NF-κB activation at higher concentrations 
of TIR8 coding plasmid (Fig.3.18A). However, overexpression of the TIR8 had no 
effect on IL-33 stimulated NF-κB activation in transiently transfected HEK293RI cells 
(Fig.3.18A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.18: TIR8 expression does not inhibit IL-33 signaling. 
(A). TIR8 expression does not affect IL-33 induced NF-κB stimulation in HEK293RI cells.
HEK293RI cells were transiently transfected with 1 μg of reporter gene plasmid, 2 μg of IL-33Rα 
encoding plasmid and increasing amount of mTIR8 encoding plasmid Next day 5 x 104 cells/well were 
kept unstimulated or stimulated with either 100 pg/ml IL-1β (grey bar) or 50 ng/ml IL-33 (black bar) in 
96 well microtiter plate. After over night incubation reporter gene activity was measured from cell 
lysates. IL-33 signaling was not affected by TIR8 co-expression.  
(B). IL-33 signaling in EL-4 cells was not affected by TIR8 over expression. EL-4 cells (10 x 106) 
were transiently transfected with 1 μg of reporter gene plasmid along with increasing amount of 
plasmid containing mTIR8 gene. 4 hours after transfection 5 x 105 cells/well were kept unstimulated or 
stimulated with either 100 pg/ml IL-1β (grey bar) or 50 ng/ml IL-33 (black bar) in 96 well microtiter 
plate. Next day reporter gene activity was measured from cell lysates. Results shown in A and B are 
representative of three independent experiments with similar results. Results are shown as mean of 
three replicates in one experiment and are expressed as fold luciferase activity (stimulated / 
unstimulated) + relative error. 
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The difference in IL-1 induced NF-κB inhibition shown in Fig.3.16C and Fig.3.18A 
may be explained by the difference in amount of TIR8 protein expression. It was not 
possible to transfect with the same amount of TIR8 encoding plasmid because 
HEK293RI cells additionally require IL-33Rα expression to render the cells 
responsive to IL-33. Relatively lower response of transfected HEK293RI cells to IL-33 
and lower concentrations of TIR8 expression may explain that no effect of TIR8 
expression was detected on IL-33 signaling. 
In order to verify these results in cells responding naturally to IL-33, a reporter gene 
assay was performed on EL-4 cells expressing increasing amounts of mTIR8. 
Expression of TIR8 showed neither inhibitory nor stimulatory effects on IL-1 or IL-33 
induced NF-κB stimulation in EL-4 cells (Fig.18B). Thus it can be concluded that 
TIR8 expression does not affect the IL-33 signaling and that the inhibitory effect 
which was seen in other systems may be an overexpression artifact. 
3.1.3.3. TIR8 does not recognize IL-33 receptor complex 
In the past it has been shown that the replacement of the cytoplasmic domain of IL-
1RI by that of other family members still resulted in NF-κB activation after IL-1 
binding to the chimera (Greenfeder et al., 1995; Mitcham et al., 1996). Assuming that 
TIR8 might function as accessary protein for IL-33 receptor, it was necessary to 
ascertain whether the extracellular domain of TIR8 could recognize IL-33 bound to 
the IL-33 receptor α-chain. In order to answer this question a TIR8-AcP chimera 
(Fig.3.19A) was generated by fusion of the extracellular and trans-membrane regions 
of murine TIR8 with the intracellular region of mIL-1RAcP (which is able to generate 
signaling). If the working hypothesis was correct, the extracellular and/or 
transmembrane domain of TIR8 should be able to recognize the ligand receptor 
complex and thus the intracellular IL-1RAcP moiety should start signaling upon 
stimulation.  
The expression of TIR8-AcP chimera could not reconstitute IL-1β (Fig.3.19C left) or 
IL-33 (Fig.3.19C right) responsiveness in EL-4 D6/76 cells as measured by NF-κB 
dependent reporter gene assay whereas wild-type IL-1RAcP was able to do so. In 
addition TIR8-AcP fusion gene expression did not affect the IL-1RAcP reconstituted 
IL-1β or IL-33 responsiveness when TIR8-AcP and IL-1RAcP were co-expressed. 
These findings indicate that extracellular and transmembrane parts of mTIR8 are 
unable to recognize IL-1 bound to IL-1 receptor and/or IL-33 bound to IL-33 receptor. 
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It must be concluded that TIR8 can not be a direct component of the receptor 
complexes for either IL-1 or IL-33. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.19: TIR8 does not recognize IL-33 receptor complex. 
(A). Schematic diagram of construction of mTIR8 (extracellular and transmembrane) and mIL-1RAcP 
(intracellular part, containing TIR domain) chimeric gene.  
(B). Western blot analysis of mTIR8-AcP fusion gene expression. mTIR8-AcP fusion gene was 
expressed in HEK293RI cells after transient transfection. Flag tagged fusion protein was analyzed by 
Western blotting from cell lysate (Cl) or after immunoprecipitation (IP) using anti-Flag M2 agarose. 
EV= cell lysate from empty vector transfected cells.  
(C). mTIR8-AcP expression does not affect IL-33 signaling in EL-4 D6/76 cells. EL-4 D6/76 cells 
(10 x 106) were transiently transfected with 1 μg of plasmid containing luciferase gene under NF-κB 
promoter along with indicated plasmids (AcP: IL-1RAcP; EV: empty vector). Four hours later 5 x 105
cells/well were kept unstimulated or stimulated with either 100 pg/ml IL-1β or 50 ng/ml IL-33 for over 
night. Next day reporter gene activity was measured from cell lysates. Results shown are 
representative of 2 independent experiments with similar results. Results are shown as mean of three 
replicates in one experiment and are expressed as fold luciferase activity (stimulated/unstimulated) +
relative error. 
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3.1.3.4. TIR domain in TIR8 is not able to transduce IL-33 signaling 
In order to investigate a possible stimulatory or inhibitory role of the cytoplasmic part 
of TIR8 as accessory protein two chimeric proteins were generated by fusion of 
coding sequences of the extracellular and transmembrane parts of mIL-1RAcP and 
the cytopasmic region of murine TIR8 or C-terminally truncated cytoplasmic region 
of mTIR8 (Fig.3.20A). In addition one C-terminally truncated version of mTIR8 
(mTIR8-ΔC) was also constructed. TIR8-ΔC was generated to examine the 
possibility whether the 100 amino acids stretch following the last conserved motif of 
the cytoplasmic region mediates an inhibitory effect (as has been suggested for the 
analogous in the toll protein (Norris and Manley, 1995). 
 
 
 
 
 
 
 
 
 
 
 
 
In order to undescore the possible stimulatory or inhibitory functions of the 
cytoplasmic part of the TIR8 as accessory protein, the constructed AcP-TIR8, AcP-
TIR8-ΔC, TIR8-ΔC, and TIR8 genes were expressed in EL-4-D6/76 cells. As 
depicted in the Fig.3.21A, the expression of neither of the chimeric genes was able 
to activate NF-κB in response to IL-1β or IL-33 as measured by reporter gene assay. 
The results indicated that the cytoplasmic region of TIR8 is not able to initiate signal 
transduction as cytoplasmic TIR domain of accessory protein. 
Fig. 3.20: Construction, molecular cloning and expression of 
mIL-1RAcP-mTIR8 chimeric gene. 
(A). Schematic diagram of construction of mIL-1RAcP (extracellular 
and transmembrane) and mTIR8 (intracellular part containing TIR 
domain) chimeric gene. 
(B). Expression of recombinant mAcP-TIR8, mAcP-mTIR8-ΔC and 
mTIR8-ΔC gene in HEK293RI cells. Flag tagged mAcP-TIR8, mAcP-
mTIR8-ΔC and mTIR8-ΔC were expressed in HEK293RI cells after 
transient transfection. The day after transfection Flag tagged 
proteins were immunoprecipitated and detected by Western blotting 
using anti-Flag antibodies. 
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In theory, if the generated chimeric proteins (containg extracellular and 
transmembrane regions of IL-1RAcP and intracellular part of TIR8) are functional as 
a co-receptor, they should be able to recognize the IL-1- and IL-33- ligated receptor 
complexes and form heterodimeric receptor complex (because the extracellular 
region of IL-1RAcP is sufficient to recognize and bind on ligand receptor complexes 
of IL-1 and IL-33). If the intracellular TIR domain of TIR8 is functional as a TIR 
domain of a co-receptor, the putative hetrodimeric receptor complex should initiate 
the signal transduction. Alternativly the chimeric co-receptor may act as dominant 
negative molecule like C-terminally truncated version of IL-1RAcP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.21: TIR8 is not the accessory protein for IL-33 receptor. 
(A). Expression of AcP-TIR8 chimeric proteins did not reconstitute IL-33 responsiveness in EL-
4 D6/76 cells. AcP-TIR8, AcP-TIR8-ΔC, TIR8-ΔC, TIR8, IL-1RAcP (AcP) encoding plasmids (1 μg / 1
x 107 cells) or empty vector (EV) were transfacted to EL-4-D6/76 cells along with the 1μg reporter 
gene plasmid. Four hours later transfectents were stimulated with 100 pg/ml IL-1β or 50 ng/ml IL-33 
and reporter gene activity was measured from cell lysates. 
(B). AcP-TIR8 chimeric proteins expression inhibits IL-1 induced NF-κB activation. Increasing 
amounts of AcP-TIR8 and AcP-TIR8-ΔC genes encoding plasmids were transfected to EL-4 cells 
along with the reporter gene plasmid (0.75 μg/ 1 x 107 cells). transfectants were kept unstimulated or 
stimulated with 100 pg/ml IL-1β or 25 ng/ml IL-33 and NF-κB mediated reporter gene activity was 
measured after over night incubation. The chimeric proteins compete with functional IL-1RAcP and 
inhibit IL-1 and IL-33 induced signaling in dose depedent manner. The results ahown are only for IL-1 
stimulation.The dipected results are representative of two independent experiments. Results are 
shown as mean of three replicates in one experiment and are expressed as fold luciferase activity 
(stimulated/unstimulated) + relative error. 
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The results depicted in Fig.3.21A demonstrate that, chimeric co-receptors (AcP-TIR8 
and AcP-TIR8-ΔC) are not able to initiate signaling, because IL-1 and IL-33 
responsiveness was not reconstitued in EL-4 D6/76 cells by expression of these 
chimeric proteins. In order to confirm the recuritment of the chimeric co-receptor 
proteins (AcP-TIR8 and AcP-TIR8-ΔC) on ligand bound receptor complexes, 
increasing amounts of AcP-TIR8 and AcP-TIR8-ΔC were expressed in EL-4 cells. 
Expression of AcP-TIR8 and AcP-TIR8-ΔC resulted in dose dependent inhibition in 
IL-1 and IL-33 induced NF-κB activation, as measured in reporter gene assay 
(Fig.3.21B). These data confirm that the extracellular region of IL-1RAcP in chimeric 
proteins recognizes the IL-1 and IL-33 ligated receptor complexes. However the 
cytoplasmic region of the TIR8 is not able to initiate the IL-1 or IL-33 induced signal 
transduction, indicating that TIR8 can not be the accessory protein for IL-33 
receptor. 
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3.1.4. Binding affinity of IL-33 to IL-33 receptor 
3.1.4.1. Radiolabelling of IL-33 and IL-1α 
In order to obtain a comparable biological response in EL-4 cells, a 500-1000 fold 
higher concentration of IL-33 was required compared to IL-1β (shown in Fig.3.2A). 
One possible explanation may be differential expression of the respective receptor 
molecules on the cells. A second one may be a difference in binding affinities of the 
two cytokines to their respective receptor complexes. To measure the binding affinity 
of IL-33 to the IL-33 receptor 3 μg of IL-33 were labelled with 125I (1 mCi) using the 
chloramine T method. IL-1α (5 μg) was also labelled in parallel as control. The 
cytokines were purified by size exclusion chromatography using Sephadex G25 
columns (Fig.3.22A). A single strong band for IL-1α-125I (Fig.3.22A upper) and IL-33-
125I (Fig.3.22A lower) showed the success of radiolabelling and demonstrated the 
purity of the cytokines used. 
The biological activity of radio-labelled cytokines was determined by reporter gene 
assay in EL-4-1B1 cells. As shown in Fig.3.22B both labelled and unlabelled forms of 
IL-33 or IL-1 stimulated NF-κB activity in a dose dependent fashion, suggesting that 
the labelling with chloramine T did not abrogate the biological activity of the 
cytokines. 
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Fig. 3.22: Radiolabelled (125I) IL-1α and IL-33 stimulate EL-4 1B1 cells. 
(A). Radiolabelling of IL-1α and IL-33 by chloramine T method. 5 μg of IL-1α and 3 μg of rmIL-33 
were radiolabelled with 1 mCi (each) 125I by chloramine T method. Radiolabelled cytokines were 
separated from free 125I by G25 columns and 10 (1 ml each) fractions were collected. 10 μl of each 
fraction was run on 15% gel and radioactive cytokines were visualized by autoradiography.  
(B). Radiolabelled (125I) IL-1α and IL-33 stimulate EL-4 1B1 cells. EL-4-1B1 cells transfected with 
reporter gene plasmid were stimulated with IL-33, IL-33-125I, IL-1α-125I, or IL-1β as indicated in figure 
and reporter gene activity was measured from cell lysates after over night incubation. Results shown 
are expressed as mean RLU + SEM calculated from three replicates of one experiment.  
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3.1.4.2. Crosslinking of IL-1α and IL-33 to their respective receptors 
In order to see the binding of the radiolabelled IL-33 to IL-33 receptor, crosslinking of 
the ligand and the receptor complex was attempted. For this purpose Flag-tagged 
versions of IL-33Rα and/or IL-1RAcP were expressed in HEK293RI cells by transient 
transfection. After incubating these transfectants with radioactive IL-33 or IL-1 for 15 
minutes, ligand-receptor complexes were crosslinked using the BS3 crosslinker. 
Results showed that BS3 crosslinked radiolabelled IL-1α to IL-1R1 and/or IL-1RAcP 
(Fig.3.23) but no crosslinking was observed in cells incubated with radiolabelled IL-33, 
indicating that either radio-labelled IL-33 did not bind to the receptor or that the BS3 
arm length (11Aº) is not suitable to crosslink the ligand receptor complex. Crosslinking 
was also tried in EL-4 cells with similar results. 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.4.3. Saturation studies 
In order to find the optimal amount required for binding and determination of binding 
affinity of IL-33 to IL-33 receptor in EL-4 cells, saturation studies were performed. EL-
41B1 cells (EL-4 cells stably transfected with IL-33Rα) were incubated with 
increasing amounts of either radio-labelled IL-1α or radio-labelled IL-33. As depicted 
in Fig.3.24 radiolabelled IL-1α bound to the receptor in dose dependent fashion up to 
5 ng/ml concentration. Then saturation was reached at which further addition of 
Fig. 3.23: Cross linking of IL-1α and IL-33 to respective receptors. 
HEK293RI cells were transfected with Flag tagged -IL-33Rα and/or -IL-1RAcP encoding plasmids. 
Transfectants were incubated either with IL-1α (cold *), IL-1α-125I or IL-33-125I for 15 minutes at 37 ºC 
and ligand receptor complex was cross linked with BS3. Cells were washed and lysed. Flag tagged 
proteins were immunoprecipitated using anti-Flag M2 agarose. For IL-1α anti-IL-1R1(Rockland) was 
also used for immunoprecipitation. Proteins from cell lysate and immunoprecipitates were separated 
on 7.5% SDS/PAGE and radiolabelled molecules were visualized by autoradiography. BS3 cross 
linked radiolabelled IL-1α to IL-1R1 and/or IL-1RAcP but not IL-33 to IL-33 receptor. Results shown 
are representative of 2 independent experiments with similar results. 
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labelled IL-1α did not increase the binding of cytokine to the cells. On the other hand, 
by addition of increasing amount of radiolabelled IL-33, there was no significant 
increase in the cell-bound IL-33 to be observed, whereas the unbound ligand 
increased in the supernatant in dose dependant manner, indicating that radiolabelled 
IL-33 practically did not bind to the receptor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.4.4. Competition studies 
In order to find whether radioactivity measured on cell surface is specifically due to 
the binding of the radiolabelled ligand to receptor, competition studies were 
performed. For competition EL-41B1 cells were incubated with radiolabelled IL-1α or 
IL-33 with or without 100 fold excess of unlabelled ligand and cell-bound and 
unbound radioactivity was determined. Presence of non radio-labelled IL-1α (100 fold 
excess) almost completely inhibited the binding of radio-labelled IL-1α to the cells 
indicating that binding of the radio-labelled IL-1α is specific for the IL-1 receptor 
(Fig.3.25 left) whereas radio-labelled IL-33 was unable to bind the IL-33 receptor 
(Fig.3.25 right). The weak signal obtained with radio-labelled IL-33 was most likely 
due to non-specific binding of the labelled protein to the cells. 
Fig. 3.24: Saturation studies of 125I labelled IL-1α and IL-33.  
Saturation studies of 125I labelled IL-1α (left) and IL-33 (right). EL-4 1B1 (5 x 106) cells were either kept 
untreated or incubated with either increasing concentration IL-1α-125I (radiolabelled) or IL-33-125I 
(radiolabelled) for 15 minutes at 37 ºC followed by 45 minutes incubation on ice. Cells were separated 
from supernatant in the presence of 200 μl silicon oil (AR20/AR200 1:1) by centrifugation and counts 
per minutes (CPM) were measured from cells (bound) and supernatant (unbound) in liquid scintillation 
counter in the presence of 1 ml scintillation solution. The radiolabelled IL-1α-125I binds to cell receptor 
but radiolabelled IL-33-125I was unable to bind in EL-4-1B1 cells. Results shown are expressed as 
mean + SEM, calculated from three replicates of one experiment.  
0
2000
4000
6000
8000
10000
0 4 8 12
Conctration of IL-1α-125I in ng/ml
C
P
M
Unbound
Bound
0
2000
4000
6000
8000
10000
12000
14000
0 40 80 120
Conc. of IL-33-125I in ng/ml
C
P
M
Unbound
Bound
75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
One must conclude from the obtained results that IL-33 can be labelled with 125I with 
chloramine T method, however labelling by this method actually inactivated the 
labelled molecules, thus abrogating binding to the receptor. The biological activity of 
the radio-labelled IL-33 sample shown in Fig.3.22B can be explained if only a part of 
the IL-33 protein is labelled with the 125I (inactive) while the rest is not labelled 
(active). So, chloramine T labelling does not seem to be a suitable technique for 
labelling IL-33 in order to perform binding studies. In the meantime Palmer et al., 
2008, published the binding affinity of human and murine IL-33 to IL-33 receptors in 
Biacore assay so the own binding studies were not followed by alternative method. 
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Fig. 3.25: Competition studies of 125I labelled IL-1α and IL-33.  
Competition studies of 125I labelled IL-1α (left) and IL-33 (right) on EL-4 1B1 cells. EL-4 1B1 (5 x 106) 
cells were either kept untreated or pre-incubated for 30 minutes at 37 ºC with 1 μg/ml IL-1α (non-
radiolabelled) or 10 μg/ml IL-33 (non-radiolabelled). These untreated or pre-treated cells were further 
incubated with either 10 ng/ml IL-1α-125I (radiolabelled) or 100 ng/ml IL-33-125I (radiolabelled) for one 
hour on ice. A part of the cells were also incubated without any cytokine as negative control. Cells 
were separated from supernatant in the presence of 200 μl of silicon oil (AR20/AR200 1:1) by 
centrifugation and CPM were measured from cells (bound, filled columns) and supernatant (unbound, 
open columns) in liquid scintillation counter. IL-1α competes with radiolabelled IL-1α-125I for binding to 
cell receptors but radiolabelled IL-33-125I was unable to bind to EL-4 cells. Results shown are 
representative of two independent experiments with similar results and are expressed as mean +
SEM, calculated from three replicates of one experiment. 
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3.2. Characterization of the processing and release of IL-33  
IL-33 is an interleukin-1-like cytokine that signals via the IL-33Rα-chain (ST2) 
(Schmitz et al., 2005) and the co-receptor IL-1RAcP as shown above (Ali et al., 2007; 
Chackerian et al., 2007; Palmer et al., 2008). Like IL-1α, full length IL-33 also 
translocates to nucleus and may act as chromatin-associated nuclear factor. mRNA 
expression of IL-33 is reported from a range of cell types including, endothelial cells, 
fibroblasts, macroghages, B cells, T cells, mast cells and dendretic cells (Schmitz et 
al.,2005 and table 3.1). Like other members of the family, IL-33 is produced as a 
precursor form, which is reported to be processed by caspase 1 to the mature form. 
Although Schmitz et al., (2005) showed in vitro cleavage of full length IL-33 by 
caspase 1, there is no clear evidence that IL-33 is indeed processed by this enzyme 
and that it is released by any cellular system. In addition the suggested caspase 1 
cleavage site in IL-33 primary structure is not conserved. Thus it seemed necessary 
to explore whether caspase 1 mediated cleavage is required in vivo for biological 
activity of interleukin-33. 
3.2.1. IL-33 is biologically active as full length molecule  
Certain members of the IL-1 family, such as IL-1β and IL-18, undergo restricted 
proteolysis to convert their inactive precursors into the active cytokine, also called 
mature cytokine. However, other cytokines in the same family, such as IL-1α, display 
biological activity irrespective of whether they are proteolytically processed or not 
(Mosley et al., 1987). Because all previous studies on IL-33 have used the mature 
form of this cytokine (IL-33109-266) no information is available whether the full length 
form (precusor) of IL-33 can bind to its receptor and exert biological actions. 
3.2.1.1. Full length IL-33 can bind to IL-33 receptor 
If the IL-33 is biological active as cytokine in full length molecular form, it must bind to 
the IL-33 receptor and recruit the accessory protein to initiate signal transduction. Full 
length murine IL-33 (flmIL-33, aa1-266) was cloned with a C-terminal Flag-epitope 
and a N-terminal Myc-epitope tag and expressed in keratinocytes (Fig.3.26A left). In 
keratinocytes it is processed constitutively to a faintly detectable breakdown product 
corresponding to the size of mature IL-33 (migrating around 20 kDa) and two major 
breakdown products of smaller sizes (only the C-terminal product is visible in 
Fig.3.2A as the Western-blot was developed with anti-Flag antibodies). Upon 
incubation of cell lysate form keratinocytes expressing double-tagged full length mIL-
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33 with an IL-33 trap (an IL-33Rα-IL-1RAcP-hIgG fusion protein), full length form of 
IL-33 bound to this soluble receptor fusion protein (Fig.3.26A left). In this experiment 
the mature IL-33 was also pulled down. Full length mIL-33 also bound to the IL-
33Rα-chain on intact cells where it allowed association of IL-1RAcP as demonstrated 
by co-immunoprecipitation experiments with epitope-tagged receptor components 
(Fig.3.26B) indicating that IL-33 initiates IL-33 receptor complex formation as full 
length molecule. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.1.2. Full length IL-33 stimulates T lymphocytes 
To confirm the biological activity of full length IL-33, N terminally-Myc and C-
terminally Flag tagged IL-33 form was expressed in mammalian cells and purified via 
N-terminal Myc tag immunoprecipitation. Purification via N terminal Myc tag 
B
 
IL-33 trap
A 
Fig. 3.26: Full length murine IL-33 binds to IL-33 receptor and allows recruitment of IL-1RAcP. 
(A). Full length mIL-33 and mature IL-33 bind to an IL-33 cytokine trap. Full length mIL-33 (flmIL-
33) was produced by transfecting keratinocytes with a plasmid encoding full length mIL-33 (aa 1-266) 
carrying a N-terminal Myc- and C-terminal Flag-tag. After 28 hr cells were lysed and full length mIL-33 
and proteolytic fragments detected by Western blot (WB) using anti-Flag mAb (left). IL-33Rα-IL-
1RAcP:IgG(Fc) fusion protein bound to Protein A beads was incubated with cell lysate from 
keratinocytes overexpressing full length mIL-33. Beads were washed, and specifically bound proteins 
detected by Western blot (WB) using anti-Flag mAb (right). 
 (B). Full length murine IL-33 binds to IL-33Rα on intact cells and allows recruitment of IL-
1RAcP. Myc-tagged IL-33Rα or Flag-tagged IL-1RAcP were expressed alone or in combination in 
HEK293RI cells. Transfected cells were incubated for 1 hr on ice without (-ve) or with full length 
murine IL-33 (Myc- and/or Flag-tagged). Cells were washed thrice with ice cold PBS and lysed. IP was 
performed with anti-Myc (upper two panels) or anti-Flag agarose (lower two panels) and co-
immunoprecipitated proteins were detected by Western blot (WB). anti-IL-33Rα (Anti-T1/ST2, MD 
Biosciences) was used for detection of IL-33Rα. The results shown (in A and B) are representative of 
two independent experiments with similar results.  
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precipitation was performed to exclude the presence of C-terminal cleavage 
products. EL-4 1B1 cells were stimulated with this purified (after elution) full length IL-
33 in the presence of protinase inhibitor cocktail (to avoid any cleavage in cell 
supernatant). Stimulation of cells with full length mIL-33 resulted in a time-dependent 
appearance of phospho-IκBα and disappearance of total IκBα (Fig.3.27A). In addition 
concentration dependent activation of NF-κB was also observed in reporter gene 
assay upon stimulation of cells with full length mIL-33 bound to the anti-myc agarose 
(Fig.3.27B). Stimulation of EL-41B1 cells with full length IL-33 bound to anti-Myc 
agarose also induced the cytokine production and release (Fig.3.27C). The results 
described here proved that full length IL-33 is able to bind to the IL-33 receptor and 
activate cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B C
Fig. 3.27: Full length murine IL-33 activates cells. 
(A). Full length murine IL-33 (flmIL-33) stimulates IκBα phosphorylation and degradation. EL-
41B1 cells were stimulated with anti-Myc affinity-purified flmIL-33 for the times indicated in the 
presence of proteinase inhibitors. After stimulation cells were immediately denatured in SDS-PAGE 
sample buffer and phospho-IκB and total IκBα were detected by Western blotting. The results shown 
are representative of two independent experiments with similar results. 
(B). Full length mIL-33 activates the transcriptional activity of NF-κB. EL-41B1 cells were 
transfected with a plasmid encoding a NF-κB dependent luciferase reporter gene and stimulated with 
increasing amounts of anti-Myc affinity-purified full length mIL-33 for 18 hr. Subsequently luciferase 
activity (RLU) was measured.  
(C). Full length mIL-33 stimulates IL-2 production in EL-41B1 cells. EL-41B1 cells were stimulated 
with increasing amounts of anti-Myc affinity-purified full length mIL-33. The next day IL-2 release was 
measured by ELISA. Data depicted (in B and C) are means +/- standard deviations from one 
experiment (triplicates) out of two similar ones with comparable results. 
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3.2.2. Full length IL-33 is processed by caspase 3  
As described above it was reported that full length IL-33 is processed to mature IL-33 
by caspase 1 cleavage at aa 111 in human IL-33 precursor corresponding to aa 108 
in the murine sequence. When N-terminally Myc- and C-terminally Flag-tagged full 
length IL-33 was expressed in keratinocytes and these cells were stimulated with 
LPS to induce processing to mature IL-33 via the inflammasome two major 
breakdown products were observed which did not correspond in size to the expected 
mature form (109-266) or the remainder (1-108) (Fig.3.27A left and 3.28A). In control 
experiments keratinocytes were able to process precursor IL-1β and IL-18 to 
respective mature forms, both well characterized substrates for caspase 1 (Fig.3.32), 
indicating that caspase 1 is active in this cellular system. Therefore, in search for 
caspase 1 cleavage sites, the peptide sequences of full length lL-33 was re-analyzed 
in silico. As already suggested in the literature (Carriere et al., 2007) no caspase 1 
cleavage site was found in the primary structure of full length IL-33. However, a non-
classical caspase 3 cleavage site (DGVD175*G) was identified in the mouse IL-33 
sequence at aa175, corresponding to aa178 in human IL-33 sequence. This 
sequence had been identified previously in PKCζ (Frutos et al., 1999) to be accepted 
by caspase 3. The calculated fragments fitted much better to the bands observed in 
the gels after digestion of full length mIL-33.  
In order to confirm this finding plasmids encoding N- and/or C-terminally epitope-
tagged versions of full length mIL-33 were generated. This was done for the wild-type 
form and, in addition, a point mutation was introduced at the putative caspase 3 
cleavage site (D175->A) with the aim of destroying it. In addition, the epitope- tagged 
N-terminal (aa1-175) and C-terminal (aa176-266) fragments were generated to allow 
clear identification of the proteolytical products. Full length mIL-33 was processed in 
intact cells to two major products (Fig.3.27A and 3.28A) corresponding in size exactly 
to the recombinant fragments aa1-175 and aa 176-266, indicating that in cells full 
length IL-33 is predominantely cleaved at position 175 rather than at position 108. A 
minor product in the size of the postulated mature IL-33 (109-266) was also observed 
(best visible in Fig.3.27A).  
This result shows that full length murine IL-33 is not predominately cleaved at 
position 108 by caspase 1 but rather at position 175 by caspase 3 in kerationcytes. In 
order to support this, a caspase 3-specific inhibitor was added to the cells. 
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Processing of full length mIL-33 was inhibited almost completely in keratinocytes by 
this caspase 3-specific inhibitor (Fig.3.28D). 
 
 
 
 
 
 
 
 
 
 
 
 
To identify which of the two caspases actually cleaves full length mIL-33  
To identify which of the two caspases actually cleaves full length mIL-33 recombinant 
full length mIL-33 (wild-type and D175A mutant) was incubated with recombinant 
caspase 1 or capase 3 in vitro. In this type of experiments caspase 1 did not accept 
full length mIL-33 as a substrate while it readily processed full length mIL-1β 
(Fig.3.29). Caspase 3 however, cleaved wild-type full length mIL-33 (and precursor 
IL-18 as a control) in a concentration- dependent manner (Fig.3.29), while mutation 
at aa 175 completely abrogated processing by recombinant caspase 3 in vitro 
(Fig.3.29) and upon overexpression also in keratinocytes (Fig.3.28B). The products 
resulting from caspase 3 processing corresponded exactly to the recombinant N- and 
C-terminal pieces of aa 1-175 and aa 176-266 (Fig.28C). These data show that full 
length mIL-33 is processed predominantely by caspase 3 at aa175 to yield two 
fragments. In these in vitro processing experiments a breakdown product 
corresponding to the “mature” form of aa109-266 was not observed. This was only 
observed as a minor processing product in intact cells. This suggests that at least 
one protease distinct from caspases 1 and 3 processes full length mIL-33 to mature 
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Fig. 3.28: Full length murine IL-33 (flmIL-33) is processed in keratinocytes at position D175. 
(A). Processing of flmIL-33 is stimulated by LPS in keratinocytes. Keratinocytes were transfected 
with a plasmid encoding C-terminally Flag-tagged flmIL-33. Cells were kept unstimulated (-) or were 
stimulated with 500 ng/ml LPS (+) for 28 hr. Expression and processing of flmIL-33 were analysed in 
total cell lysates by Western blotting (WB) using anti-Flag mAb, detecting flmIL-33 and the C-terminal 
product. 
(B). D175A point mutation abrogates IL-33 processing in keratinocytes. Wild-type flmIL-33 (wt) or 
mutant flmIL-33D175A(mut) were expressed in keratinocytes and constitutive processing measured in 
cell lysates by Western blotting (WB) using anti-Flag mAb. D175A mutation abrogated constitutive 
processing while wt flmIL-33 was cleaved to two products (only Flag-tagged C-terminal product visible 
in anti-Flag WB: arrow head).  
(C). Identification of caspase 3 processing products using recombinant N-terminal and C-
terminal fragments. The sizes of the rec. Myc-mIL-33176-266-Flag (C) and rec. Myc-mIL-331-175 (N) 
confirm that processing of Myc-flmIL-33-Flag (wt) was mainly at the DGVD175*G caspase 3 cleavage 
site. 
(D). Inhibition of caspase 3 reduces processing of IL-33 in cells. Keratinocytes over expressing 
flmIL-33 were incubated with 50 μM cell-permeable (DEVD-CHO) caspase 3 inhibitor (Calbiochem) for 
28 hr. Processing of Myc-flmIL-33-Flag to Myc-tagged N-terminal cleavage product was detected in 
cell lysates by anti-Myc WB. The results shown in A-D are representative of three different 
experiments it  similar results. 
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IL-33 in intact cells. However, it is likely that mature IL-33 is only a transient product 
in cells as the caspase 3 cleavage site at aa175 is present in mature IL-33. This 
might explain why this product appears only as a minor band in cells overexpressing 
full length mIL-33 as it will be further processed to the C-terminal product of aa 176-
266 and to a small piece of about 70 aa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.29: Full length murine IL-33 (flmIL-33) is processed by caspase 3 at D175 but not by 
caspase 1 in vitro. Affinity-purified full length mIL-33 (flmIL-33) or full length flmIL-33D175A (flmIL-
33D175A) were incubated with recombinant caspases 1 or 3. Full length mIL-1β (flmIL-1β) and full length
mIL-18 (flmIL-18) were used as control substrates for caspases 1 and 3, respectively. Caspase 1 
cleaved flmIL-1β at two positions but did not affect wild-type or mutant form of flmIL-33 (upper panel). 
Incubation of wild type Myc-flmIL-33-Flag with caspase 3 yielded a product corresponding in size to 
Myc-IL-331-175 (N). D175A mutation abrogated processing of flmIL-33, while flmIL-18 was also cleaved 
(lower panel) (fl: full length; N: N terminal; cl: cleaved; Mat: mature). 
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3.2.3. Full length IL-33 is inactivated by caspase 3 
In order to clarify whether the caspase 3 breakdown products were able to bind to the 
receptor, pull down assays were performed using a soluble IL-33Rα-chain:Fc-fusion 
protein with wild-type full length IL-33, the D175A mutant, or the N- and C-terminal 
caspase 3 breakdown products, respectively. Wild-type and mutated flmIL-33 bound 
to the IL-33Rα-chain (Fig.3.30A) and activated NF-κB in cells (Fig.3.30B), but neither 
the N-terminal product of aa 1-175 nor the C-terminal product of aa 176-266 were 
able to bind to the receptor (Fig.3.30A) or activate cells (Fig.3.30B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B
Fig. 3.30: Full length murine IL-33 (flmIL-33) is inactivated by caspase 3. 
(A). Caspase 3 cleavage products do not bind to IL-33R, while flmIL-33 and flmIL-33D175A do. IL-
33Rα: (hIgG) Fc fusion protein bound to Protein A sepharose was incubated over night at 4 ºC with 
lysates from keratinocytes overexpressing flmIL-33 (wt), IL-331-175 (N), IL-33176-266 (C) or IL-33D175A
(Mut). Beads with bound proteins were washed, and IL-33 forms bound to IL-33Rα were detected by 
Western blot (WB) using anti-Flag (upper) or anti-Myc mAb (lower), Expression of different fragments 
was confirmed by WB in lysates (in put control, lower right). The results shown are representative of 
three different experiments with similar results.  
(B). Caspase 3 cleavage products do not activate NF-κB. EL-41B1 cells transfected with a NF-κB 
dependent reporter gene were stimulated with IL-33 forms purified via their N-terminal Myc-tag (fl: IL-
331-266, N: IL-331-175, C: IL-33176-266, Mut: IL-33D175A) or commercial mIL-33109-266 (Alexis, Mat). After 
overnight incubation with stimuli luciferase activity (RLU) was measured in cell lysates. Data depicted 
are means +/- standard deviations from one experiment (carried out in triplicates) out of two with 
comparable results. 
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3.2.4. Induction of apotosis in cells inactivates IL-33 
Caspase 3 is well-knwon as a protease activated in the course of apoptosis. Thus it 
was asked whether induction of apoptosis would initiate breakdown of full length mIL-
33 and result in its inactivation. Apotosis was induced in U937 cells by TNFα 
treatment in the presence of the protein biosynthesis inhibitor cycloheximide. 
Induction of apotosis resulted in proteolysis of procaspase 3 (Fig.3.31A) leading to 
enzymatically active caspase 3. Incubation of full length mIL-33 with lysates from 
these cells in which apoptosis was induced resulted in proteolysis of full length mIL-
33 in a few minutes. The IL-33 form with the D175A mutation, however, was not 
cleaved (Fig.3.31B). The data suggest that induction of apoptosis leads to 
inactivation of full length mIL-33 as a cytokine by proteolytic cleavage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.5. Caspase 3 cleavage affects the dual functions of IL-33 differently 
IL-33 was originally identified as a nuclear factor in specialized endothelial cells 
(Baekkevold et al., 2003) before it was designated a cytokine. Therefore IL-33, like 
IL-1α and HMGB1, was called a dual function cytokine (reviewed in (Haraldsen et al., 
2009). The biological activity of IL-33 has to be separated into the classical cytokine 
function which requires release and interaction with the IL-33 receptor in a paracrine 
Fig. 3.31: Induction of apoptosis in cells results in processing of full length murine IL-33. 
(A). Induction of apoptosis in cells cleave procaspase 3. Apoptosis was induced in U937 cells by 
incubation with 1 ng/ml TNFα, and 50 μg/ml cycloheximide for indicated time points. Procaspase 3 
was detected by Western blotting from cell lysate obtained from apoptosis induced U937 cell.  
(B). Induction of apoptosis in cells results in processing of full length mIL-33. Apoptosis was 
induced in U937 cells (1 ng/ml TNFα, 50 μg/ml cycloheximide, 1.5 hr). Washed cells were lysed by 3 
cycles of freeze thawing followed by sonication in caspase reaction buffer. flmIL-33 and flmIL-33D175A
were incubated with lysates from control cells (right panel) or apoptotic cells (left panel). flmIL-33 was 
cleaved in a time-dependent manner, while the D175A mutant was unaffected. Full length molecules 
(fl, upper panel) and the N-terminal fragment (N, middle panel) were detected by anti-Myc Western 
blot (WB), the C-terminal fragment (C, lower panel) by anti-Flag WB. The results shown are 
representative of three independent experiments with similar results. 
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fashion and its intracrine gene regulatory function which requires its nuclear 
translocation. 
3.2.5.1. IL-33 is not released as a classical cytokine after activation of cells 
Activation of the inflammasome results in the processing of precursor IL-1β or 
precursor IL-18 in cells and the release of biologically active cytokines into the 
extracellular milieu (Fig.3.32). In order to find out whether biologically active IL-33, 
i.e. the classical cytokine form, is also released by cells constitutively or after 
activation, immunoprecipitation of biologically active IL-33 was attempted from 
supernatants collected from cells transiently transfected with the different variants of 
mIL-33. Surprisingly, no detectable bioactive IL-33 in supernatants of intact cells was 
immunoprecipitated, although these cells produced readily detectable amounts of IL-
33 inside of the cell. Even stimulation by LPS did not result in the release of bioactive 
IL-33. In contrast to IL-33, bioactive IL-1β, or IL-18, and even IL-1α (which is 
processed by calpain not by capase 1), were easily detectable in supernatants 
indicating that the inflammasome had been activated successfully (Fig.3.32). Thus, it 
must be concluded that classical activation of the inflammasome (and thus caspase 
1) does not result in the release of bioactive IL-33. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.32: Bioactive IL-33 is not released by intact cells upon overexpression after stimulation. 
N-terminally Myc- and C-terminally Flag- tagged full length versions of IL-1α, IL-1β, IL-18 or IL-33 
were overexpressed in keratinocytes. Cells were either kept unstimulated (-) or stimulated with 500 
ng/ml LPS (+) for 28 hr (-ve: empty vector). Released Flag-tagged molecules (C-termini, identifying 
mature forms) were precipitated from cell free supernatants and detected by anti-Flag Western blot 
(WB) (upper). The expression of the cytokines was confirmed in cell lysates by anti-Myc WB or anti-
Flag for IL-1α (lower). The results shown are representative of three independent experiments with 
similar results. 
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3.2.5.2. Nuclear translocation of full length mIL-33 is not abrogated by caspase 
3 processing  
Finally, the issue whether proteolytical processing of full length murine IL-33 (flmIL-
33) affects its ability to translocate to the nucleus was addressed. Upon 
overexpression full length IL-33 translocates to the nucleus (Fig.3.33), a feature it 
shares with IL-1α and IL-1F7b (reviewed in (Dinarello, 2009). Interestingly, not only 
full length IL-33 translocated to the nucleus but also the N-terminal fragment aa1-175 
(Fig.3.33). The C-terminal breakdown product did not translocate to the nucleus and 
remained completely in the cytosol (Fig.3.33). Presently it is not known whether this 
N-terminal fragment regulates gene transcription comparable to full length mIL-33, 
but it seems that one has to separate the classical cytokine function of IL-33, i.e. via 
receptor interaction in an auto- or paracrine manner, from its intracrine function in the 
nucleus. While processing of full length murine IL-33 at aa175 destroys its cytokine 
property it does not abrogate nuclear translocation, presumably still allowing gene 
regulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.33: Processing of full length mIL-33 does not abrogate nuclear translocation.  
Constitutive nuclear translocation of full length murine IL-33 (wt), IL-331-175(N), IL-33176-266 (C) and IL-
33D175A(mut) was measured in transfected HEK293RI. Cytosolic and nuclear fractions were prepared 
and the presence of IL-33 was detected by anti-Myc Western blot (upper). Purity of cytosolic and 
nuclear fractions was confirmed by anti-GAPDH and anti-Lamin B WB (lower). The results shown are 
representative of three independent experiments with similar results. These data were generated in 
collaboration with Dang Quan Nguyen. 
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3.3. Comparison of signaling induced by IL-1, IL-18 and IL-33  
Among the well known members of the IL-1 family of cytokins, IL-1α and IL-1β are 
well characterized pro-inflammatory cytokines. IL-18 is a Th1 driving pro-
inflammatory cytokine with the unique capacity of inducing the production of INFγ. lL-
33 drives Th2 responses and was suggested to act as anti-inflammatory cytokine. 
Although little is known about IL-33 activites some evidence suggests that IL-33 may 
have a dual role of pro-inflammatory and anti-inflammatory activities. All three 
cytokines (IL-1, IL-18 and IL-33) are member of same IL-1 family and are closly 
related with respects to their structure, receptor binding, and signal transduction. All 
three share a large part of signal transduction pathways. However they also have 
unique functions. Therefore it is important to compare the signaling induced by all 
three cytokines and to identify the unique molecules/pathways which are responsible 
for the discrete biological functions. This cytokine-specific signaling molecules would 
be attractive targets to develop highly selective drugs useful for effective anti-cytokine 
therapies.  
3.3.1. Screening of triple responsive cell lines 
In order to compare the signaling pathways induced by each of the above said 
cytokines under similar conditions, a suitable cell line was required, which expresses 
all receptor components and subsequent downstream molecules needed for 
signaling for these cytokines. To find such a triple-responsive cell line, steady state 
mRNA levels coding for IL-1RI, IL-1RAcP, IL-33Rα, IL-18Rα, and IL-18Rβ, were 
detected by RT-PCR analysis from mRNA isolated from a set of stimulated and 
unstimulated cell lines. Cell lines included in the screening were from different 
immunologically important lineages including B cell lines, T cell lines and freshly 
differentiated T cells (a kind gift of Prof. M. Lohoff, University of Marburg), dendritic 
cells line and fibroblasts. mRNA from these different cell lines were analysed by RT-
PCR for the expression of the above described membrane molecules. As shown in 
table 3.1 only a few cell types express all known receptor components of the three 
receptor complexes. These inculded IL-1 stimulated and unstimulated EL-4 cells (Th0 
cell line), unstimulated Xs106 cells (dendritic cell line) and freshly differentiated 
unstimulated Th0 cells, unstimulated and anti-CD3 -stimulated Th1 cells, as well as 
anti-CD3 stimulated Th2 cells. Some of the cell lines lacked the expression of one of  
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Table 3.1. Expression of different IL-1 family receptors and cytokines in diffteren cell types 
at mRNA level. Cell were either kept unstimulated or stimulated as described for overnight for IL-
1β and LPS and for 6 hours for anti-CD3. RNA was isolated, cDNA was generated  and expression 
of given molecules was detected by PCR. Each PCR reaction was performed under controled 
conditions including positive and negative controles and each reaction was repeated at least once 
from same cDNA.  
Cell Type Stimu IL-1R1 IL-1RAcP IL-33Rα IL-18Rα IL-18Rβ IL-1α IL-1β IL-18 IL-33 Actin 
EL-4 − + + + + + − − + + + 
EL-4 IL-1β + + + + + + + + + + 
D10G4.1 − + + + − +  − + + + 
D10G4.1 IL-1β + + + − + + + + + + 
D10N − + + − − + + + + + + 
Xs106 − + + + + + + + + + + 
Xs106 LPS + − + + + + + + + + 
RAW264.7 − + + + − + + + + + + 
RAW264.7 LPS + + + − + + + + + + 
Wehi − + + − − − + + + + + 
Wehi LPS + + + − − + + + + + 
70Z/3 − + + + − + − − + + + 
70Z/3 LPS + + + − + − − + + + 
P388D1 − + + + − + + + + − + 
P388D1 LPS + + + − + + + + − + 
RGK − + + + − + − − + − + 
RGK LPS + + + − + + + +  + 
Keratino − + + + − + + + + − + 
Keratino LPS + + + − + + + + + + 
NIH 3T3 − + + + − + − + + − + 
NIH 3T3 LPS + + + − + + + + − + 
Fibroblast 
IRAK cont. 
− + + + − + + − + + + 
Fibroblast 
IRAK cont. 
LPS + + + − + + + + + + 
L929 − + + − − + − + + + + 
L929 LPS + + − − + − − + + + 
Th0 − + + + + + + − + − + 
Th0 CD3 + + + − + + + + + + 
Th1 − − + + + + + + + − + 
Th1 CD3 + + + + + − − + + + 
Th2 − + + + − + + + + + + 
Th2 CD3 + + + + + + + + + + 
Th17 − + + + − + + + + − + 
Th17 CD3 + + + − + + − + + + 
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the required receptor component and thus are good candidates to generate a triple 
responsive cell line by stable transfection of the required receptor component. 
EL-4 cells responded readily to IL-1β, IL-33 and IL-18 by producing mIL-2 (Fig.3.2A) 
and stimulating NF-κB (Fig.3.6A left). Although EL-4 cells respond to all three 
cytokines, more than 100 times higher concentrations of IL-18 and IL-33 were 
required compared to IL-1β to achieve comparable bio responses. Response to IL-33 
could be enhanced by over-expressing the IL-33Rα chain (Fig.3.6A right).  
Stable transfectants of EL-4 cells were generated which expressed higher numbers 
of Flag-tagged IL-33Rα molecules (cell lines were generated by Jessica Endig during 
her Diploma thesis in this laboratory). Characterization of cell responsiveness (to IL-
1, IL-18 and IL-33) of the EL-41B1 clone showed that it responded much better than 
the parent EL-4 cells not only to IL-33 but also to IL-1 and IL-18 by producing mIL-2 
as measured by ELISA (Fig.3.34A) and and by stimulating NF-κB as measured by 
reporter gene assay (Fig.3.34B). Thus, the EL-41B1 cell line was selected as a triple-
responsive cells for analyzing differential mRNA expression by microarray analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.34: EL-4-1B1 responds better to IL-1 family of cytokines than the parent EL-4 cells.  
(A). EL-4-1B1 produce more IL-2 than parent EL-4 cells. EL-4 and EL-4-1B1(EL-4 cells stably 
transfected with mIL-33Rα) (2.5 x 104) cells were stimulated for overnight with increasing 
concentrations of rhIL-1β (left, grey) or rmIL-33 (right, black) and mIL-2 was measured with ELISA 
from cell free supernatants. Results shown are mean of two replicates in one experiment.  
(B). IL-1 family cytokines induced NF-κB activation is more in EL-4-1B1 than parent EL-4 cells.
Reporter gene transfected EL-4 (grey bars) and EL-4-1B1 (black bars) cells were either kept 
unstimulated or stimulated with indicated concentrations of rhIL-1β, rmIL-33, rmIL-18 or rTNFα for over 
night and reporter gene activity was measured from cell lysates. Data depicted are representative of 2 
experiments and are expressed as fold increase in signal + relative error. 
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3.3.2. Genome wide investigations of IL-1, IL-33 or IL-18 regulated genes 
Microarrays were performed on the triple responsive cell line EL-41B1 to identify 
genes differentially regulated by IL-1, IL-18, and IL-33. EL-41B1 cells were either 
kept unstimulated or stimulated with 100 pg/ml IL-1β, 100 ng/ml IL-33 or 100 ng/ml 
IL-18. After 2 hours stimulation cells were lysed for RNA extraction. This RNA was 
used for microarray analysis (all arrays were perfomed at the Institute of 
Pharmacology, Hannover Medical School by Dr. Oliver Dittrich-Breiholz). 
At first the gene expression was determined using the inflammation array (Inflamus, 
2nd version inflamation array) developed by the cytokine microarray project at the 
Institute of Pharmacology, Hannover Medical School (Dr. Oliver Dittrich Breiholz and 
Prof. Michael Kracht). In these inflammatory array seven upregulated genes were 
identified. As shown in the Fig.3.35 the expression of all genes was stimulated by all 
three stimuli in the similar fashion and none of the genes was differentially regulated 
by any particular cytokine, indicating that the same signaling pathways were 
activated by IL-1, IL-33, and IL-18. However the expression intensities of the genes 
were different in response to different stimulus, which may be explained by the 
difference in receptor expression and binding affinity of the individual cytokines to 
their respective receptors. 
In order to find more differentially regulated genes whole mouse genome oligo 
microarrays (4x44k, Agilent Technologies) were performed on unstimulated and IL-1, 
IL-33 or IL-18 stimulated EL-41B1 cells. Flourescent intensity values of all measured 
spots are plotted in a scatter plot (Fig.3.36). Spots outside of the grey line represent 
differentially expressed genes between stimulated and unstimulated cells. As shown 
in Fig.3.36 based on the primary data obtained from the assay IL-1 stimulation 
increased the expression of 794 gene entries (based on 2 fold increase as 
upregulated) and downregulated the expression of 629 gene entries. Similarly, IL-33 
and IL-18 upregulated 669 and 872 genes and decreased the expression, up to 
equal or more than 2 fold of 752 and 788 gene entries, respectively. 
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Fig. 3.35: Similarities and differences of inflammatory gene expression in response to IL-1, IL-
33 and IL-18 in inflammation gene array.  
EL4-1B1 cells were either kept unstimulated or stimulated with IL-1β (100 pg/ml, lower light grey), IL-
33 (100 ng/ml, middle black) or IL-18 (100 ng/ml, upper dark grey) for 2 hours and gene expression 
was determined using Inflammation array (Inflamus, 2nd version inflamation array) developed by 
cytokine microarray project (SFB566) at Institute of Pharmacology Medical School Hannover. (nfkb1, 
nfkb2, and rel: transcription factor; tnfaip3 (TNFα inducing protein 3), nfkbia (nuclear factor of kappa 
light chain gene enhancer and  birc2 (baculoviral iap repeat containing 2 protein), all play role in signal 
transduction; ccl5, (a chemokine) were up regulated by IL-1, IL-18 and IL-33 stimulation. Results 
shown are the mean of two different arrays with similar results from the same RNA samples and are 
presented as relative induction compared to unstimulated controls. Only the regulated genes by at 
least one of these stimuli (2 fold induction by any of the cytokine) are shown in the figure. 
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Fig. 3.36: High density (whole genome mouse microarray) microarray analysis of the genes 
regulated by IL-1, IL-33 and IL-18. 
Murine EL-41B1 cells were stimulated for 2 hours with IL-1β (100 pg/ml), IL-33 (100 ng/ml) or IL-18 
(100 ng/ml) or were left untreated. Subsequently total RNA was isolated, converted to cRNA and 
labelled with Cy5 or Cy3 respectively. Labelled cRNAs of stimulated or unstimulated cells were mixed 
and co-hybridized on to whole mouse genome oligo microarrays (4x44k, Agilent Technologies), which 
carry oligonucleotide probes for mouse genome. Depicted graffically are the flouriscent intensity 
values of all measured spots. Spots out side from liner line represents differentialy expressed genes 
between stimulated and unstimulated cells. Results shown are from internally controled single array. 
Spots above and below grey lines indicates 2 fold up and down regulated genes respecetively.  
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Data depicted in Table 3.2 and Fig.3.37 are obtained after filtration and analysis 
considering pValue log ratio > 0.0001 significant. Considering 2 fold increase or 
decrease in mRNA transcripts as upregulation and downregulation, 74 genes were 
found to be upregulated (Fig.3.37) and 15 genes down regulated (Table 3.1) by 
stimulation with one or more cytokine. There are some quantitative differences is 
mRNA transcripts of some of these genes upon stimulation with different cytokines 
(Fig.3.37 and table 3.2) however no qualitative difference among mRNA expression 
in response to IL-1β, IL-18 and IL-33 was observed. 
Among the upregulated genes Ccrl2, Nfkbia, Serpinc1, IL-2, Icam1, LOC620807,  
Cd69, Gbp4, Slfn2, and A_52_P1173559 were more than 2 fold upregulated by IL-1 
stimulation compared to IL-33 or IL-18 stimulation. Cxcl10 (chemokine) gene was 
most strongly upregulated by IL-18 followed by IL-1 and by IL-33 (387, 274 and 217 
fold respecetively) and IL-22 gene was most strongly upregulated by IL-33 (13.47 
fold) compared to the IL-1 (7.83 fold) and IL-18  (9.13 fold). Expression of a set of 
genes was almost similarly increased, expression of most up regulated genes, 
however, was higher in IL-1 -treated cells followed by IL-18 and IL-33 (Fig.3.37). 
Table 3.2. Down regulated genes in mouse whole genome microarray from EL-4 1B1 cells 
stimulated with either IL-1β, IL-33 or IL-18. Genes with 2 fold signal reduction were considered 
down regulated. Results expressed are fold signal change calculated by dividing signal by stimulated 
cells/unstimulated control. 
GeneName Reference Description/function IL-1 IL-33 IL-18
Sbsn NM_172205 Suprabasin, epidermal differentation 0.41 0.38 0.18 
Nrp2 BC057028 Axon guidance receptor, development 0.28 0.59 0.45 
Nr2c2 AK036508 Nuclear receptor, growth 0.73 0.73 0.38 
AF315352 AF315352 Leucine zipper protein, pituitary development 0.74 0.72 0.46 
B3galt5 NM_033149 Enzyme, metabolism 0.40 0.73 0.63 
Tgfb3 NM_009368 Growth factor 0.43 0.70 0.56 
Ccr2 NM_009915 Chemokine receptor  0.43 0.64 0.69 
4833431D13Rik AK029407 Riken, unknown 0.58 0.73 0.50 
AK040293 AK040293 Riken, unknown 0.62 0.71 0.49 
Spon2 
 
NM_133903 
 
Extracellular matrix protein, immune-
enhancing agent 0.34 0.50 0.37 
Sall4 AK017633 Transcription factor, development 0.44 0.70 0.60 
Marveld3 NM_028584 Unknown 0.49 0.69 0.63 
Aph1a NM_146104 Role in embryogenesis 0.58 0.54 0.50 
2310005P05Rik NM_026189 Eepd1, DNA binding 0.48 0.50 0.37 
Txnip NM_023719 Enzyme inhibitor, protein binding 0.50 0.58 0.54 
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Fig. 3.37: Similarities and differences of IL-1, IL-33 and IL-18 induced gene expression by whole 
genome microarray. Murine EL-41B1 cells were stimulated for 2 hours with IL-1β (100 pg/ml), IL-33 
(100 ng/ml) or IL-18 (100 ng/ml) or were left untreated. Total RNA was isolated, converted to cRNA and 
labelled with Cy5 or Cy3 respectively. Labelled cRNAs of stimulated or unstimulated cells were mixed 
and co-hybridized on to whole mouse genome oligo microarrays (4x44k; Agilent Technologies), which 
carry oligonucleotide probes for mouse genome. Depicted graffically are the fold change in flouriscent 
intensity values (P value log >0.0001) of all upregulated genes. Genes with 2 fold increase in 
flouriscent value were considered upregulated. Results shown are from internally controled single 
array. Genes are grouped with respect to the functions. Values above grey line are more than 2 fold 
signal increase.  
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3.3.2.1. Confirmation of gene expression by quantitative PCR 
To validate the results obtained in microarray analysis, quantative-RT-PCR assays 
were carried out for representative genes. Changes in mRNA level for IL-2, Csf2, IL-
22, Ccl5, Cxcl10, Tnfrsf9, Icam1 and Serpinc1 genes were measured in EL-4-1B1 
without addition of cytokines (control) and after stimulation with IL-1, IL-33 or IL-18 for 
2 h (Fig.3.38). In quantitative -RT-PCR analysis, master mix with SYBR Green was 
used and the obtained data were normalized against expression level of GAPDH. 
Data shown in Fig.3.38 for qantitaive-RT-PCR and Fig.3.37 for microarray, showed 
the similar trend in the expression level of selected genes in response to IL-1, IL-33 
and IL-18 for both methods. However, in most cases the changes in gene expression 
observed in quantative -RT-PCR are more pronounced than in microarray analysis. 
Since in the two methods the same conditions for cell stimulation, RNA templates 
isolation were employed the differences in the obtained results may be explained with 
following, 1: Slight difference in biological conditions, which can not be controlled; 2: 
Different reverse transcriptases, with different efficiencies in cDNA synthesis, are 
being used; 3: Normalization of data for quantitative-RT-PCR was done for one gene 
(GAPDH) whereas in microarray a global normalization was carried out.  
A slight discrepancy in the expression level of some genes in response to different 
cytokines was also observed in the two methods. Data depicted in Fig.3.38 show that 
IL-1, IL-33 and IL-18 stimulated the expression of a set of genes (IL-22, Csf2, and 
Tnfrsf9) almost at the same level where as the expression of Serpinc1 (a protinase 
inhibitor) transcripts is different in response to all three cytokins. No difference in the 
expression of IL-2 transcripts was observed in response to IL-1 and IL-33 but IL-18 
stimulated the expression of IL-2 mRNA significantly lower than IL-1 and IL-33. 
Upregulation of chemokine (Cxcl10 and Ccl5) and adhesion protein (Icam1) genes 
expression was almost similar both in response to IL-33 and IL-18 where as IL-1β 
induced expression of these genes was higher than that of IL-33 and IL-18. Although 
IL-1, IL-33 and IL-18 stimulated the expression of a similar set of genes qualitatively, 
clear differences in the quantitative expression of genes in response to these 
cytokines were observed.  
In summary, the microarray data show that IL-1, IL-18 and IL-33 induce the 
regulation of the same set of genes, suggesting that the signal transduction pathways 
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used are identical for all three cytokine / cytokine receptor systems, at least in this 
cell line. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.38: Confirmation of microarray results by quantitative PCR. 
Murine EL-41B1 cells were stimulated for 2 hours with IL-1β (100 pg/ml), IL-33 (100 ng/ml) or IL-18 
(100 ng/ml) or were left untreated. Total RNA was isolated, converted to cDNA and gene expression 
was analyzed by quantitative PCR using specific primers and cyber green master mix. Depicted 
graffically are the mean fold increase in gene expression compared to the unstimulated control +
relative error. Results shown are representative of three biologically independent experiments with 
similar results. Genes are grouped with respect to the gene functions. 
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Chapter 4 
 
Discussion 
 
The IL-33Rα-chain, formerly known as ST2/T1, is a member of the IL-1 receptor 
family of TIR-domain-containing receptors. IL-33Rα-chain (ST2) possesses a TIR 
domain in its cytoplasmic moiety, which is required for signaling (Sims, 2002). The IL-
33Rα-chain interacts with IL-33, which results in the recruitment of signaling 
molecules also found in the IL-1RI complex (Schmitz et al., 2005). This demonstrates 
the close relationship of IL-33R and IL-1R complexes as also suggested by the use 
of chimeric molecules (Born et al., 2000). Thus, it has been proposed that the IL-
33Rα-chain also requires a β-chain containing a TIR domain and that this may be a 
member of the IL-1 receptor family (Dinarello, 2005; Schmitz et al., 2005). The aim of 
this thesis was to identify and characterize the components of the functional IL-33 
receptor complex, which are required for IL-33 mediated biological activities. In 
addition the processing of IL-33 itself needs to be clarified. Only Schmitz et al., 2005 
data suggests the caspase-1 dependent maturation of IL-33 in vitro however, no 
evidence of in vivo processing of IL-33 is published. Moreover it is not yet clear how 
IL-33 may be released from the cells to exert its cytokine activities towards target 
cells expressing the IL-33 receptor. These questions are addressed in this thesis. 
 
4.1. IL-33Rα needs IL-1RAcP for signal transduction 
IL-1 family cytokines undergoes ligand-mediated heterodimerization of the respective 
receptor and co-receptor for initiation of signal transduction. IL-1 signals through a 
heterodimer receptor complex consisting of IL-1RI and IL-1RAcP. IL-1R1 binds to IL-
1 and IL-1RAcP, recognizes the ligated IL-1RI (Greenfeder et al., 1995; Hofmeister et 
al., 1997; Korherr et al., 1997; Wesche et al., 1997b). The signaling IL-18 receptor 
complex is also a heterodimer in which the IL-18 binds to IL-18Rα-chain (Born et al., 
1998; Torigoe et al., 1997) and the IL-18Rβ-chain (Born et al., 1998) serves as a co-
receptor. Two additional heterodimeric receptor complexes in the IL-1R system have 
also been described. IL-1F6, IL-1F8, and IL-F9 bind to IL-1Rrp2 and induce signaling 
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events practically identical to IL-1 (Towne et al., 2004; Debets et al., 2001) only in the 
presence of functional IL-1RAcP (Towne et al., 2004). 
Here it is shown that IL-33Rα (ST2) requires IL-1RAcP for initiation of IL-33-induced 
signaling in different types of cells. In addition, it is also shown that central signaling 
pathways activated by IL-33 are strictly dependent on IL-1RAcP and are comparable 
to those also stimulated by IL-1. IL-33 was able to activate NF-κB similar to IL-1 
which is in accordance with previous report from transiently transfected HEK293 cells 
(Schmitz et al., 2005), In present work a transient JNK activation by IL-33 was 
detected in a time frame comparable to the transient activation of these protein 
kinases by IL-1. Schmitz et al., 2005 observed a slight shift in JNK activation 
compared with IL-1 in transiently transfected HEK293 cells (Schmitz et al., 2005). In 
EL-4 cells this effect was not seen, suggesting subtle differences in different cell 
types. Although the affinity of mIL-33 for ST2 (616 pM KD) is higher than the affinity 
of the IL-1β to IL-1R1 (1 nM KD) (Palmer et al., 2008), interestingly, rhIL-1β was 
active in the picomolar range in EL-4 or transfected D6/76 cells, where as nanomolar 
concentrations of rmIL-33 (or rmIL-18) were required to achieve a comparbale effect. 
This result demonstrates the great potency of IL-1 when compared to its sister 
cytokines, IL-18 and IL-33.  
The essential requirment of IL-1RAcP in IL-33-mediated signaling was also proved in 
loss of function experiments using monoclonal antibody 4C5, which recognizes mIL-
1RAcP (Greenfeder et al., 1995; Hestdal et al., 1994) and neutralizes IL-1β-mediated 
signal transduction. 4C5 behaved similarly to the mAb M49, which neutralizes hIL-
1RAcP and was used to inhibit IL-1RAcP-dependent signaling of IL-1F6 by IL-1Rrp2 
in human Jurkat and NCI/ADR-RES cells (Towne et al., 2004). If 4C5 recognizes 
mIL-1RAcP and functions by inhibiting the association of the co-receptor with the IL-
1-ligated IL-1RI, it also should work in the IL-33 receptor system. And indeed, a 
concentration-dependent inhibition of IL-33 effects was observed in the T cell lines 
EL-4 or D6/76 (after reconstitution with mIL-1RAcP). The study was extended to 
murine BMD mast cells, which are nontransformed and nontransfected primary cells, 
in a close collaboration with Prof. Huber at the MPI in Freiburg. These cells 
responded readily to IL-33 by producing IL-6, comparable to IL-6 produced by LPS 
stimulation. In these primary cells mAb 4C5 inhibited IL-33 induced IL-6 production in 
dose dependent mannar.  
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It was observed that 4C5 was less effective in IL-33 stimulation compared to IL-1β. It 
is difficult to explain why 4C5 was less effective in inhibiting IL-33-stimulated 
responses when compared with IL-1β. However, it has been described that this anti-
IL-1RAcP antibody differs in its neutralizing capacity between IL-1α or IL-1β 
containing receptor complexes (Hestdal et al., 1994). Thus, it is conceivable that this 
antibody also distinguishes between IL-1β in IL-1RI and IL-33 in IL-33Rα. 
The D10 cell line is classified as a Th2 type T lymphocyte and expresses ST2 
(Yanagisawa et al., 1997). D10 cells respond to IL-33 in proliferation assay. A 100-
fold excess of IL-33 was sufficient to achieve response comparable to IL-1β in D10 
cells, where as 1000 fold excess of IL-33 was needed in EL-4 cells. This indicates 
that the expression of IL-33 receptor is not as limiting as in EL-4 cells or that the cells 
may express some additional molecules, which results in an increase in the binding 
affinity of the IL-33 to its receptor or the efficacy of IL-33 signaling. The absolute 
requirement of IL-1RAcP as accessory protein for IL-33 receptor was also proved in 
D10 cells by competition experiments. Here, a truncated version of the IL-1RacP 
which lackes the TIR domain was overexpressed in order to compete with 
endogenous IL-1RAcP. And indeed, this resulted in an inhibition of IL-33 effects, due 
to the dominant negative effect of the co-receptor lacking the signaling domain. 
Interestingly however, the result obtained employing the neutralizing antibody 4C5 in 
D10 cells was in contrast to that obtained in EL-4 or in mast cells. 4C5 did not affect 
IL-33 induced signaling in D10 cells although it neutralized the effect of IL-1β 
completely. This observation strengthens the hypothesis (concept) of involvement of 
a putative additional chain in the IL-33 receptor system of D10 cells. Interaction of 
this postulated additional chain in the IL-33 receptor system may result in a change in 
the conformation of the IL-1RAcP, so that the 4C5 antibody is no more able to 
recognize/ gain access to IL-1RAcP. Alternatively, presence of an additional chain 
may allow the recruitment of IL-1RAcP in a way that the epitope region recognized by 
4C5 antibody is not involved in the interaction of IL-1RAcP with IL-33 ligated IL-33 
receptor α-chain. Further experiments in that direction are required to identify such a 
third chain participating in the IL-33 receptor complex formation. 
The requirement of the TIR domain for IL-33-induced signal transduction in the EL-4 
cell system, was investigated by over-expressing a C-terminally truncated version of 
IL-1RAcP, lacking the TIR domain. IL-33 signaling was totally dependent on the 
presence of the TIR domain of the IL-1RAcP. Similar findings have also been 
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reported in a recent study by Chackerian et al., 2007. In fact TIR domains of both 
receptor and co-receptor are essential for IL-33 signaling. A C-terminally truncated 
version of the IL-33Rα-chain was not produced to prove this stringently in present 
study. However, the essencial requirment of TIR domain of ST2 and IL-1RAcP for IL-
1 induced signaling has been shown by generating chimeric receptor (Brint et al., 
2002; Towne et al., 2004; Thomassen et al., 1999). Therefore, it must be concluded 
that the TIR domains of the receptor and co-receptor are necessarly required for 
signal initiation. 
Here It is shown that the binding of IL-33 to the IL-33Rα chain allows the formation of 
a complex with IL-1RAcP in the plasma membrane, as described for IL-1 binding to 
IL-1RI or IL-1RII (Brint et al., 2002; Lang et al., 1998; Towne et al., 2004). 
Furthermore, results suggest that similar to IL-1α/β and IL-18, IL-33 does not 
dimerize IL-33Rα but rather signals through recruitment of accessory protein. These 
findings are in agreement with recently published data indicating that IL-33 and IL-
33Rα form a complex with IL-1RAcP in vitro, that IL-1RAcP is required for IL-33 
induced in vivo effects and that IL-33 induced signal transduction is inhibited by 
dominant negative IL-1RAcP (Chackerian et al., 2007). Similarly another recent study 
described that IL-1RAcP associates with IL-33Rα in ligand dependent manner and 
that the affinity of IL-33 binding to IL-33Rα increased by 4 fold in the presence of IL-
1RAcP (Palmer et al., 2008).  
It has been shown in several studies that soluble forms of cytokine receptors function 
as positive and negative regulators in the signaling of cytokines and growth factors. 
The existence of soluble ST2 (IL-33Rα) has been well documented and circulating 
levels of IL-33Rα (soluble ST2) are increased under different pathological situations 
(Kuroiwa et al., 2000; Oshikawa et al., 2001). In the present study the antagonistic 
effect of soluble IL-33Rα on IL-33 signaling is demonstrated in EL-4 cells. 
Antagonistic effects of soluble IL-33Rα on IL-33 signaling have also recently been 
described in EL-4 cells and murine model of asthma (Hayakawa et al., 2007). In 
addition, it is shown here that a soluble IL-33Rα-chain can interact with soluble IL-
1RAcP in the presence of IL-33. The formation of such soluble receptor complexes in 
the presence of ligand has been reported in the IL-1 system  (Smith et al., 2003), 
where soluble IL-1RAcP seems to stabilize the ligated soluble IL-1R, allowing 
neutralization and sequestration of the cytokine also in vivo. Moreover, it has been 
proposed that soluble IL-1RAcP may be helpful to neutralize IL-1β in chronic 
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inflammatory diseases such as rheumatoid arthritis (Smeets et al., 2003; Smith et al., 
2003). It is tempting to speculate that the combination of soluble IL-33Rα and soluble 
IL-1RAcP can act in synergistic manner to inhibit IL-33 activities. In that context 
soluble IL-1RAcP could also be used to neutralize and sequester IL-33 in the 
presence of soluble IL-33Rα-chain in Th2-biased diseases (e.g., IgE-mediated 
allergic reactions). 
In conclusion, the results obtained in this study demonstrate that the IL-33 does not 
induce dimerization of IL-33Rα but rather IL-33 biology is mediated through a 
hetrodimeric receptor complex. The functional IL-33R complex consists of IL-33Rα 
and IL-1RAcP. In addition to the membrane-inserted forms, also the soluble forms of 
IL-33Rα and IL-1RAcP can form complexes in the presence of IL-33 (depicted in 
Fig.4.2) however these soluble receptor complexes are not able to initiate signal 
transduction. These findings suggest the novel role of soluble form of IL-1RAcP in 
modulating the IL-33 activities.  
In summary of the results presented here and published in the literature, IL-1RAcP 
can act as a common β-chain for four discrete members of the IL-1 receptor family: 
IL-1RI, IL-RII, IL-1Rrp2, and IL-33Rα. This situation is reminiscent of the role of 
common receptor chains in other cytokine families, like gp130 in the IL-6 receptor 
system or the common γ-chain in the IL-2 receptor family. In addition, the sharing of 
IL-1RAcP and the fact that it also can interact with receptors in its soluble form opens 
new levels of cross talking among the different members of the IL-1 receptor family 
(schematically depicted in Fig.4.1). 
 
 
 
 
 
 
 
 
IL-1RAcP 
IL-1 α/β IL-1 α/β IL-33 IL-1F6/8/9 
IL-1RII IL-1RI IL-33Rα IL-1Rrp2 
Fig. 4.1: Summary of usage of IL-1RAcP as co-receptor by the receptor-like members of the IL-
1 receptor family of TIR receptors. IL-33 like IL-1 (α and β), IL-1F6, IL-1F8 and IL-1F9 uses IL-
1RacP as second component of its signaling complex.  
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4.2. IL-33 induces pro-inflammatory cytokine release  
IL-33 has been previously described to drive essentially Th2 responses and 
production of Th2-associated cytokines from in vitro polarized Th2 cells (Kondo et al., 
2008; Schmitz et al., 2005). In vivo, IL-33 injection induced the expression of IL-4, IL-
5, and IL-13 and led to severe pathological changes in the lung and the digestive 
tract (Kondo et al., 2008; Schmitz et al., 2005). In this thesis, it is reported that in 
addition to Th2 cytokine production, IL-33 is capable to stimulate secretion of pro-
inflammatory mediators in IL-1RAcP dependent mannar. IL-33 induces IL-6, IL-1β, 
and TNFα in bone marrow derived mast cells, IL-2 in EL-4 cells, IL-6 in fibroblasts 
and IL-8 production in transiently transfected HEK293RI cells. In addition, IL-33 was 
also able to induce mRNA expression of cytokines and chemokines such as IL-22, 
Csf2, Cxcl10 and Ccl5 in EL-4 cells. In accordance with the findings reported here 
production of IL-6, IL-1β, TNFα and PGD2 in response to IL-33 in murine mast cells 
(Moulin et al., 2007) and pro-inflammatory cytokine and chemokines in human mast 
cells (Allakhverdi et al., 2007; Iikura et al., 2007) have recently been reported. In 
addition, IL-33 induced interferon-γ production in NK and NKT cells has also been 
described in recent reports (Smithgall et al., 2008; Bourgeois et al., 2009). Taken 
together it seems that similar to the other members of family, IL-33 can contribute as 
a co-stimulatory factor to innate cellular immune responses and might also be 
involved in pathogenesis of the inflammatory disorders including arthritis.  
 
3.3. TIR8 (SIGIRR) is not a component of the IL-33 receptor complex 
It has been shown exprimentally that IL-1RAcP is absolutely required for IL-33-
induced activation of the cells (Ali et al., 2007; Chackerian et al., 2007; Palmer et al., 
2008). Thus IL-1RAcP is definitely a component of the IL-33 receptor complex, 
however this does not exclude that at least in some cell types additional molecules 
may participate in the IL-33R complex. TIR8 (SIGIRR) was also a proposed 
candidate that may be a component of the IL-33 receptor complex (Dinarello, 2005; 
Schmitz et al., 2005; Barksby et al., 2007; Gadina and Jefferies, 2007). To 
understand the precise role of IL-33 and IL-33 receptor in the immune response, it is 
necessary to identify and define all the components of the IL-33 receptor complex 
and its regulatory molecules. It has been published that TIR8 may function as a 
negative regulator of Toll like receptors because TIR8 deficient mice are reported to 
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be more susceptible to the systemic toxicity of bacterial lypopolysaccharide (Wald et 
al., 2003) and intestinal inflammation (Garlanda et al., 2004).  
TIR8 possesses all of the conserved motifs found in the cytoplasmic domain of the 
IL-1R superfamily. In addition, TIR8 contains distinct structural and functional 
features that are not found in other IL-1R homologous proteins. Its extracellular 
domain, is very short, however it appears long enough to fold into one Ig-like domain 
(Mantovani et al., 2004; Martin and Wesche, 2002). The peptide sequence of the 
conserved cytoplasmic regions is closely related to that of the other members of 
family. However, similar to the drosophila Toll, its long cytoplasmic tail extends 
beyond the last conserved region by 98 amino acids compared to the other type 1 
members of the IL-1 receptor family. It was shown that this region in drosophila Toll 
contains inhibitory activity (Norris and Manley, 1995).  
In the experiments performed within this thesis, it was possible to reproduce the 
inhibitory function of TIR8 in IL-1- and LPS- induced activation of cells in over-
expression system. The over-expression of both human  and murine TIR8 inhibited 
LPS- induced production of IL-6 in L929 cells and IL-1- induced NF-κB activation in 
HEK293RI cells. This observation is consistent with the previously published data 
suggesting that TIR8 is an inhibitor of IL-1R/TLR signaling (Polentarutti et al., 2003; 
Wald et al., 2003). This effect of TIR8 overexpression was also measured on IL-33 
induced NF-κB stimulation in a reporter gene assay. A slight inhibition of IL-33 
induced NF-κB was also observed in some experiments. However, this inhibition was 
only achievable when there was very high expression of TIR8.  
It has been shown that TIR8 exerts its negative regulatory function in IL-1/TLR 
mediated signaling pathways through its direct effect on the immediate signaling 
events, including NF-κB and JNK activation (Wald et al., 2003). Detailed molecular 
mechanism, how TIR8 negatively regulate IL-1/LPS mediated signaling have not yet 
been described. It has been reported that TIR8 associates with IL-1R1 and TLR4 and 
also led to the formation of complex between TIR8, MyD88, IRAK4, IRAK and TRAF6 
(Qin et al., 2005; Wald et al., 2003). TIR8 may negatively regulate IL-1 and LPS 
pathways by interfering with the appropriate recruitment and activation of the 
receptor- proximal signaling components (such as MyD88, IRAK molecules or 
TRAF6) or, alternatively, may attenuate the dissociation of the activated signaling 
components from the receptor complex.  
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By BIAcore analaysis it has been demonstrated that TIR8 is not able to bind either IL-
1α, IL-1β or IL-1Ra (Thomassen et al., 1999). Its single Ig-domain is too short to fold 
around an IL-1-like ligand in the same manner as the three Ig folds of the IL-1R 
(Vigers et al., 1997). It was assumed that TIR8 could function as part of a ligand 
binding complex in a way similar to the IL-1RAcP or the common β chain of the IL-3, 
IL-5 and GM-CSF receptor complexes (Tavernier et al., 1991). These proteins can 
not bind a ligand on their own but bind to the high affinity receptor plus bound ligand. 
The involvement of TIR8 as a putative third part of the IL-33 complex or as a 
substitute for IL-1RAcP was tested by transfecting it with/or without IL-1RAcP in IL-
1RAcP- negative cells (EL-4 D6/76). Wild type TIR8 and truncated versions of it did 
not have an effect on IL-1, or IL-33-dependent NF-κB activation. In addition, IL-33 
stimulated EL-4 cells did not alter NF-κB activitation in presence or absence of TIR8 
overexpression, which suggests that TIR8 does not function as a silencing or 
stimulating part of IL-33 receptor complex.  
The direct interaction of TIR8 with IL-33 receptor was not investigated by co-
immunoprecipitation. But the results from biological assays suggests that, TIR8 can 
not be used as co-receptor by IL-33Rα, as transiently transfected EL-4 D6/76 cells 
are not  able to restore IL-33 induced signaling despite TIR8 over expression. EL-4-
D6/76 expresses enough of IL-33Rα, as these cells readily reconstitute IL-33 
responsiveness upon IL-1RAcP expression. Moreover, expression of TIR8 with IL-
1RAcP did not affect IL-33-induced signaling in EL-4 and EL-4 D6/76 cells 
expressing mIL-1RAcP, indicating that mTIR8 exerts neither stimulatory nor inhibitory 
effects on IL-33-induced signaling in EL-4 and EL-4 D6/76 cells. The inhibitory effect 
which was observed in some experiments most likely is due to the strong over 
expression.  
In the past it has been shown that replacement of the cytoplasmic domain of IL-1R1 
by that of other family members still resulted in NF-κB activation after IL-1 binding to 
the chimeric molecule (Greenfeder et al., 1995; Mitcham et al., 1996; Thomassen et 
al., 1999). Assuming that TIR8 might function as accessory protein for the IL-33 
receptor α-chain, it was necessary to ascertain whether the extracellular domain of 
TIR8 could recognize IL-33 bound to the IL-33 receptor α chain. It was observed that 
extracellular and/or transmembrane domain of TIR8 was not able to recognize the IL-
1 or IL-33 ligand receptor complex, as the expression of a TIR8-AcP chimera 
(extracellular and transmembrane part of TIR8 and cytoplasmic part of IL-1RAcP) 
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could not reconstitute IL-33 responsiveness in IL-1RAcP lacking cells (EL-4 D6/76). 
Thus it must be concluded that TIR8 can not be a direct component of the receptor 
complexes for either IL-1 or IL-33. Results reported here are in contradiction with the 
previously published data showing that TIR8 can recognize IL-1R1 in IL-1 dependent 
manner (Qin et al., 2005; Wald et al., 2003) and ST2 in IL-33 dependent mannar 
(Bulek et al., 2009) but are in agreement with the data generated in BIAcore and 
reporter gene assays indicating that TIR8 is not able to bind to IL-1, IL-1R/IL-1 
complex or IL-1RI/IL-1/IL-1RAcP complex (Thomassen et al., 1999).  
Inability of involvement of cytoplasmic part of TIR8 in IL-33 or IL-1 signaling was 
proved by replacement of the cytoplasmic part of the IL-1RAcP with that of TIR8. 
After expression, this chimera was able to recognize IL-1 and IL-33 bound to 
respective receptors, as extracellular three Ig like domains of IL-1RAcP are sufficient 
to recognize the ligand bound IL-1 receptor and IL-33 receptor. Similar findings are 
repoted by others for IL-1 receptor. (Huang et al., 1997; Jensen et al., 2000; 
Neumann et al., 2000). However expression of AcP-TIR8 was unable to replace the 
function of full length IL-1RAcP for initiating IL-1 or IL-33 mediated signal 
transduction. If TIR8 is functional as the accessary protein for IL-33 receptor, the 
intracellular TIR8-moiety in the chimeric proteins should be able to start signaling 
upon interaction of Ig-like domains of IL-1RAcP with IL-33 bound IL-33 receptor.  
In summary, TIR8 (SIGIRR) is neither the accessory protein for IL-1 receptors nor for 
the IL-33 receptor. In addition evidence for a regulatory function in those two cytokine 
receptor complexes could not be produced in this work. There are some contradictory 
reports of modulatory role of TIR8 in IL-1R/Toll like receptors, however the exact 
function of TIR8 needs to be investigated in more detail. 
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4.4. IL-33 does not need processing for bioactivity 
Like IL-1α IL-33, is a dual function cytokine (reviewed in (Haraldsen et al., 2009). IL-
33 exerts its function as a classical cytokine in a receptor-mediated fashion, normally 
in a paracrine manner, on target cells. In addition, IL-33 is able to translocate to the 
nucleus of the producing cell (Carriere et al., 2007) where it exerts gene regulatory 
functions. Similar to IL-1β and IL-18, IL-33 is produced as a precursor molecule 
which is reported to be cleaved by caspase 1 to yield a biologically active mature 
form (Schmitz et al., 2005). In contrast to previous report by Schmitz et al., 2005, this 
thesis demonstrates that IL-33 does not require caspase 1 mediated maturation for 
biological activity as a cytokine. Here it is shown that full length IL-33 can bind to the 
IL-33 receptor in vitro and on intact cells. Similar to the mature form reported by 
Scmitz et al., 2005, full length IL-33 bound to IL-33Rα allowed association and 
recuritment of IL-1RAcP which resulted in concentration- and time-dependent 
activation of NF-κB, as well as induction of cytokine production. In agreement with 
these findings activation of cells with full length IL-33 is also reported in three very 
recent publications (Cayrol and Girard, 2009; Luthi et al., 2009; Talabot-Ayer et al., 
2009). 
It was reported that caspase 1 cleaves full length human IL-33 at aa111 
(corresponding to aa108 in full length murine IL-33)(Schmitz et al., 2005). Over 
expression of C-terminally tagged full length IL-33 in murine keratinocytes resulted 
two different C-terminal processing products. A faint band of processed IL-33, fits the 
mature form described by Schmitz, et al., 2005 however, major processing product 
was around 12 kDa protein which did not correspond in size to the expected mature 
form (aa109-266). In silico re-analysis of IL-33 sequences did not reveal a caspase 1 
cleavage site, as suggested by some others as well (Carriere et al., 2007; Haraldsen 
et al., 2009; Talabot-Ayer et al., 2009), however, a non-classical caspase 3 cleavage 
site (DGVD175G) located in the middle of the IL-1-like domain was found in the IL-33 
sequence. This (DGVD175G) sequence motif is conserved in mouse, rat and human 
IL-33 and had been previously identified in PKCζ (Frutos et al., 1999) to be accepted 
by caspase 3. The calculated fragments fitted much better to the bands observed in 
the gels after digestion of full length mIL-33. Caspase 3 cleavage sequence in full 
length IL-33 at aa175, was also identified recently by (Cayrol and Girard, 2009; Luthi 
et al., 2009). 
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Using N- and/or C-terminally epitope-tagged versions of full length murine IL-33 as 
wild-type form and with a point mutation at D175 (D175->A) it is confirmed that full 
length murine IL-33 was mainly processed at aa175 (DGVD175G) in intact cells and in 
vitro by apoptotic caspase 3. However no cleavage (neither at aa108 nor at aa175) 
was observed by pro-inflammatory caspase 1. These results are in part contradictory 
to those reported recently in which it was shown that caspase 1 cleaved full length 
murine IL-33 at aa 108 (Schmitz et al., 2005) or at the caspase 3 cleavage site 
(aa,175) (Cayrol and Girard, 2009). Talabot-Ayer et al., 2009 and Luthi et al.,2009 
however, reported that caspase 1 is not responsible for processing of full length IL-33 
(Luthi et al., 2009; Talabot-Ayer et al., 2009). This discripincy in the results may be 
because of the contaminating proteases which are known to be present in 
reticulocyte lysates used by Schmitz et al., 2005 and Cayrol and Girad, 2009. 
Caspase 3 cleavage at aa 175 inactivated the full length IL-33 bioactivity as a 
cytokine, while neither the N-terminal product of aa 1-175 nor the C-terminal product 
of aa 176-266 were able to bind to the receptor or activate cells. This finding is also 
reported very recently by Cayrol and Girad, 2009 and Luthi et al.,2009. Similar to IL-
33 inactivation of IL-18 has also been reported by caspase 3 cleavage (Akita et al., 
1997). In agreement with the recent reoprt by Cayrol and Girad, 2009 full length IL-33 
with a point mutation at aa175 (D175->A) was able to bind and activate IL-33Rα in 
experiments performed in present work however, a D175->A mutant generated by 
Luthi et al., 2009 was inactive as acytokine. It is difficult to explain the difference in 
results however use of different epitope tags may explain the discrepancy in results.  
Induction of apoptosis is known to activate apoptotic caspases including caspase-3 
(Creagh et al., 2003). Here it was investigated that induction of apoptosis could 
initiate processing of full length IL-33 by endogenous caspases in cells undergoing 
apoptosis. Similar findings have been reported very recently by Cayrol and Girad, 
2009 and Luthi et al., 2009. In addition caspase 7-mediated inactivation of IL-33 is 
also demonstrated in a recent report (Luthi et al., 2009). IL-33 has diverse target cell 
populations, including mast cells, CNS glia, basophils, eosinophils, NK, iNKT and 
others cells of the innate immune system (Ali et al., 2007; Allakhverdi et al., 2007; 
Iikura et al., 2007; Moulin et al., 2007; Pecaric-Petkovic et al., 2008; Smithgall et al., 
2008; Suzukawa et al., 2008). Processing of IL-33 by caspase 3 may therefore 
provide a mechanism to inactivate pro-inflammatory cytokine activities of IL-33 during 
apoptosis, a process that does not trigger inflammation in vivo. 
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IL-33 was originally identified as a nuclear factor in specialized endothelial cells 
(Baekkevold et al., 2003) before it was designated a cytokine. Therefore IL-33, like 
IL-1α, was called a dual function cytokine (reviewed in (Haraldsen et al., 2009)). IL-
33 is reported to be located in the nucleus of a variety of cell types, including 
endothelial and epithelial cells from different sources, glial cells, and skin associated 
keratinocytes (Carriere et al., 2007; Hudson et al., 2008; Kuchler et al., 2008; 
Moussion et al., 2008; Schmitz et al., 2005). It is not yet clear how IL-33 is released 
from cells. In the experiments depicted in this thesis, release of any bioactive IL-33 
form was not detected in supernatants of intact cells, although the cells produced 
amounts of IL-33 readily detectable inside of the cell. In contrast to IL-33, bioactive 
IL-1β, or IL-18, even IL-1α, were easily detectable in supernatants indicating that the 
inflammasome had been activated and release mechanism worked. In consistant 
with these observations Cayrol and Girad, 2009 were also unable to find any 
evidence of release of IL-33 from endothelial cells under physiological conditions. 
However very recently release of bioactive IL-33 have been identified from glial cells 
(Hudson et al., 2008), and THP-1 cells (Li et al., 2008; Talabot-Ayer et al., 2009). 
Two mechanism of the release of  prototypical alarmin HMGB1 have previously been 
shown, secretion by activated macrophages after hyperacylation of the lysine 
residues (Bianchi, 2007) or by passive release during cell damage or tissue injury 
(Scaffidi et al., 2002). Passive release of IL-1α has also been reported (Chen et al., 
2007; Rao et al., 2007; Eigenbrod et al., 2008). In addition, IL-1α is also known to be 
released by an unconventional caspase 1-dependent mechanism which needs 
inflammasome activation (Keller et al., 2008). Keeping in view the result depicted in 
present work and some recent reports (Hudson et al., 2008; Kuchler et al., 2008; Li et 
al., 2008; Moussion et al., 2008; Cayrol and Girard, 2009; Luthi et al., 2009; Talabot-
Ayer et al., 2009) it is highly likely that similar to IL-1α, IL-33 is released from cells 
both by cell or tissue damage and by inflammasome-dependent mechanism (Keller et 
al., 2008). Thus, similar to IL-1α (Dinarello, 1996; Chen et al., 2007; Rao et al., 2007; 
Eigenbrod et al., 2008) and the prototypical alarmin HMGB1 (Klune et al., 2008), IL-
33 may also function as an endogenous danger signal (Matzinger, 2002) or alarmin 
(Bianchi, 2007), to alert cells of the innate immune system after tissue injury. 
Upon overexpression full length IL-33 translocates to the nucleus, a feature it shares 
with IL-1α and IL-1F7b (reviewed in (Dinarello, 2009)). Interestingly, not only full 
length IL-33 translocated to the nucleus but also the caspase 3 cleaved N-terminal 
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fragment aa1-175, which is in accordance to previous reports stating that the 
sequences responsible for nuclear translocation reside in the N-terminus of full length 
IL-33 (Carriere et al., 2007). The C-terminal breakdown product did not translocate to 
the nucleus and remained completely in the cytosol. It remains to be demonstrated 
that this N-terminal fragment regulates gene transcription comparable to full length 
IL-33. While processing of full length murine IL-33 at aa175 destroys its cytokine 
function it does not abrogate nuclear translocation, presumably still allowing gene 
regulation.  
In summary, IL-33 is functionally closer related to IL-1α than to IL-1β or IL-18, as it is 
also a member of the IL-1 family with dual function. IL-33 is able to interact with its 
receptor complex as a full length molecule, and it may also be processed to a mature 
bioactive form. In addition, the full length molecule and its N-terminal caspase 3 
processing product translocate to the nucleus where they may exert gene regulatory 
functions. However, in contrast to IL-1α which is released from activated cells after 
processing by calpain, IL-33 does not seem to be released from intact cells after 
activation. Like full length IL-1α, full length IL-33 may act as an alarmin after cellular 
destruction or necrosis, e. g. after mechanical injury or hypoxia, which is released by 
dying cells into the environment where it acts as an alarm mediator signaling cellular 
damage, rather than cellular activation.  
 
4.5. Comparison of IL-1, IL-18 and IL-33 induced gene expression  
Among the well known members of the IL-1 family of cytokins, IL-1α and IL-1β are 
well characterized pro-inflammatory cytokines (Dinarello, 2006). IL-18 is a Th1 driving 
pro-inflammatory cytokine with the unique capacity of inducing the production of IFNγ 
(Dinarello, 1999). lL-33 drives Th2-responses (Schmitz et al., 2005) and was 
suggested to act as anti-inflammatory cytokine (Gadina and Jefferies, 2007).  
Although little is known about IL-33 activites some evidence suggests that IL-33 may 
have a dual role of pro-inflammatory and anti-inflammatory activities (Gadina and 
Jefferies, 2007). All three cytokines (IL-1, IL-18 and IL-33) are member of same IL-1 
family and are closly related with respects to their structure, receptor binding, and 
signal transduction (reviewed in (Dinarello, 2005). All three share a large part of 
signal transduction pathways. However, they also have unique functions. Therefore it 
was important to compare the signaling induced by all three cytokines. 
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By global analysis of gene expression in EL-41B1 cells, significant induction of 
expression of a number of genes by IL-1, IL-18 and IL-33 was observed. The 
expression profile obtained by these stimuli suggests identical gene expression 
profile induced by IL-1, IL-18 and IL-33. No really differentially regulated gene was 
found, which can clearly suggest the involvement of unique molecules/pathways, 
that can be considered as target candidate to inhibit the signaling of one of these 
cytokines (other than specific receptor). Results reported here complements other 
recent studies that IL-1, IL-18 and IL-33 utilise similar signaling molecules/pathways 
(Schmitz et al., 2005; Dinarello, 2005; Barksby et al., 2007).  
Receptors serve as gateways to pro-inflammatory signaling pathways. IL-1 receptor 
are expressed predominantly on T cells, fibroblasts, epithelial and endothelial cells 
(reviewed in (Boraschi and Tagliabue, 2006). IL-18 receptor are expressed mainly in 
mononuclear phagocytes, neutrophils, Th1 cells, NK cells, endothelial cells and 
smooth muscle cells (reviewed in (Boraschi and Tagliabue, 2006) where as the 
expression of IL-33 receptor is predominantly restricted to Th2 mast cells and 
fibroblasts (Lohning et al., 1998; Xu et al., 1998; Yanagisawa et al., 1997; Boraschi 
and Tagliabue, 2006; Kakkar and Lee, 2008). In addition the expression of cytokines 
is also restricted to the specified tissues. Thus, it is highly likely that the biological 
activities of IL-1 family members are mainly modulated in certain cell types 
according to the unique expression profile of the cytokines in specific cell/tissue 
types and expression of specific receptors on effecter cells. Detailed studies are 
needed to clarify the question of differential biological functions of these cytokines, 
when they seem to follow the same signaling pathway. 
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4.6. A model of IL-33 signaling 
Taken together the data presented in this thesis and published in recent reports, a 
working model of IL-33 signaling is depicted in Fig.4.2. IL-33 is expressed in the 
variety of cell types constitutively and/or upon stimulation with pro-inflammatory 
molecules (Carriere et al., 2007; Hudson et al., 2008; Kuchler et al., 2008; Moussion 
et al., 2008; Schmitz et al., 2005). Similar to IL-1α it translocates to the nucleus of 
producing cells, associates with heterochromatin and in contrast to IL-1α exhibits 
transcriptional repressor properties (Roussel et al., 2008; Mizel et al., 1987; Gadina 
and Jefferies, 2007; Carriere et al., 2007). IL-33 does not need processing by 
caspases for this activity. Probably it is released from the cells by cell lysis during 
tissue injury. Upon release it can work as a classical cytokine via interleukin-33 
receptor complex formation (comprising IL-33 receptor α-chain and IL-1RAcP) on cell 
surface of target cells. 
In intracellular spaces IL-33 binds ST2/IL-33Rα (Schmitz et al., 2005), which in turn 
interact with IL-1RAcP and heterodimerize (Palmer et al., 2008; Chackerian et al., 
2007; Ali et al., 2007). Similar to other members of the family recruitment of 
accessory protein is necessarily required for initiation of the signal transduction. 
Moreover, the TIR domains of receptor and co-receptor are crucial for initiation of 
signal transduction (Ali et al., 2007). Soluble form of IL-33 receptor also exists which 
can neutralize IL-33 activities (Hayakawa et al., 2007) by competing with the 
membrane IL-33 receptor α-chain for IL-33 binding and/or by formation of soluble-IL-
33Rα-IL-33-membrane IL-1RAcP complex on cell surface. Existence of soluble form 
of IL-1RAcP is also well documented (Smith et al., 2003; Smeets et al., 2003; Lang et 
al., 1998). Soluble IL-1RAcP binds to ligand bound IL-33 receptor and may synergize 
the moudlatory activities of soluble IL-33 receptor (Palmer et al., 2008; Ali et al., 
2007). However whether sIL-1RAcP can bind to the ligand receptor complex on cell 
suface is still to be investigated. 
Like the other members of the family the activated IL-33 receptor complex has the 
ability to recruit and interact with MyD88, IRAK4, IRAK1 and TRAF6  (Schmitz et al., 
2005). Similar to IL-1 and  IL-18, IL-33 also activate the NF-κB, ERK1/2, JNK and 
p38 MAPK (Schmitz et al., 2005; Sanada et al., 2007; Kurowska-Stolarska et al., 
2008; Ali et al., 2007). The ERK1/2, JNK and p38 MAPK activated transcription 
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factors and active NF-κB translocate to the nucleus and regulate the expression of 
various genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is generally accepted that the adaptor proteins MyD88 and the IL-1R-associated 
protein kinase (IRAK) activate downstream mitogen-activated protein kinase (MAPK) 
kinases through TRAF6, which activates TAK-1 which in turn activates JNKs and p38 
MAPK. TRAF6 also activates the inhibitor of NF-κB  (IKK) complex, leading to 
downstream liberation of active NF-kB from the complex (reviewed in (Kakkar and 
Lee, 2008; Dinarello, 2005; Martin and Wesche, 2002). Studies from mouse 
embryonic fibroblasts (MEFs) obtained from MyD88 and TRAF-6 knockout animals 
showed that p38, JNK and NF-kB activation induced by IL-33 is completely 
dependent on MyD88 and TRAF6, however IL-33-induced ERK activation might be 
TRAF6 independent (Funakoshi-Tago et al., 2008). 
Fig. 4.2: A model for IL-33/ST2 signaling. 
IL-33 does not need processing by caspase-1 for activation. It is likely that IL-33 may be released by 
cell damage during tissue injury. IL-33 binds to its receptor and generates a complex composed of IL-
33Rα and the IL-1RAcP. Subsequent recruitment of the adaptor proteins MyD88 and MAL results in 
modulation of IRAK mediated TRAF6 activation and subsequent activation of JNK, p38 MAPK,
ERK1/2 and IKK/NF-kB. Interestingly, although TRAF6 appears to be required for IL-33 mediated NF-
kB activation and downstream induction of cytokines, IL-33 mediated ERK activation might be TRAF6 
independent. Furthermore, the regulation of IL-33 signal modulation is still unclear. However, before 
IL-33 binds to its receptor, its action could be altered by the decoy receptor soluble ST2 (sST2). sST2 
in the extracellular environment might bind free IL-33, thereby effectively decreasing the concentration 
of IL-33 that is available for IL-33Rα binding and reducing the biological effect of IL-33. Soluble form of 
IL-1RAcP may also contribute to neutralization of IL-33 activity. 
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4.7. Perspectives  
In summary IL-33 is an extremly interesting member of the IL-1 family of cytokines 
with distinct properties mainly its role in Th2 and mast cells activation and maturation 
and cardiovascular pathophysiology. Pharmacological intervension seems desirable 
in diseases in which IL-33 plays an essential role such as asthma, rheumatoid 
arthritis, atherosclerosis and cardiovascular disorders. 
Given the fact that signal transduction pathways activated by IL-33, IL-1 and IL-18 
are more or less identical, the IL-33 receptor complex appears to be the most 
prominent target structure to achieve IL-33 -specific inhibition. This may be achieved 
by soluble receptors or anti -IL-33 receptor or anti-IL-33 antibodies.  
However, before IL-33 is neutralized in disease its definite biological role should be 
absolutely clear. Is it produced after tissue –damage or does it enhance 
pathogenicity after necrosis?  
The coming months and years will provide the necessory informations to confirm IL-
33 and its receptor complex as therapeutic target structures for pharmacological 
intervention.  
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